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Abstract
Escherichia coli O157 is a persistent pathogen linked to food and waterborne infectious
outbreaks with severe health consequences such as hemorrhagic colitis and hemolyticuremic syndrome (HUS). Because it is considered one of the major pathogens that
contributes to the global burden of foodborne disease, its early detection within the food
chain is an important milestone towards reducing foodborne diseases and economic losses
due to contaminated food. Herein, the development and validation of a lateral flow
immunoassay (LFIA) point-of-care (POC) device is described. Application of the LFIA
test kit was focused on detection of E. coli O157 in raw meat products due to the fact that
ground beef has been one of the major food items implicated in E. coli outbreaks and recalls
within Canada. Moreover, the LFIA Test Kit was subjected to an independent validation
study based upon Health Canada’s guidelines for the validation of alternative
microbiological methods as established in the Compendium of Analytical Methods. The
protocol comprised a pre-collaborative study, where the LFIA Test Kit was compared
against the reference culture method, MFHPB-10, using eight different raw meat products
following an unpaired samples experimental layout. The results demonstrated that the
newly developed LFIA Test Kit exceeds the performance parameters criteria established
by the Microbiological Methods Committee (MMC), thus suggesting that the LFIA Test
Kit represents a reliable alternative for meat producers in order to obtain presumptive
presence/absence results in less than one day. The design and expression of a single-chain
variable fragment (scFv) targeting E. coli O157 is also presented. Recombinant antibody
fragments such as scFv have not been extensively exploited within food safety diagnostics,
especially for pathogen detection. Thus, in this project the anti-O157 mouse monoclonal
antibody (mAb) used as the detection reagent in the LFIA Test Kit was genetically
sequenced prior to bioengineering a scFv that could potentially be used to improve the
performance of the LFIA Test Kit.
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CHAPTER 1 INTRODUCTION
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1.1. General Overview of Food Safety
Food Safety
The World Health Organization (WHO) defines food safety as a set of actions necessary
to ensure that all food is as safe as possible throughout the production chain (1). Moreover,
it is considered a multidisciplinary activity that requires full integration of a broad spectrum
of disciplines, from technological to legal, while requiring the engagement of the different
stakeholders within the food supply chain in order to create a successful food safety
management system. Borchers et al. defined food safety as a “reasonable certainty of no
harm” because it is impossible, from a feasible and economic perspective, to ensure with
absolute certainty that all food will be safe (2). In addition, food safety can be considered
as an intrinsic attribute that refers to the absence of hazards with an acceptable risk (3).
In the last few decades, food safety has been gaining more attention as a global health issue
due to the huge impact that foodborne illness is having on public health and socioeconomic development (4). Main concerns involve the emergence and/or redistribution of
microbial and chemical hazards (e.g. mycotoxins), especially due to extreme weather
conditions (5–7) and the increase in global food trade (7,8). Safe food and water supplies
are relevant components of a healthy environment; therefore any new threats caused by the
world’s evolution and dynamics can alter the agro-food production chain. The latest
estimations from WHO indicate that >200 different diseases, including diarrhea and
cancer, are linked to consumption of unsafe food (9), causing approximately 1 in 10 people
worldwide to become ill and 420,000 to die annually, representing 33 million disability1

adjusted life years (DALYs) lost due to consumption of unsafe food (10). Specifically
within Canada, approximately 3,000 food safety investigations are carried out each year,
resulting in almost 250 recalls with an estimate of 4 million cases of food-related illness
reported annually (11).

1

The disability-adjusted life year (DALY) measure was developed by the WHO to summarize the years of
healthy life lost due to an acute illness and sequelae because it includes data on premature mortality and
morbidity (58).

3

In fact, in 2000 food safety was recognized as an essential public health function by the
Member States of the WHO (1). More recently, in April 2015, the WHO official World
Health Day was dedicated to raising awareness about food safety and to highlight the
impact of food safety on public health (9). At the national level, governments have
implemented new programs and initiatives with the aim of increasing food safety
awareness among all parties involved in food production, from farm-to-table and from
governments-to-consumers. As an example, in 2010 the Healthy People 2020 initiative was
launched in the USA. Included as one of its main goals is the reduction of foodborne
diseases by improving food safety measures (12). Meanwhile in Canada, the Safe Food for
Canadians Action Plan came into force in 2015. Among the activities included in this
Action Plan are strengthening and developing food safety rules to update the Canadian
food safety system and to better protect Canadians from food safety risks as a result (13).
1.1.1.1 Microbiological food safety
The WHO recently published the latest burden of foodborne illnesses, where a total of 600
million cases and 418,000 deaths worldwide were estimated in 2010 (4). Interestingly,
more than 50% of these estimates (360 million cases and 273,000 deaths) were linked to
bacterial agents (4), emphasizing their prominent role as food safety hazards. In addition,
the latest data from the Centers for Disease Control and Prevention (CDC), estimated that
14 million illnesses, 60,000 hospitalizations, and 1,800 deaths occurred annually in the
USA due to known foodborne pathogens (2). The CDC identified seven bacterial pathogens
and two parasites as the major causes of foodborne illnesses with an incidence (in cases
per 100,000 people, in 2008) of 12.68 for Campylobacter, 16.2 for Salmonella, 6.59 for
Shigella, 2.25 for Cryptosporidium, 1.12 for Escherichia coli O157, and <1 for the other 4
pathogens (Listeria, Vibrio, Yersinia, Cyclospora) (2). In Canada, 1.6 million cases of
domestically acquired foodborne disease happen annually caused by 30 known pathogens
(14). Based on these data, the first Canadian report of hospitalizations and deaths due to
foodborne diseases estimated that 3,943 hospitalizations and 105 deaths are caused every
year, from which 66% and 76%, respectively, are due to bacterial pathogens (15). Of note,
the top bacterial pathogens found to cause most of the foodborne illness cases are
C. perfringens, Campylobacter spp. and nontyphoidal Salmonella spp., in this order (14).
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These differ from those considered to be major contributors to the number of
hospitalizations (nontyphoidal Salmonella spp., Campylobacter spp. and verotoxigenic
E. coli O157 (VTEC O157), in order) and deaths (L. monocytogenes, nontyphoidal
Salmonella spp., and VTEC O157, in order), suggesting that the latter tend to have more
severe outcomes (15). The statistics presented showed that foodborne pathogens result in
considerable morbidity and mortality. Unlike toxic agents, foodborne pathogens can enter
at almost any stage during the food production chain. In addition, bacterial pathogens can
easily reach a new host using food as a vehicle because they can adapt, survive and/or grow
within the food chain (8,16). Moreover, foodborne pathogens are dynamic and their effects
are difficult to predict; they are constantly evolving into new, resistant strains and emerging
in unusual food commodities (8). For this reason, microbiological food safety requires
different approaches and strategies than food toxicity, in order to counteract the challenges
that microorganisms represent to food safety (16). Specifically within Canada, the Safe
Food for Canadians Framework is expected to establish effective prevention and control
measures targeting the pathogens responsible for the greatest burden of disease and most
severe illness. Focusing on microbial food safety, such measures include more stringent
controls and testing requirements for pathogens like E. coli and Listeria, better tracing
systems and compliance verification (11).
1.2. Escherichia coli O157 and Its Role in Food Safety
General Overview of Pathogenic E. coli
Through the years, Escherichia coli spp., a Gram negative facultative anaerobe, has been
one of the most studied microorganisms. Although it is a typical resident of the human and
animal intestinal tracts (17–19), several strains have acquired specific virulence factors that
are known to cause diseases to either humans or animals (20–22). Based on the virulence
mechanism(s) they use to interact with eukaryotic cells, these pathogenic strains have been
classified into pathotypes, six of which have been identified as diarrheagenic:
enterohemorrhagic E. coli (EHEC), enterotoxigenic E. coli (ETEC), enteroinvasive E. coli
(EIEC), enteropathogenic E. coli (EPEC), enteroaggregative E. coli (EAEC), and diffusely
adherent E. coli (DAEC) (20,22–24). EPEC and ETEC most commonly cause diarrhea in
infants and mostly frequently in developing countries (20,24). On the other hand, EIEC,
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which causes dysentery and bloody diarrhea, is an intracellular pathotype that invades and
replicates within colonic epithelial cells (20,23). In fact, EIEC is the only pathotype that
does not adhere to the epithelial cells using their fimbriae or pili, as the rest of the
pathogenic E. coli do (22). EAEC and ETEC are known to be major causes of traveler’s
diarrhea. In addition, the EAEC mechanism of pathogenicity relies on bacterial cell
stacking attachment to enterocytes from either the large or the small bowel, forming
“bricked wall” biofilms on the cell surface (20,22,25). DAEC is a relatively new pathotype,
which requires attachment to eukaryotic cells, but through the formation of finger-like
cellular projections that engulf the bacterial cell (20,23,26). All five of these pathotypes
are relevant to public health due to their potential to cause disease through consumption of
contaminated food and water. Much research has focused on understanding the EHEC
pathotype that has been in the spotlight since the first serotype, E. coli O157:H7 was
discovered in 1982 during an outbreak related to contaminated ground beef hamburgers
(21,27,28). Since then, E. coli O157 has been persistently linked to food and waterborne
outbreaks with severe health consequences including hemorrhagic colitis and hemolyticuremic syndrome (HUS). In addition, several studies have reported that E. coli O157 has
an extremely low infectious dose (<100 cells) (20,26,29,30), thermal resistance above
normal ground beef cooking temperature (71°C) (29,31,32) and acid resistance that allows
survival in environments with low pH (33–36). These features, together with the
production of one or both of the potent Shiga toxins, Stx1 and Stx2, (18,37,38) have made
E. coli O157 a major foodborne pathogen that requires sensitive and precise surveillance
coupled with control measures to counteract its public health and economic effects.
Main Reservoirs and Transmission
Through the years, the primary reservoir of E. coli O157 was shown to be the gut of
ruminants (39,40), most frequently cattle, sheep, and goats (40,41). However, cattle are
considered the major source of E. coli O157 (31,39,40) mainly due to the consumption of
beef, which can become contaminated during slaughtering through contact of the carcass
with hides contaminated with feces (27). In fact, from all food categories, ground beef has
been consistently considered as the main cause of human EHEC infections (27,42,43).
Interestingly, cattle remain asymptomatic while carrying and shedding the pathogen in
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their feces (43–45) at a typical range of 10 to 100 CFU/g of feces (44). Normally, E. coli
O157 is found at the terminal end of the colon, although colonization has been shown to
be more prominent at the recto-anal junction (44,46). This has led to the hypothesis that
some cattle, called “supershedders”, can excrete higher levels, >104 CFU/g of feces, of
E. coli O157 (18,44,46,47). Although they represent less than 10% of the total cattle,
studies have shown that “supershedders” might be responsible for 99% of the E. coli O157
environmental contamination (44). This represents a major risk factor for humans because
E. coli O157 is known to remain viable in feces, soil, and water for extended periods of
time (40,46). For example, contamination of produce fields directly with feces or indirectly
through contaminated water has been traced as the potential cause of the increasing number
of E. coli O157 outbreaks linked to leafy green vegetables (45,48).
Focusing on North America, two recent studies estimated that 65-68% of E. coli O157
infections in the USA are transmitted by food products (27,43). In fact, many of the recent
outbreaks are linked to leafy vegetables, which, together with beef, caused >25% of the
E. coli O157 outbreaks and >40% of the illnesses reported in the 2003-2012 period in the
USA (27). In agreement with USA findings, the most recent source attribution of enteric
illness data in Canada estimated that foodborne transmission is still considered the main
route (49). However, these estimations were obtained through an expert elicitation rather
than an outbreak data analysis and were based on the analysis of a broad range of
transmission routes, including water, person-to-person and animal contact in addition to
food. Concerning this, E. coli O157 outbreaks are also linked to additional minor
transmission routes besides contaminated food (2,27,43,44), such as water (2,27,43,44),
direct contact with infected animals (27,43,44) or their environment (27,43) (Figure 1A).
Moreover, person-to-person contact and fomite are also possible sources (27,43), although
from 1982-2002 it only accounted for 14% of E. coli O157 outbreaks, mainly in child
daycare centers (43); while from 2003-2012 it represented only 10% of the outbreaks
identified in the USA (27).
A different study, using a historical analysis of outbreaks from 1976 through 2005
estimated that 37% of the E. coli infections were linked to beef while 23% and 11% were
related to cooked multi-ingredient dishes and other types of meat except beef, respectively
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(50). This study provided the first extensive analysis of illness attributions from Canadian
foodborne outbreaks however, it did not reflect the emerging impact of fresh produce. In
light of the high consumption rate of fresh fruits and vegetables in Canada, a recent report
gathered data from 27 produce-related outbreaks occurring from 2001 through 2009 and
estimated that 66% of these were caused by bacteria, of which 33% were attributed to
E. coli O157 (51). These data show that, together with beef, fresh produce is becoming a
major source of E. coli O157 infections (51).
Mechanisms of Pathogenesis
E. coli O157 is considered a zoonotic foodborne pathogen of major public health concern
and is one of the predominant pathogens in the etiology of gastrointestinal diseases.
Infection of humans occurs after ingestion of contaminated food or water. Due to its acid
resistance, E. coli O157 is able to overcome the acidic environment of the stomach and
colonize the intestine, the early stage of the infection (18). It is believed that attachment to
epithelial cells occurs in the colon and distal small intestine (22,52) through the formation
of an attachment and effacing (A/E) lesion, which is frequently related to the development
of bloody diarrhea and HUS (18). EHEC possesses a pathogenicity island called the locus
of enterocyte effacement (LEE), which contains the genetic information that encodes for
the synthesis of all proteins necessary for the A/E lesion (18,20). Intimin, which is a product
of the eae (E. coli attaching and effacing) gene, is the outer membrane protein involved in
the A/E lesion and is responsible for the adherence of E. coli O157 to the surface of the
epithelial cells, triggering structural changes, such as loss of microvilli and pedestal
formation (18,21,42) (Figure 1B). Therefore, the A/E lesion is a localized effect, whereas
systemic complications arise due to the release of Stxs (18,37). The presence of the LEE
virulence factor distinguishes EHEC strains from other Shiga toxin producing E. coli
(STEC) strains. Therefore, EHEC, including E. coli O157, is considered a subset of the
STEC group, which is known to produce hemorrhagic colitis and HUS due to the presence
of the LEE and expression of Stxs (21,52).
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Figure 1. Overview of the routes of transmission and human disease due to E. coli
O157. A) The main source of E. coli O157 (cattle) is represented together with the major
routes of transmission to humans: a) direct contact with cattle, b) consumption of
contaminated food from bovine origin like milk and/or meat or c) through environmental
contamination by feces that can be passed on to water or soil and thus, spread
contamination to other food products. B) Once E. coli O157 is ingested by humans, it
survives passage through the gastrointestinal tract until it reaches the colon, where it
adheres to the epithelial cells through the membrane protein intimin. The latter is required
for the formation of the characteristic A/E pedestal lesion and triggers the release of Stxs.
The Stxs are then absorbed into blood vessels where it can travel to the kidneys, a major
organ site for E. coli O157 infection. Images were modified from Gyles (18) and Croxen
et al. (22).
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Stxs are the other major virulence factor that E. coli O157 possesses. They are classified
into two main groups, Stx1 and Stx2, based on their antigenicity (53). E. coli O157 can
produce both or only one type of Stx (21,42,54). Although Stx1 is structurally identical to
the toxin produced by S. dysenteriae type 1, some studies have shown that Stx2 is 1,000
times more toxic for renal cells thus Stx2 is commonly associated with the pathogenesis of
HUS (18,21,42,54). Once the A/E lesion is formed, Stxs are released and bound to their
receptor within epithelial cells (18), triggering the uptake of the toxin by endocytosis
(18,21). It is after the onset of hemorrhagic colitis that Stxs enter the blood, leading to renal
failure associated with HUS (53) (Figure 1B). Stxs will produce damage to the vascular
endothelial cells in the glomeruli and arterioles of the kidney, triggering clotting and
clogging resulting in accumulation of waste in the blood (20,21), Meanwhile in the
intestine, Stx is also involved in the development of bloody diarrhea, hemorrhagic colitis,
and induction of apoptosis and necrosis of the epithelial intestinal cells resulting in
perforation (20,22).
Signs and symptoms may appear within an incubation period of 3-8 days (2,21),
progressing from stomach cramps (2,27,54), watery diarrhea (52,54,55), bloody diarrhea
(2,27,52,54) and vomit (2,27) to hemorrhagic colitis (52), renal failure (56) and/or HUS
(27,52,56). However, the severity of the disease depends on complex mechanisms that
interplay between regulation of the expression of virulence features and host factors (57).
In fact, the role of other virulence factors can be as relevant as the LEE island, because
atypical EHEC strains lacking the LEE have occasionally been shown to produce HUS
(20,42,54). Additional virulence factors include hemolysin, a toxin that can contribute to
the disruption of erythrocytes (18,21,57), O157 lipopolysaccharide that has a
proinflammatory effect (53), and secreted proteins that aid in the formation of the A/E
lesion (21,42), among many others.
Recovery from the disease can take 8-10 days (2). Generally, infants, young children, the
elderly and the immunocompromised are more susceptible. In fact, 5-15% of patients may
develop HUS, especially young children (53–55). HUS involves acute renal failure,
thrombocytopenia, and microangiopathic hemolytic anemia (20,21,54) with a fatality rate
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of 3-5% (2,21). Thus far, there is no treatment for E. coli O157 infections, other than
monitoring the illness, providing comfort, and preventing dehydration through proper
hydration and nutrition. In addition, patients who develop complications may need further
treatment, such as dialysis, to treat kidney failure (54). Although treatments have been
developed, it has been shown that some E. coli O157 strains can increase the production of
Stxs when exposed to antibiotics such as ampicillin, tetracycline or norfloxacin (55). On
the other hand, some approaches have focused on preventing the release of Stxs during the
diarrheal phase to decrease further damage, however results lacked efficacy (37).
Therefore, current research is focused on improving the prevention of infections by
adopting measures throughout the food chain to reduce the risk of transmission of E. coli
O157 to humans.
Epidemiology and Economic Burden of E. coli O157 Infections
In 2015, several published national, regional and global assessments of the burden of
foodborne disease described E. coli O157 as one of the foodborne pathogens contributing
to the overall burden of foodborne disease (4,15,27,58,59). The global initiative launched
by WHO, namely the Foodborne Disease Burden Epidemiology Reference Group (FERG),
estimated that STEC infections accounted for 1 million incidents, causing 128 deaths and
loss of 13,000 DALYs in 2010, worldwide (4). A 2014 study of the global incidence of
STEC infections estimated 2,801,000 acute illnesses, 3890 cases of HUS, 270 cases of
permanent end-stage renal disease and 230 deaths annually (56). Of note, global estimates
grouped STEC O157 and non-O157 together, however findings suggested that sequelae
and fatalities were higher with STEC O157 cases (56). On the contrary, the number of
STEC cases was below those attributed to other foodborne pathogens including typhoid
fever and nontyphoidal salmonellosis nevertheless, the relevance of STEC infections relies
on the severe sequelae that follow infection (56). Frenzen et al. reported that in the USA,
medical care and loss of productivity due to STEC O157 cost approximately $30 million
and $5 million in the USA annually, respectively (60). Moreover, an average of $635
million US was estimated to be the total economic cost of 63,000 annual cases of STEC
O157 caused foodborne illness, according to Scharff (61). On the other hand, in Canada,
Sockett et al. estimated that long-term outcomes cost $377 million CAD annually for
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approximately 37,800 on-going cases, while new primary cases had a cost of illness of
$26.7 million CAD (22,300 cases annually), adding up to a total annual cost of illness of
$403 million CAD (62). Despite these estimates being dramatic, they do not represent the
true total cost of E. coli O157 illness because they mainly focus on medical and
productivity losses, which ignore industrial and/or government costs (i.e. cost due to
recalls) (61,62).
E. coli O157 Outbreaks, Recalls and Regulatory Aspects
The first E. coli O157 outbreak ever reported was in 1982 during an investigation of
hemorrhagic colitis linked to contaminated hamburgers (28,63). However, in 1992 the Jack
in the Box E. coli O157 outbreak, the largest outbreak ever recorded up to that time, caused
502 illness cases from which 31% were hospitalized, 9% developed HUS and 0.6% died
(64,65). Further investigations found that improper processing and cooking of hamburgers
were the main causes, which stimulated the establishment of regulatory measures to reduce
meat contamination and public health actions to educate consumers about proper meat
handling (64,65). In fact, this outbreak is considered a breakthrough in the evolution of
food safety, especially for the control of E. coli O157 in food products. Indeed, in 1994 the
United States Department of Agriculture Food Safety and Inspection Service (USDAFSIS) established that E. coli O157 was to be considered an adulterant in beef, prohibiting
the sale of contaminated meat and, subsequently, starting programs for its detection (66–
68). Other measures that were taken to prevent outbreaks were as follows: 1) establishment
of new cooking temperature guidelines in the Model Food Code for restaurants by the US
Food and Drug Administration (FDA) (63,67); and 2) development of objective measures
of meat doneness suggested by the National Livestock and Meat Board’s Blue Ribbon Task
Force in the USA (63,67). More recently, the USDA-FSIS determined that E. coli O157
was more prevalent than initially thought, and thus stricter regulations that included testing
of hides and pre-eviscerated carcasses were recommended (69). These modifications to the
testing programs influenced members of the beef industry positively, which was reflected
in declining numbers of positive E. coli O157 beef samples and thus in the incidence of
infection cases in 2002 (43).
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Meanwhile in Canada, in 1990, STEC (including E. coli O157) became a notifiable disease,
requiring the Public Health Agency of Canada (PHAC) to report any cases (66). Recently,
the Canadian “Guidance Document on Escherichia coli O157:H7 and E. coli O157:NM in
Raw Beef” was released. This document provides better recommendations, focusing on
Good Agricultural Practices (GMPs) and Hazard Analysis and Critical Control Point
(HACCP) programs, aiming to enhance the verification and control to minimize the
prevalence of E. coli O157 in raw beef products (70). Due to the nature of raw beef, it
possesses a high risk for contamination with E. coli O157 either during slaughtering or
further processing and/or packaging. In addition, according to Statistics Canada and the
Canadian Meat Council, beef continues to be the meat with the highest per capita
consumption of 12 kg (boneless weight) annually (71). Therefore, in pursuit of minimizing
the risk that this highly-consumed product represents to Canadians, Health Canada
established that both precursor materials and finished raw ground beef products and beef
products processed for raw consumption should not contain detectable levels of E. coli
O157 (70).
Despite the improvement of food safety practices, including creation and implementation
of more stringent regulations, outbreaks are still occurring sporadically around the world.
Of note, outbreaks not only have a huge health impact, but they also represent an economic
burden for food manufacturers. In 2007, Topps Meat Company recalled approximately
21.7 million pounds of frozen ground beef patties (72), which caused the company to leave
the market shortly afterward (68). Moreover, global food trade means greater responsibility
towards ensuring food safety across national borders because international distribution
scales up the effect of potential outbreaks. Indeed, cases such as the XL Foods Inc. recall
in 2012 proved the tremendous impact not only to the company, but also to our country’s
beef industry. XL Foods Inc. exported products to over 20 countries; thus the safety of
Canadian beef was questioned after the recall, not only within Canada but worldwide. This
lead to an estimated cost to the Canadian beef industry between $16 million and $27 million
CAD (73). Not surprising, this recall is considered the biggest recall in Canada. Some of
the major outbreaks in North America are presented in Table 1. Although beef products
continue to be the main source of E. coli O157 outbreaks and recalls in Canada and the
USA (27,43,50,74), it is evident that fresh produce is becoming just as relevant in the
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Table 1. Major E. coli O157 foodborne outbreaks in the USA and Canada, 2006-2016.
No. of cases

Country

Product Recall
(lbs product)

Reference

0

USA

NR

(72)

NR

0

Canada

No

(75)

NR

NR

NR

Canada

NR

(75)

19

5

2

0

USA

Yes

(72)

Wolverine Packing Company’s ground beef

12

7

0

0

USA

(1.8 million)

(72)

2013

Gort’s Gouda Cheese Farm

28

4

1

1

Canada

Yes

(75)

2013

Cardinal Meat Specialists Limited’s frozen
beef burgers

8

2

0

0

Canada

Yes

(75)

2013

FreshPoint Inc.’s shredded lettuce
distributed to some KFC and KFC-Taco
Bell restaurants

30

13

1

0

Canada

Yes

(75)

2013

Glass Onion Catering’s ready-to-eat salads

33

7

2

0

USA

(181,620)

(72)

2012

State Garden’s pre-packaged leafy greens

33

13

2

0

USA

(31,000)

(72)

2012

XL Foods’ beef products

18

6

0

0

Canada

(12 million)

(75)

2011

Romaine lettuce

58

34

3

0

USA

NR

(48,72)

2011

Palmyra Bologna Company’s Lebanon
bologna

14

3

0

0

USA

(23,000)

(72)

2011

DeFranco & Sons’s in-shell hazelnuts

161

12

0

0

USA and
Canada#

(20,000)

(72,76)

2010

Bravo Farms’ cheese

38

15

1

0

USA

(105,000)

(72)

2010

National Steak and Poultry’s beef

21

9

1

0

USA

(248,000)

(72)

2009

Chicken (suspected)

69

5

NR

NR

Canada

NR

(77)

2009

Fairbanks Farm’s beef

26

19

5

2

USA

(545,700)

(72)

Year

Implicated food

2016

Total

Hospitalizations

HUS

Deaths

Jack & The Green Sprout’s alfalfa sprouts

11

2

0

2015

Not identified

31

7

2015

Leafy greens

12

2015

Taylor Farm Pacific, Inc. celery and onion
diced blend used in Costco rotisserie
chicken salad)

2014

15

Year

Implicated food

2009

No. of cases

Country

Product Recall
(lbs product)

Reference

Total

Hospitalizations

HUS

Deaths

JBS Swift Beef Company’s beef

23

12

2

0

USA

(421,280)

(72)

2009

Nestle Toll House raw refrigerated cookie
dough

72

34

10

0

USA

3.6 million
packages

(72,78)

2008

Aunt Mid’s Produce Company’s iceberg
lettuce

742

21

NR

0

USA and
Canada

No

(51,77)

2008

Romaine lettuce

29

NR

1

NR

Canada

No

(51,77)

2008

Harvey’s Restaurant (Spanish onions
(suspect))

235

26

NR

0

Canada

No

(51,77)

2008

Kroger/Nebraska Ltd. ground beef

49

27

1

0

USA

(5.3 million)

(72)

2007

Totino’s and Jeno’s frozen pizza (pepperoni)

21

8

4

0

USA

5 million pizzas

(72,79)

2007

Topp’s ground beef patties

40

21

2

0

USA

(21.7 million)

(72)

2006

Lettuce (suspect)

7

NR

NR

NR

Canada

NR

(51)

102

31

3

USA and
Canada#

NR

(51,72,80,81)

2006

Natural Selection Foods, LLC’s fresh
bagged spinach

199

3

2006 Taco Bell
71
53
8
NR
USA
NR
(72)
NR: not reported; Yes: there was a product recall but no information regarding quantities; No: there was no product recall linked to the outbreak.
1In Canada, 8 cases were found, all of them hospitalized
2Three cases were in Canada
3One case was reported in Ontario, Canada.
#The recall comprised both countries.
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increasing number of E. coli O157 outbreaks in Canada and the USA (43,48,51,80). In fact,
after the 2006 outbreaks caused by fresh spinach in the USA, the FDA announced the
implementation of the “Leafy Greens” initiative with the aim of identifying the potential
public health concerns inherent to these products (82). Finally, outbreaks and recalls
represent a relevant source of information and provide an opportunity to learn while
prompting governments to improve guidelines and regulations to strengthen the food safety
systems throughout the whole food chain.
1.3. Current State-of-the-Art in Detection of Food Pathogens
It is evident that food pathogen detection is an important environmental health milestone
towards reducing the burden of foodborne diseases and economic losses due to
contaminated food. The major objective of testing plans is to verify the adequacy of control
manufacturing processes during food production (83). Focusing on E. coli O157, the
impact of testing strategies on reducing risk has been proved since 2002, when the USDAFSIS reassessed the HACCP plans and extended the testing programs, after determining
that E. coli O157 is likely to occur at all stages of raw beef production (69). Further
implementation of these measures, resulted in a reduction of the prevalence of E. coli O157
in ground beef from 0.73% in 2002 to 0.17% in 2006 (70), while the number of recalls also
decreased from 21 in 2002 to 5 in 2005 (84). In Canada, data from 2009 have been
encouraging, showing that testing of beef trim, potentially used for the production of
ground beef, has prevented contaminated product to be further processed (70). Currently,
as part of the new guidance document on E. coli O157, it is recommended that all precursor
material used for the production of raw ground beef and beef products should be tested and
only lots below detectable levels should be accepted (70). Therefore, testing programs,
combined with proper sampling protocols and process controls, have played a key role not
only in reducing the risk of E. coli O157 contamination, but also in determining the efficacy
of the control measures established to prevent E. coli O157 contamination throughout the
manufacturing process.
In order to implement successful testing programs, effective detection methods must be
available. Ideally, pathogen detection methods used for food testing should be rapid and
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easy-to-use for early identification of potential hazards. Conversely, however, the “gold
standard” conventional testing methods are known to be time-consuming and lengthy
because they rely on culture, isolation, and biochemical identification. Food pathogens are
commonly found in lower concentrations than food microbiota (85); thus a selective
enrichment step is required to enable the recovery of the target microorganism while
suppressing non-target organisms (86,87). The enrichment step involves transferring the
food sample into a selective nutrient medium and incubation to allow the multiplication of
the target pathogen to a detectable level (86,88,89). Furthermore, an isolation step using
selective and differential agar plating helps to identify presumptive colonies of the target
pathogen. Lastly, typical colonies are screened using biochemical and/or serological
analysis. Presumptive results from this procedure can take up to four days, while
confirmation may require up to one week (86,90,91). Therefore, one of the main challenges
that food producers normally face when implementing testing protocols is that lengthy
methods can delay the release of minimally processed products with short shelf life such
as raw meat until they are screened and considered to be microbiologically safe (88,92).
Consequently, a major research field has focused on the refinement of current methods and
the development of more efficient technologies designed improve testing programs. Based
on the needs of the food sector, three main characteristics of such tests are crucial: speed,
sensitivity, and ease-of-use (16,91,92). Interestingly, the food pathogen testing market was
valued at 7.42 billion USD as of 2015 and is expected to continue growing due to the
establishment of ever more stringent regulations (93). Moreover, in a report from 2003, it
was estimated that the beef and poultry industry in the USA performed approximately 369
tests per processing plant per week, representing 22% of the total microbial tests within the
USA food industry (91). Therefore, due to the establishment of new testing plans and recent
enhancement of regulations applicable to the meat industry, it is expected that the food
pathogen rapid testing market will continue growing.
Trends in Rapid Point-of-Care (POC) Methods
The combination of scientific and technological approaches to improve global health care
has been the basis of the exponential growth of novel POC diagnostic techniques. The main
application of POC tests has been in the clinical diagnostics field to screen for infectious

18

diseases such as dengue, hepatitis B, HIV/AIDS, malaria and syphilis in patients from
developing countries (94–97). The success achieved by on-site disease diagnosis and the
rise in the market availability of POC tests helped to establish the optimal characteristics
that a POC test should have. Indeed, in 2004 WHO’s Sexually Transmitted Diseases
Diagnostics Initiative determined that a POC test should comply with the “ASSURED”
principle, which means: Affordable, Sensitive, Specific, User-friendly, Rapid, Equipmentfree and Delivered (95–98). Based on this, a POC test can be defined as a simple and
affordable assay for food producers that is performed at the location where the sample is
found, and will provide a rapid outcome, which is crucial for taking appropriate immediate
action (95,98,99).
Even though most of the progress has been achieved in developing medical diagnostic
tools, affordable and rapid technologies are also necessary to improve other fields such as
environmental and food safety (99–101). As noted above, there is a dire need in food safety
diagnostics for more rapid and sensitive methods that can replace traditional techniques
that require more than two days to determine the presence of pathogens in food samples
(91). However, due to recent advances in biotechnology, chemistry, and molecular biology,
it has been possible to address some of the challenges that conventional pathogen detection
possesses. In fact, significant advances towards developing rapid state-of-the-art
microbiological methods that do not require laboratory facilities or special training so that
they can be used throughout the food chain, but maintain high specificity and sensitivity,
have occurred (101). The upcoming sections will provide an overview of the most relevant
methodologies that are influencing the development of rapid POC tests for food safety.
1.3.1.1 Molecular methods
This research field has significantly grown in the last few decades with an increasing
number of commercial diagnostic tools available not only in the clinical market but also in
the food safety market. Application of nucleic acid-amplification tests (NAATs) such as
polymerase chain reaction (PCR), quantitative reverse transcription polymerase chain
reaction (RT-qPCR) (90,102–107), and nucleic acid sequence-based amplification
(NASBA) (68,86,90,106–109) have been commonly reported in the literature for pathogen
detection. Moreover, a recent approach has focused on developing NAATs based on loop-
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mediated isothermal amplification (LAMP), with the advantage that it does not require
thermocycling instruments or purified DNA (90,102,106), an important advantage for a
POC test model. LAMP is known to be more specific and sensitive than standard PCR
methods (106). Conversely, multiplex quantitative PCR (qPCR) has focused on the
detection of several pathogens using only one sample, markedly reducing the labor
intensive limitation of culture methods and traditional single PCR techniques
(86,90,106,107).
Regardless of the advantages that molecular diagnostic methods have such as specificity
and sensitivity (95), one of their major shortcomings is they can detect DNA/RNA from
dead microorganisms, resulting in misinterpretation of results in complex samples such as
food (107). Moreover, most of these methods still require complex equipment, special
training, several steps for sample preparation, and are considered to be expensive processes
for routine food analysis when compared to a conventional culture method (95,107,110).
1.3.1.2 Optical methods
Although some optical techniques have been used for more than a decade, the main
challenge has been to transfer them into portable POC tests. The best example is surface
plasmon resonance (SPR), which has the advantage of detecting molecular interactions
without the need for labeled reagents (95,96). Thus, it can be used with nucleic acids or
immunoassays (96). SPR has been used to detect C. jejuni, S. enterica ser. Typhimurium,
Y. enterocolitica and E. coli O157, as well as other pathogens (108). Another optical
technology that has been exploited for potential POC test development is surface enhanced
Raman spectroscopy (SERS). Contrary to SPR, this technique requires a SERS tag
component, normally gold or silver nanoparticles coated with a SERS dye encapsulated
with silica and conjugated with the detection antibodies, which is combined with traditional
Raman spectroscopy (111,112). This technique has been used to monitor, in real time, the
growth of E. coli O157 during enrichment, showing high sensitivity and specificity with
food samples (111). Some of the advantages of Raman spectroscopy are speed and minimal
manipulation of samples (94).
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1.3.1.3 Nanotechnology
Some of the advances in nanotechnology in the diagnostics field are focused on labeling
with metal or magnetic nanoparticles for immunoassays (96,111,113). The range of
reagents for labeling goes from antibodies (106,114–116) to nucleic acids (99), the basis
for biosensors (nanosensors) for real-time detection (108,117). Quantum dots are also a
novel alternative for fluorescent labeling because they possess higher brightness,
photostability and are more resistant to chemical degradation that traditional fluorescent
dyes (96,99,118). In the food safety field, quantum dots have been used for detection of
E. coli O157, Salmonella and L. monocytogenes (115). Working with nanomaterials has
the advantage of increasing the number of reactive sites, resulting in higher sensitivity and
specificity (94). The development of nanosensors represents a portable alternative with a
shorter time-to-result at a low cost (117). Nanocantilevers, which are made of silicon-based
materials and can detect biological binding interactions with high sensitivity and short
time-to-result, exemplify this novel class of label-free nanosensors (101,117).
1.3.1.4 Microfluidics
Microfluidics represent a breakthrough in the POC research field with the development of
the lab-on-a-chip or micro total analysis systems (µTAS) technology, recently applied to
the analysis of a variety of biological samples (96,100,119). The introduction of this type
of nanosensors has the advantage that sample processing, reactions, and reading of results
happens in a miniature flow-through format requiring only small sample volumes
(95,96,117). In addition, engineering efforts have resulted in platforms that are accessoryfree but contain complete analysis systems including fluid handling, and sample separation
(119,120). Interestingly, low-cost devices have been produced using paper instead of
plastic molds or nitrocellulose, with the extra benefit that paper allows multiplex analysis
using microchannels (100,121,122). Moreover, paper is easily modifiable to bind proteins,
DNA or other small molecules and allows for the development of colorimetric assays due
to its inherent white color (122). Microfluidics have been combined with other techniques
such as immunoassays, capillary electrophoresis, and DNA-analysis to design efficient
microreactors (119). In fact, it has been possible to create DNA microarrays, which have
been used to better understand the interactions between host and pathogens as well as the
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mechanisms of microbial drug resistance (95). It is evident that microfluidics represents
one of the most promising research areas in POC test development, with the potential to
optimize sensitivity and specificity without requiring laboratory equipment.
1.3.1.5 Immunoassays
Enzyme immunoassays are one of the first described immunochemical techniques still
widely used for diagnostics due to its ability to produce a colorimetric reaction that can be
quantitated and visualized at a macroscopic scale (95,123). The most well-known
immunoassay is the enzyme-linked immunosorbent assay (ELISA), which has become a
notable tool for in vitro diagnostics, regulatory and quality assessments. Immunoassays are
a versatile method that has been combined with several of the technologies described
above. Recently, Weidemaier et al. reported a nanotechnology-based immunoassay using
antibody-conjugated magnetic SERS nanoparticles added directly into the food sample,
which capture the target pathogens as they grow and produces a real-time detectable signal
read through the sample vessel (111). Moreover, Ho et al. developed a colorimetric
immunoassay based POC test using immunoliposomes with an encapsulated visible dye to
detect E. coli O157 (124). However, in light of developing POC tests, lateral flow
immunoassays (LFIA) or immunochromatographic test strips are considered the most
popular POC technology in clinical diagnostics (95,96). In fact, they are defined as an
ASSURED technology (125,126). Thus, it is not surprising that it has also gained
popularity within other fields such as food safety and has become a target technology for
research (127). LFIAs are similar to an ELISA because they rely on the principle of
antigen-antibody binding (128). Therefore, their sensitivity and specificity will be
completely dependent on the concentration and accessibility of the target analyte in the
sample, as well as of the binding strength and affinity between the antibody and the antigen
(106). Contrary to ELISA, LFIAs have the advantage that results can be obtained relatively
fast and do not require intensive training (95,96). Similar to other immunoassays, LFIAs
have been combined with other techniques such as the prototype developed by Mondesire
et al. This device consists of a POC LFIA, which relies on a solid-phase extraction merged
with a NASBA or PCR technique for analysis of clinical samples and detection of
pathogenic bacteria (129). Lateral flow assays that are combined with nucleic acids are
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commonly known as NALF or NALFIA (nucleic acid lateral flow or nucleic acid lateral
flow immunoassay). The former does not require antibodies because it uses amplicons or
probes as capture and detection reagents, while the latter uses antibody recognition against
a labeled amplicon (128). By combining LFIA not only with DNA/RNA techniques and
also with nanoparticles labeling or miniaturized thin-layer chromatography, the sensitivity
and selectivity of the assays has been improved (130).
1.4. Overview of Lateral Flow Immunoassays (LFIAs)
The first lateral flow or dipstick assay was developed in the 1960s for quantifying glucose
in urine (131). Its principle relied on an enzymatic reaction that caused a color change,
which was compared to a color chart to obtain a semi-quantitative result (131). However,
it was two decades later, in the mid-1980s, when LFIAs were introduced to the clinical
diagnostic field with the development of the pregnancy test (100,127). Shortly after, their
application gradually expanded to other fields, where on/off signals were sufficient, such
as drug screening (100), detection of cardiac markers (121), food (130,132,133) and
environmental applications (100,130,133), particularly in resource-limited countries.
LFIAs possess a long history within medical diagnostics. Several publications have
focused on compiling state-of-the-art of LFIAs (130), which includes the development of
quantitative or semi-quantitative LFIAs by using photometric readers (96,132) or signal
amplification enhancement (95,96). However, LFIAs are relatively new in the food safety
industry, where they have gained attention for detection of toxic compounds such as
mycotoxins and pathogenic bacteria (90,133). Of note, detection of mycotoxins has been
the major focus for developing quantitative LFIAs complemented with a mobile scanner
(134–136). However, for pathogen detection, LFIAs have been unable to detect
concentrations as low as 10 cells per g or ml, the infectious dose of some pathogens, such
as E. coli O157 (21). Therefore, concentration techniques such as magnetic and
paramagnetic beads (95,137,138) and/or pairing with enrichment steps (23,68,86) have
been developed for maximizing sensitivity and improving the limit of detection. Following
the recent implementation of stringent food safety regulations, the scientific and industrial
desire to develop LFIAs to detect the major pathogens has increased due to their ease-ofuse, rapid outcome, and lack of training needed to perform the test. As such, development
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of LFIAs has mainly focused on presence/absence formats for rapid and easy screening of
food samples (90,106,133). Indeed, progress has been such that Dzantiev et al. compiled
the recent advances on immunochromatographic assays developed for food analysis
between 2007 and 2013 (132). These authors estimated that 14% of the scientific
publications on immunochromatographic test systems were focused on the development of
LFIAs for pathogen detection whereas 30% focused on mycotoxins detection.
Furthermore, low development costs and facile production (127) give LFIAs an extra
advantage over other technologies. From an economic perspective, a publication from 2009
estimated that the food and beverage sector are the largest producer of rapid tests while
being the third highest consumer of LFIA-based tests with $30 million USD generated in
2007, just below the clinical and veterinary sectors (139). LFIAs combine the selectivity
and sensitivity of immunoassays, such as ELISA, with the simplicity and speed of
operation of a POC device. LFIAs are designed to provide results in less than 15 min after
loading the sample; thus they represent an excellent alternative for the routine testing of
food products.
LFIAs Principle and Main Components
LFIAs rely on the movement, through capillarity, of a liquid sample that is initially loaded
onto a sample pad found at one extreme of the nitrocellulose membrane, towards the other
extreme where an absorbent pad will capture the remainder of the liquid. Capillary
movement through the membrane allows the sample to pass through different zones, where
immobilized recognition reagents will interact with the target analyte to form complexes
that will attach within the test zone, while unreacted reagents will continue flowing to the
control line, where they will attach (130,140). The target analyte complexes captured in
the test zone will produce a visible line, similar to the one produced by unreacted reagents
captured within the control line. However, the control line will develop whether or not the
sample contains antigen, thereby ensuring that the test system is functioning properly
(Figure 2).
A typical LFIA format, besides the sample and absorbent pad, will include a conjugate
release pad right after the sample pad, where recognition reagents are kept ready to interact
with the target analyte as the sample starts flowing (130,140). Recognition reagents can be
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Figure 2. Overview of the main components of a typical LFIA. Once the sample is
applied in the sample pad, it will move through capillarity along the conjugation pad and
nitrocellulose membrane until it reaches the absorbent pad. In the conjugation pad, the
target antigen will react with some of the detection reagents, which will vary depending
the type of assay (e.g. colloidal gold nanoparticles). In a direct assay, the detection
reagent-antigen complex will continue traveling until it reaches the test line, where an
immobilized capture reagent will trap the complexes and produce a positive signal. The
rest of the unbound reagents bind to the control line.
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formed by the primary detection antibody or a secondary antibody against the primary,
which are conjugated to a label or marker (141). Although new alternatives for preparing
recognition reagents, such as quantum dots (141,142) and liposomes with colored dyes
(124,141,143), are being introduced, colloidal gold nanoparticles remain the most
frequently used label alternative for LFIAs mainly due to their availability and low cost for
large scale production (114,130,140,141). In addition, two main types of reactions are
commonly used, which are based on the analyte to be determined. The direct assay
normally is selected when the target has more than one epitope. In this case, the recognition
reagent will bind to one epitope, while the capture reagent, normally attached to the test
line, will bind an alternative epitope (130,133,140). In this case, the development of a test
line is directly linked to the presence of the target analyte. On the other hand, the
competitive assay is frequently selected when the target analyte is a small molecule, which
is the case for mycotoxins (134,144). Two alternatives can be used, either the capture
reagent is attached to the test line and labeled analyte competes with the sample analyte, or
a protein-analyte is attached to the test line while the labeled antibody is initially mixed
with the sample. In both cases, a colored test line will be indirectly linked to the presence
of the target analyte in the sample (114,130,133). Therefore, because bacteria possess
several surface antigens, the sandwich assay is preferred for development of LFIA for
pathogen detection.
Since the development of the LFIA technology, its main structural components have
remained the same, while major improvements have focused on the analytical reagents and
reaction conditions to enhance the performance of the assay according to its final
application. In fact, the proper functionality of a LFIA depends on the selection of the
capture and detection reagents, which are often antibodies. Generally, two types of
antibodies are included in a sandwich assay, a polyclonal and a monoclonal antibody (pAb
and mAb). The former is often immobilized in the test line zone acting as a capture
antibody, while the latter will act as detection antibody either by direct labeling or by using
a secondary labeled antibody against the mAb. Generally, the detection reagent will be
dried in the conjugation pad, waiting for the sample to start running through the device for
interaction with the target analyte. However, an alternative consists of the dried detection
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reagents being stored in a tube, to which the sample is added, acting as a reconstituent,
before inserting the LFIA test strip (145). Although both capture and detection antibodies
are responsible for the analytical characteristics of the LFIA based on their interactions
with the target analyte (146), mAbs are key in determining the specificity of the method.
Therefore, efforts are continuously being made to maintain and improve the affinity of the
mAbs. This includes using labeled secondary antibodies instead of direct labeling of the
mAb because it has been shown that conjugation can decrease the affinity of the antibody
while interfering in the antibody-antigen binding due to steric hindrance (130). In addition,
research has focused on developing more specific antibodies with the adequate binding
characteristics for their application in immunoassays. This has included optimizing
hybridoma technologies as well as the development of antibody derivatives through genetic
engineering (147). As a result of these approaches, LFIAs have evolved to comply with the
needs demanded by the recent diagnostics markets.
1.5. LFIAs for Detection of E. coli O157 in Food
LFIAs, similar to most of the novel technologies that have been developed for pathogen
detection, rely on biorecognition of surface antigens in order to detect whole bacterial cells
(101). Some of the surface antigens found in E. coli O157 are commonly used as detection
biomarkers, while also serving to classify E. coli isolates by serotyping. The latter is a
technique based on three main antigens: “O”, “H” and “K”, which are frequently identified
by serology (52,148). The former is the outermost variable part of the polysaccharide in
the outer membrane (somatic antigen), the second is a flagellar protein, and the third is a
capsular antigen (18,52,149,150). However, the K-antigen is rarely used by laboratories;
only the O:H combination is considered the standard for classifying or serotyping E. coli
strains (150–152). Of interest is a recent publication from the Escherichia coli O-antigen
database (ECODAB) which suggested the existence of 180 O-antigens and >60 H-antigens
(151). The O-antigen structure is extremely variable within E. coli spp. It is hence
considered antigen-specific and therefore, particular to each serogroup (52,151). Although
it is not considered a virulence factor, it has shown to play a relevant role in overall bacterial
virulence, and hence it is closely associated with the pathogenicity of certain serotypes
(149,153). Due to the fact that it is expressed in the outer membrane and is extremely
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immunogenic, it is considered a target for both immune cells and bacteriophages (149).
Furthermore, contrary to other surface antigens, it is heat-stable (149). Therefore, the Oantigen is of particular interest for epidemiological studies, classification during outbreak
investigations and as a diagnostic target (150). Indeed, through surveillance and
epidemiological data, different O-serogroups have been associated more often with
outbreaks than others, despite their H-antigen. This has been the case of E. coli O157:nonH7 strains, which have been isolated from humans and patients with diarrhea including
E. coli O157:H45, O157:H39 and O157:H16, among others (154). In light of these findings
and considering E. coli O157 as one of the most implicated serotypes involved in human
illness, antibodies against the O157-antigen have been constantly produced and used in the
development of LFIAs for routine screening of E. coli O157 in food (155,156) or clinical
samples (157,158).
While there have been numerous LFIAs described for detecting E. coli O157 in food
samples, only a few of them have been marketed. Nine gold nanoparticle-based LFIAs and
one using magnetic nanoparticles, were commercially available at the time of writing
(Table 2). Six of these were previously reported by Farrokh et al. and Jasson et al. (42,159)
as validated methods for the detection of E. coli O157 in different types of food. Contrary
to this, the remaining four methods, MaxSignal®, Quicking, SAS™, and SMART™-II, did
not possess supporting information regarding their validation status (160–163). Besides
commercialized LFIAs, Singh et al. summarized the information of six non-commercial
LFIAs for the detection of E. coli O157, which have been developed and published by
different research groups (133). Overall, the LFIAs described thus far, require an
enrichment step in order to achieve detectable levels that range between 104 and 105
CFU/ml (Table 2) (133,159). Despite the fact that the enrichment step can be as short as 6
h, it is still necessary and a major feature to be considered when selecting a rapid POC
method.
Validation of Alternative Microbiological Methods
It is evident that through the years, national and international food legislation is becoming
more stringent with respect to food safety, emphasizing surveillance and monitoring along
the production chain as major components of programs such as HACCP and GMPs.
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Table 2. Commercial LFIAs for detection of E. coli O157 in food samples (as of June, 2016).
Enrichment (h)
Brand

Manufacturer

Food Type

Enrichment
broth

Sensitivity

Validation

Reference

Dupont™ Lateral
Flow System

DuPont

Ground beef, boneless
beef trim

Yes (8-18)

1 CFU/ 25g

AOAC-RI PTM

(42,164)

FoodChek™*

FoodChek™
Systems Inc.

Raw ground beef, beef
trim

Yes (6-8)

1 CFU/ 25g

AOAC-RI PTM

(42,165,166)

MaxSignal E. coli
O157 Strip Test Kit

Bioo Scientific
Corporation

Meat and meat
products, dairy
products

Yes (18-24)

1×104 CFU/ml
post-enrichment

N/S

(160)

Quicking

Quicking Biotech
Co., Ltd.

N/S

Yes

1×105 CFU/ml
post-enrichment

N/S

(161)

RapidChek® E. coli
O157 (incl. H7)

Romer Labs

Raw ground beef, raw
boneless beef, apple
cider

Yes (8-18)

N/S

AOAC-RI PTM
USDA FSIS MLG

(42,167)

Reveal 2.0

NEOGEN
Corporation

Raw ground beef, raw
beef trim

Yes (8-20)

1 CFU/ 25 or
375g

AOAC-RI PTM

(42,168)

N/S

N/S

(162)

1 CFU/ml or 25g

AOAC-RI PTM

(42,169)

®

SAS™ E. coli O157
and O157:H7 Test
®

Singlepath E. coli
O157

SA Scientific

N/S

P/E

mTSB
mEC (meat)/
mTSB-n (dairy)

P/E, mEC or EEB

P/E

Yes (16-24)

104 CFU/ml post
enrichment

mEC
EMD Millipore
Corporation

Raw ground beef,
pasteurized milk

Yes (24)
mTSB-n and/or
EEB

Health Canada
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Enrichment (h)
Brand

Manufacturer

Food Type

Enrichment
broth

Sensitivity

Validation

Reference

SMART™-II Rapid E.
coli O157 Strip Test

New Horizon
Diagnostics

N/S

Yes

1 CFU/25g

N/S

(133,163)

VIP® Gold- EHEC

4

3.3×10 CFU/ml
post-enrichment

BioControl
N/S
Yes
N/S
AOAC OMA
(42,170,171)
Systems, Inc.
The information provided in this table is based on the latest version of the manufacturer’s web pages, product data sheets and/or validation
certificates available at the time of writing.
*FoodChek™ test is a magnetic nanoparticle LFIA.
AOAC OMA: AOAC INTERNATIONAL Official Method of AnalysisSM
AOAC-RI PTM: AOAC Research Institute Performance Tested MethodSM
N/S: not specified
P/E: proprietary enrichment
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Consequently, the development and commercialization of rapid methods have advanced
because they represent an alternative to maintaining processing efficiency while complying
with screening requirements. However, due to the critical role rapid methods play in
ensuring the safety of food, evidence regarding their performance and fit for purpose is
required before they can be considered reliable alternatives for pathogen screening
(159,172,173). This process is known as validation and normally involves two main
phases: 1) comparison of the alternative rapid method against a reference method, and 2)
an interlaboratory study (105,159,174). The latter requires the participation of different
laboratories in order to assess the reproducibility and repeatability of the results obtained
with the alternative method (105). During the validation process, the alternative method is
represented by the method that has been designed and is intended to be used instead of a
gold standard, also known as the reference method (172). Most often an alternative method
will be a system that intends to reduce the time necessary for getting a reliable result (159).
Therefore, a rapid alternative method will be any new technique or system that can be used
instead of a traditional culture method and provide results in a shorter time with a high
degree of reliability. On the other hand, a reference method will comprise of any widely
accepted method, normally internationally recognized with a well-established protocol,
such as traditional culture methods (159,172).
Something to highlight regarding the validation process is that it has to be recognized by
all the parties involved; hence several private and regulatory standards have been
developed worldwide that provide protocols for the validation of new microbiological
methods (159,172). In North America, regulatory bodies such as Health Canada, FSIS
Microbiology Laboratory Guidebook (MLG), and FDA Bacteriological Analytical Manual
(BAM), have established validation protocols for microbiological detection methods in
Canada and the USA, respectively (175), while in Europe the main standard for validation
is the International Standardization Organization (ISO) 16140 (105,159). On the other
hand, independent validation bodies include the Association of Analytical Communities
(AOAC), mainly in North America, while NordVal, AFNOR or MicroVal are European
organizations, which adopted ISO 16140 (127,159,172). Although these protocols agree
with the main aim of ensuring the proper performance of the alternative methods, they are
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specifically designed to comply with the needs of their particular market. They may not be
fully recognized worldwide or by all stakeholders. In addition, validation by any of these
bodies is not considered mandatory, however, the use of alternative methods may be
restricted by the needs of certain stakeholders that require a specific validation scheme (e.g.
official control by government agencies) (159). For this reason, method developers need
to select carefully the type of validation protocol they will follow.
1.5.1.1 Health Canada’s procedure for the validation of alternative microbiological
methods
In Canada, the Microbiological Methods Committee (MMC) is responsible for supplying
the appropriate methods for ensuring food safety throughout the supply chain. To do that,
the MMC reviews all submitted methodologies to guarantee that they are fit for purpose
and that sound science was used along the validation procedures (174). Once a method is
approved, it is included in the Compendium of Analytical Methods, which contains all
methodologies that are used by Health Canada, the Canadian Food Inspection Agency
(CFIA), and other organizations, to determine compliance with standards and regulations
(174).
In order for an alternative method to request inclusion in the Compendium, it must follow
the “guidelines for the relative validation of indirect qualitative food microbiological
methods”, which are found within the Compendium as well. Briefly, the method developer
has to submit a package containing a pre-collaborative study, inclusivity/exclusivity
studies, determination of the limit of detection (LOD) and a transfer study (174). The precollaborative study involves comparison of the alternative method with a cultural reference
method using a paired or unpaired protocol for further determination of the performance
parameters (sensitivity, specificity, false negative and false positive rates, and efficacy)
(174). Overall, the results obtained should show that the alternative method meets or
exceeds the performance criteria established by the MMC: sensitivity ≥98%, specificity
≥90.4%, false negative rate <2%, false positive rate <9.6%, efficacy ≥94%, and LOD 3-5
CFU/25g (174). Once a complete submission package is received by the MMC, a Technical
Group is formed and is responsible for making recommendations to the MMC after
assessing all the data from the alternative method against the MMC criteria (174).
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Furthermore, a final decision is made by the Bureau of Microbial Hazards Director, who
then notifies the MMC and relays the decision to the developer. (174). Finally, an accepted
method gains a Laboratory Procedure (MFLP) status, which means that the method
complies with the minimum requirements of the Compendium of Analytical Methods
(174). Interestingly, at the time of writing, the latest summary of methods for E. coli O157
published in the Compendium contained 13 MFLPs and one MFHPB, represented by the
gold standard for isolation of E. coli O157 from foods and environmental samples (174).
Of note, an MFHPB is a fully validated and documented method (174). From the 13 MFLPs
alternative methods, only one (MFLP-82: Merck Singlepath® Kit) involves an
immunological approach whereas seven are genetic-based methods and one is based on
phage technology, three are focused on detection of verotoxins, and the final one is for
isolation of VTECs (174). Although rapid alternative methods, in addition to the ones listed
in the Compendium, can be used by food manufacturers for their routine analysis, it is
evident that methods accepted by Health Canada present a greater advantage, especially
considering that CFIA-mandated testing requires use of methods included in the
Compendium (174). In fact, this request is clearly stated in the Guidance Document on
E. coli O157:H7 and E. coli O157:NM in Raw Beef and the Meat Hygiene Manual of
Procedures, where only an approved rapid method should be used for screening of E. coli
O157 in precursor material or ground beef or beef products (70,176).
Overall, validation of alternative methods is highly recommended regardless of the
protocol selected, as long as it fulfills the current needs of the different stakeholders
involved in the food chain. Regarding detection of E. coli O157 in Canada, it is evident
that stricter policies can indirectly restrict the options of alternative methods available for
meat producers. However, for method developers, this also represents an opportunity to
provide meat producers with new alternatives that can satisfy the criteria established by
competent authorities.
1.6. Development of Single-Chain Variable Fragments (scFv) for Pathogen Detection
LFIAs have become an inexpensive, rapid and easy-to-use screening method with the extra
advantage that they can be performed on-site. As noted above, the proper performance of
this type of assay relies on high-affinity and specificity, attributed to the antibodies used
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against the target antigen. Despite the fact that antibodies are currently widely used in
research and commercial applications, their study started with the basis of immunology.
The field of immunology as we know it can be traced back to the late 19th century, when
Paul Ehrlich laid the groundwork by introducing the concepts of “antibody” and presented
the “lock-and-key” principle, giving rise to the “magic bullet” theory (177,178). The latter
explains the idea of a chemical substance that should target, with high affinity, any
pathogen or toxin entering the body, while remaining harmless to the host (177,179). In
1975, Köhler and Milstein expanded Ehrlich’s work by developing hybridoma technology,
which allows production of limitless amounts of a single specific antibody, also known as
monoclonal antibody (mAb) (179–181). Hybridoma technology represented a
breakthrough in medical science because it provided endless opportunities to produce
mAbs with precise specificities for clinical treatments and diagnostics (180). However,
despite the advantages of being considered a standardized in vitro technique, it has
limitations that led to the further application of genetic engineering techniques. The most
well-known limitation is the human anti-mouse antibody reaction developed when mouse
mAbs are used as human therapeutics (147,182). In addition, sometimes hybridomas are
unstable and low yielding resulting in increased production costs whenever high amounts
of mAbs are necessary (182,183). In light of this, researchers have focused their efforts on
increasing knowledge on structure and function of antibodies by applying molecular
biology techniques in order to overcome some of the limitations of conventional hybridoma
technology through advanced antibody bioengineering.
Structure of Immunoglobulins (Ig)
Antibodies are Y-shaped molecules belonging to the glycoproteins family, formed by four
polypeptides: two identical heavy chains and two identical light chains (123,184). Each
heavy and light chain possesses a molecular weight of approximately 50-75 and 25 kDa,
respectively, which contributes to the total IgG molecular weight estimated of 150 kDa
(123,184,185). There are five types of heavy chains that define the different isotypes of
immunoglobulins: IgA, IgD, IgE, IgG, and IgM (123,184). In addition, two types of light
chains are commonly found, κ and λ, which only differ structurally and not functionally
(184). IgGs are the isotype most frequently exploited in research for therapeutics and as a
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diagnostics tool. Interestingly, mice IgGs are primarily formed by κ light chains, while
human IgGs can be 40:60 λ:κ (184). Despite the species, IgGs share a similar structure,
consisting of the two heavy chains connected to each other by two to four inter-disulfide
bonds at the carboxy-terminal and each light chain joined to the amino–terminal region of
one of the heavy chains, respectively, by one disulfide bond (123,185). The inter-chain
bonds are found close to the flexible hinge region, which separates the IgG into two
important fragments: the crystallizable fragment (Fc) and the dimeric-antigen binding
fragment [F(ab)2] (123,184). The former is the effector region and corresponds to the base
of the “Y” (183,184), while the F(ab)2 region is responsible for the specificity that each
IgG will have because it is involved in antigen recognition (123) (Figure 3A).
The F(ab)2 is a dimeric structure that entails two Fab sites, each one containing a complete
light chain and a fraction of the heavy chain corresponding to the first constant region (CH1)
and the entire heavy variable region (VH) (186). Contrary to the heavy chain that has three
CH, two of which form the Fc, light chains consist only of one constant region (CL)
belonging entirely to the Fab together with its variable region (VL) (187). The Fab can be
divided into a variable fragment (VH and VL) and a constant fragment (CH1 and CL) (186).
Although the Fab region is involved in the interaction of the IgG with an antigen, the
biggest impact relies on the variable fragment, which is suggested to be responsible for the
great diversity of IgGs that exist. However, within the variable region, researchers have
identified hypervariable segments, which have been proposed to be the actual sites where
the antigen interacts with the IgG (123,187). Three hypervariable segments or
complementarity determining regions (CDRs) are known in each VH and VL. When the
first X-ray crystal structure of a Fab region was obtained, these CDRs were found to form
six loops that were separated by relatively conserved regions that act as support; thus they
are known as framework regions (FRs) (123,187). As noted, the six hypervariable CDR
loops, derived from both heavy and light chains, form the binding site that will interact
with its antigen through specific regions known as epitopes (123) (Figure 3B).
The mechanism through which the variable domains are assembled is known as VDJ
recombination for VH and VJ for VL (188). Through this process, three (or two for the VL)
separate gene segments - variable (V), diversity (D), and the joining (J) - suffer a somatic
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Figure 3. Overview of the structure of an IgG antibody. Schematic representation of A)
a complete IgG molecule consisting of two heavy (H) and two light (L) chains. In general,
an IgG molecule is divided into (Fab)2 and the Fc regions, which are joined by the hinge
region, B) the (Fab)2 region, which is responsible for binding to the antigen, mainly through
the six CDR loops found in the variable region of the heavy and light chain (VH and VL)
(left chains). The right chains show the different segments based on the encoding germlines
V, D, J and the constant regions found within the Fab. The composition of the diversity
segment (D) is highlighted with the nontemplated (N) nucleotides represented by black
lines on each side of the D segment, and C) VH and VL chains structure based on the somatic
recombination process of the V, D, and J gene segments. The difference in the CDR 3 from
the VH and VL is emphasized. Images are based on Georgiou et al. (189), Sarantopoulos
(322), and Ahmad et al. (205).
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rearrangement that is accompanied by other mechanisms such as imprecise joining of any
of the three segments, trimming and/or random addition of nucleotides (N nucleotides)
(188,189). The V gene encodes the first three FRs, CDR1, CDR2, and the amino-terminal
of the CDR3 in both VH and VL (186,190). Moreover, the J gene, which is found between
the V and the constant region of either the heavy or light chain, contains the carboxyterminal of the CDR3 and the last FR4 (186,190). Finally, the D gene, found between the
V and the J regions within the VH, complements the CDR3 (123). The latter is considered
the hallmark of any IgG because it is highly variable due to the random insertion of Nnucleotides at any of the extremes of the D gene (186). Thus, CDR3 can vary not only in
sequence, but also in length (Figure 3C). These whole variable region assembly
mechanisms, together with the numerous possibilities of association between different
heavy and light chains, are responsible for creating an infinite repertoire of IgGs from a
finite number of genes (123,186,189).
Antibody Engineering
Traditionally, mouse hybridomas have been the main source of monoclonal antibodies for
medical applications. However, they possess a major limitation when used as therapeutics
because they trigger the human anti-mouse antibody reaction (147,191). Thus, it is not
surprising that most of the focus on engineering antibodies has been towards reducing their
immunogenicity through techniques such as humanization or chimerization (147,191).
Humanization involves grafting the murine CDRs into a human FR, while a chimeric
antibody is constructed by replacing the murine constant regions (192) (Figure 4). Through
these genetic engineering advancements, the market of recombinant antibodies has rapidly
grown with a global value estimated at $20 billion per year in 2007 (193). Yet, recombinant
antibodies have not been intensely exploited in other fields besides therapeutics (194). This
can be attributed to the fact that great variability implies higher complexity, which hinders
the use of simple techniques such as PCR because two primers are not sufficient to amplify
the sequences of all VH and VL chains (194). Therefore, more complex approaches have
been necessary in order to discern their specific sequence for further recombination.
Techniques such as degenerate primers have been developed in order to overcome antibody
variability during PCR (194–196). In addition, other novel PCR techniques such as
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Figure 4. Examples of antibody engineering. Schematic representation of some
recombinant antibodies using a murine IgG as template. On the left, an intact murine IgG
is shown. On the right, three different structures are depicted: first, a chimeric antibody,
which comprises the variable regions of the murine antibody joined to a constant human
region. The second example is a humanized antibody consisting of the murine CDRs
grafted into a human backbone. The last one, is a scFv, which is the most common
antibody fragment that only contains the variable regions joined by a peptide linker.
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5’-rapid amplification of cDNA ends (5’-RACE) (189,197) have been complemented with
methods already applied for the development of therapeutic antibodies including phage
display (198,199), leading to the production of newly improved antibodies. Furthermore,
the advantages of recombinant over murine hybridoma antibodies surpass their production
process, because properties such as their binding and specificity towards a particular
antigen can be easily enhanced (147,194).
1.6.2.1 Single-chain variable fragments (scFv)
Several formats of recombinant antibodies have been developed, from chimeric antibodies
to smaller fragments such as Fab, F(ab)2, or single-chain variable fragments (scFv) as
monomers, dimers (diabodies), or trimers (triabodies) (200). However, one of the most
frequently used formats used for production of recombinant antibodies is the expression of
scFv, which are composed of the VH and VL domains of an antibody with a molecular
weight between 27-30 kDa (201). Both chains are covalently bound by a flexible peptide
linker forming a single polypeptide (197,202) (Figure 4). scFv are becoming extremely
useful as drug therapies when complete antibodies struggle to reach their target due to their
size, as proven for some cancer treatments (202). In some cases, the Fc is not crucial for
functionality; in fact, it can increase the chances of non-specific binding due to interactions
with other cells present in the samples. Thus, scFv, which are considered the smallest
antibody fragment that contains the complete antigen binding site, can have better
penetration and biodistribution within their target organs and cells (197,203). Besides the
development of scFv for treatment purposes, the study of these antibody fragments has led
to a better understanding of the stability and roles that each variable chain plays in antibody
functionality; thus scFv are also a model system for antibody research (204,205).
Moreover, scFv represent potential immunodiagnostics reagents because they can bind to
a series of antigens such as proteins, haptens, chemicals and even whole bacterial cells
using different immunoassay formats (205). Table 3 summarizes some of the most recent
technologies that have been combined with the development and application of scFv as
immunodiagnostics reagents.
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Table 3. Summary of applications of scFv as immunodiagnostics reagents (as of June,
2016).
Target Antigen

Organism

Technique

Research
Group

Reference

Aflatoxin B1

N/A

SPR

Dunne et al.
(2005)

(206)

Deoxynivalenol
(DON)

N/A

Competitive ELISA

Wang et al.
(2007)

(207)

Diverse antigens

Entamoeba
hystolytica

SERS microspectroscopy
combined with nanoyeastscFv

Wang et al.
(2014)

(208)

Fluoroquinolone

N/A

ELISA

Wen et al.
(2012)

(209)

Fumonisin B1

N/A

Competitive ELISA

Zou et al.
(2014)

(210)

Heat-labile and
heat-stable toxins

ETEC

Immunoblotting/ ELISA

Ozaki et al.
(2015)

(201)

Heat shock protein
6o (HSP6o)

Strongyloides sp.

ELISA

Levenhagen et
al. (2015)

(211)

Protective antigen
(PA)

Bacillus anthracis

Protein chip
(immunoassay)

Wang et al.
(2006)

(212)

Protein D (OmpD)

Salmonella enterica
serovar
Typhimurium

Competitive ELISA

Meyer et al.
(2011)

(213)

N/S

Brucella melitensis

ELISA

Hayhurst et al.
(2003)

(214)

N/A: not applicable; N/S: not specified
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Production of scFv requires the proper folding of the VH-linker-VL peptide and formation
of disulfide bonds (215), which has been accomplished through bacterial expression
systems, especially using E. coli (203,216). Moreover, other expression systems have also
been used including, but not limited to yeast (204,205,217) and plants (204,205) with
encouraging results. Wörn et al. summarized several studies that have reported the
production of scFv with similar monomeric binding affinity as their mAb counterpart
(204). Even though several scFv have been effectively produced as alternatives to whole
antibodies, some others have proven to be challenging due to protein solubility and stability
issues after expression (202,218). Some of these limitations are due to the great variability
of the primary amino acid sequences that resulted in the development of two different
approaches to solve these issues. The first group, involves modifications to the primary
sequence of the scFv, including loop grafting by transplanting the CDRs into an acceptor
framework to improve biophysical properties (218,219). Site-directed mutagenesis is based
on the rational modification of specific amino acid residues (218,220). The second
approach focuses on modifying protein expression conditions to favor the proper folding,
such as expression hosts, isolation and purification (203,217). Together, these techniques
have increased the success rate for obtaining functional scFv, promoting their applications
beyond therapeutics and clinical diagnosis.
1.6.2.2 Application of scFv to food pathogen detection
As discussed above, intensive efforts have been made to improve the production of scFv
has resulted in an increasing scientific and commercial interest to progressively introduce
scFv into other fields such as immunodiagnostics (200,221). Within the food safety field,
antibodies have been widely used for detection of toxic compounds and pathogenic bacteria
using an extensive variety of immunological techniques. Even though there have been few
reports of the application of scFv as alternatives to whole antibodies, scFv have already
shown to be valuable reagents when used in biosensors due to their smaller size and high
specificity (101,206,221). Thus far, most of the studies have focused on detection of
mycotoxins for food analysis (Table 3). However, production of scFv for detection of food
pathogenic bacteria has been recently reported, mainly using phage display technology for
detection of Salmonella enterica serovar Typhimurium infections using competitive
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ELISA (213). This scFv developed by Meyer et al. targeted protein D (OmpD) found in
the outer membrane of S. enterica ser. Typhimurium, which is considered highly
immunogenic (213). To our knowledge at the time of writing, this is the only study focused
on the application of scFv for food safety purposes. It is thus evident that the use of scFvs
for food safety can be considered a rather new research field, which could greatly benefit
from the application of scFv as detection reagents. This knowledge provides the foundation
for the antibody engineering work described in this thesis.
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CHAPTER 2 RATIONALE, HYPOTHESES AND OBJECTIVES
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2.1. Rationale
It is clearly evident that E. coli O157 remains one of the major foodborne pathogens with
huge implications for public health. Foodborne infection with E. coli O157 was first
identified in 1982. Due to the severity of the disease and its long-term negative outcomes,
E. coli O157 was designated as a food adulterant in 1994 by the USDA-FSIS, leading to
the establishment of a detection program in beef (66).
Meanwhile in Canada, mandatory testing programs, with a zero tolerance were established
for E. coli O157 initially in ground meat (222). Since then, control and detection of E. coli
O157 have become active research fields in food safety. The current standard detection
method requires up to a week to confirm the presence of E. coli O157 in food samples, an
obstacle for some food producers to promptly deliver safe food. On the other hand,
alternative methods, approved by Health Canada, are mostly genetic-based and thus require
special equipment, multiple steps or specialized training for their performance. In the work
to be described, it was sought to develop and validate a POC test, based on the LFIA
principle. This is intended to provide a reliable alternative for meat producers to enable
easy and rapid detection of E. coli O157. Early detection of this pathogen is vital to prevent
contaminated food from reaching consumers, attenuating or preventing the effects arising
from a recall or an outbreak. Although the expansion of LFIA into the food safety field is
relatively new, an increase in the development of new tests has followed the establishment
of more stringent regulations mainly for food pathogen detection (139). Recently, advances
in molecular biology have been combined with the LFIA principle to develop more
sensitive, specific and faster LFIAs. The synthesis of single-chain variable fragments
(scFv) can offer significant advantages over monoclonal antibodies as detection reagents.
These advantages include enhancement of the specificity and sensitivity of the
immunoassays (108). Previous to the work described in this thesis, synthesis and
application of scFv as detection reagents has been mainly applied for the detection of
mycotoxins using ELISA or SPR (206,210). The second part of this thesis focuses on the
design and expression of a scFv that can be used to detect E. coli O157 in an immunoassay.
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2.2. Hypotheses
1) The LFIA Test Kit developed in this study will have similar or better performance,
measured by the determination of the performance parameters and Probability of
Detection when compared to the traditional culture method using a relative
validation study.
2) Proper pairing of the enrichment step and the LFIA device will result in shorter
time-to-result, when compared to the time required for detection of E. coli O157
using the traditional culture method and other immunoassays found in the current
Compendium of Analytical Methods.
3) Using the anti-O157 mAb as a starting point, a scFv will be derived by expression
in E. coli cells, which will retain the binding properties of the parental anti-O157
mAb when used in a functional immunoassay such as ELISA.
2.3. Objectives
1) To develop a rapid POC test based on the LFIA principle that can be used to visually
demonstrate the presence or absence of E. coli O157 in meat samples.
2) To compare the performance parameters of the newly developed LFIA Test Kit
versus the criteria established by the MMC as stated in the current Compendium of
Analytical Methods.
3) To design, clone, express, and characterize the functionality of a scFv based upon
the structure of the anti-O157 mAb used as the detection reagent in the LFIA Test
Kit.
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CHAPTER 3 MATERIALS AND METHOD
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3.1. Bacterial Strains, Sample Preparation and Culture Conditions
Inclusivity and Exclusivity Strains
The objective of this study was to ensure that the LFIA test kit had the ability to selectively
detect a wide range of E. coli O157 strains (including H7 and non-motile), while excluding
non-target organisms closely related to E. coli O157 and/or commonly found in raw meat
products. The inclusivity panel was assembled considering the variability within E. coli
O157 strains and the relevance of other O157:non-H7 E. coli as causes of human illness
(27,154,223). A total of 50 E. coli O157 strains (including H7 and non-motile) was selected
from different sources. Only 39 were O157:H7 serotype, 5 were O157:NM, and 6 of them
were O157:non-H7 serotypes (H45, H42, H29, H25, H19, H12). In addition, 27 strains
were from bovine origin isolated from different sources such as feces and meat (ground
and salami). Around 18 strains were from human origin; 16 mainly from clinical isolation
and 2 from feces. However, four strains did not have an origin specified, but their original
depositor was stated by the contributor. Only one strain did not have any information
regarding its history. All strains were biochemically characterized and confirmed as E. coli
O157 prior to testing (Appendix A).
For exclusivity, 37 non-E. coli O157 strains were selected from different sources that
reflected the variability of organisms that can be present in the food matrices chosen for
this study. Most of these (33) were Gram negative and belonged to the Enterobacteriaceae
family, with the exception of Aeromonas hydrophila. From those Enterobacteria, 18 were
E. coli non-O157, while the rest were bacteria frequently found in meat and closely related
to E. coli O157. In addition, four Gram positive strains that can be found in meat were
included in the panel (Bacillus subtilis, Enterococcus faecalis, and Listeria monocytogenes
4a and 1/2c). Strains obtained from the Public Health Agency of Canada (PHAC) in
Guelph, ON, Canada, were verified using the Vitek® microbial identification system
before they were provided (Appendix A).
Upon receipt, all 87 strains were initially grown in 5 ml of BBLTM TrypticaseTM Soy Broth
[TSB; Becton, Dickinson and Company (BD), Sparks, MD, USA] or BactoTM Brain Heart
Infusion (BHI) medium (BD, USA) incubated overnight at 37°C to reach late-exponential
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phase (108–109 CFU/ml). A sub-culture was prepared by transferring 50 µl of the initial
culture into 5 ml of TSB or BHI and incubated as previously stated. Cells were harvested
by centrifugation (Eppendorf Centrifuge 5430, Rotor FA-45-30-11, Eppendorf AG,
Hamburg, Germany) at 5000 ×g and re-suspended using TSB or BHI with 20% (v/v)
glycerol as cryoprotectant and stored at -80°C for long-term storage. Furthermore, working
cultures were prepared from frozen stocks by loop inoculation of 5 ml of TSB incubated
overnight at 37°C to reach late-exponential phase (108–109 CFU/ml).
Bacterial Culture Enumeration
Bacterial enumerations or plate counts were performed by plating 50 µl on TrypticaseTM
Soy Agar (TSA; BD, USA) and/or the E. coli O157:H7 selective agar, cefixime rhamnose
sorbitol MacConkey (CR-SMAC; Oxoid Limited, Basingstoke, Hampshire, UK) using the
Spiral Plate Method (224) (Eddy Jet Spiral Plater, E Mode; Neu-tec Group Inc.,
Farmingdale, NY, USA) then incubating the plates at 37°C for 18-24 h. Two serial dilutions
were normally plated per sample. Colonies on the agar plates were counted using the spiral
plate counting grid and following the “rule of 20 colonies”. In brief, a wedge from the grid
was selected and colonies were counted from the outer edge towards the center until more
than 20 colonies had been reached. A similar area in the opposite side to the wedge selected
was also counted, added up and divided by the sample volume deposited in those two areas
as shown in the formula below:
!"#$% 1 + !"#$% 2 !34
=
*"+#,- .-/"01%-.
,+
Results were reported as CFU/ml of sample plated and recorded for further use in dilution
calculations or estimation of cell concentration in samples (CFU/g or ml).
Preparation of Stressed E. coli O157 Cells.
The protocol selected was adopted from a previous study done by Jasson et al. (225), which
consisted of mimicking inherent factors normally present in food. Working cultures of E.
coli O157 DSM17076, EC20060233, EC20001018, EC19970515, and EC20040339 were
prepared as described in Section 3.1.1. In addition, a “food” broth was formulated using
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TSB supplemented with 0.6% yeast extract (Sigma-Aldrich, St. Louis, MO, USA)
(TSBYE) and acidified with HCl until a pH of 4.9 was reached. In addition, 130 g/L NaCl
was added to simulate the salt concentration of a fermented sausage. The broth was filter
sterilized and kept at 4°C. To determine the initial cell concentration, cultures were plated
on TSA supplemented with 0.6% yeast extract (TSAYE) and CR-SMAC agar plates, which
were considered non-selective and selective respectively. Serial dilutions were performed
using the “food” broth up to a level of 106 CFU/ml. The inoculated broths were kept at 4°C
for 10 d after which aliquots were plated on TSAYE and CR-SMAC plates for
enumeration. The percentage of sub-lethal injury was determined by comparing the number
of colonies in non-selective and selective agars using the formula below:
% 0#6 − +-%ℎ9+ 1$:#;< =

$"$0-+-=%1>- − 0-+-=%1>? 100
$"$0-+-=%1>-

For each strain, at least three different experiments were undertaken and the percentage of
sub-lethal injury was expressed as the average ± standard error of the mean. The % of sublethal injury caused solely by the stress treatment was confirmed by determining if
significant difference between selective and non-selective media performance existed
using a two-sided t-test with α= 0.05.
Artificial Inoculation of Food Samples
Fresh retail lean ground beef or trimmed beef was obtained from local supermarkets one
day before starting the experiments (Loblaws, London, ON, Canada) and aseptically
divided into 25 g samples using Stomacher® bags. In order to mimic real scenarios,
samples were inoculated either with healthy or stressed E. coli O157 cells prepared as
described in Section 3.1.3. Both cultures were serially 10-fold diluted using DifcoTM
Buffered Peptone Water (BPW; BD, USA) in order to achieve three inoculation levels: low
(1-10 CFU/25 g), medium (102 CFU/25 g) and/or high (103 CFU/25 g), as per the objective
of each experiment. Cell concentrations of inocula were confirmed by plate counts on TSA
and CR-SMAC. In addition, an uninoculated 25 g sample was included as a negative
control. After manual homogenization, samples were stored at 4°C for 48 h for
equilibration before further use.
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Determination of Aerobic Plate Count (APC) of Food Samples
APC, also known as total viable count (TVC), was also determined to establish the initial
level of contamination in the food samples. A 25 g sample, from the same batch used in
each experiment, was weighed into a Stomacher® bag and mixed with 225 ml (1:10) of
BPW. The bag was loosely closed and stomached using a lab blender (BagMixer® 400P,
Interscience Laboratories Inc., Woburn, MA, USA) for 1 min. A 10-fold dilution was
prepared using BPW and an aliquot of both was plated on TSA. Plates were incubated at
37°C for 48 h for enumeration. Cell concentrations were expressed as CFU/g of food
sample.
Evaluation of Enrichment Conditions
Table 4 summarizes the commercially available enrichment broths used throughout the
development process. The first screening involved using pure cultures. Briefly, a working
culture of E. coli O157 DSM 17076 was prepared as previously described and serially
diluted in TSB to a final concentration of 102 CFU/ml. Initial inoculation levels were
confirmed by plate counts on TSA and CR-SMAC. Cultures were incubated at 42°C for a
maximum of 24 h. When necessary, bacterial growth was monitored by plating 50 µl every
2 h on TSA and CR-SMAC.
The final selection of the enrichment broth was based on the following: 1) the ability to
recover E. coli O157 from artificially inoculated food samples prepared as per Section
3.1.4; and 2) its interaction with the LFIA Test Kit. Therefore, after equilibration,
Stomacher® bags containing the inoculated samples were filled with 225 ml of the
appropriate enrichment broth, stomached for 1 min and regenerated 40 min at RT (room
temperature). Food samples were incubated at 42°C for a maximum of 24 h. When
necessary, a time-course study was performed with sampling every 2 h starting at 16 h. For
enumeration, samples were plated on TSA and CR-SMAC and, if needed, they were
previously serially diluted using BPW.
Cloning and Expression Bacterial Strains
E. coli XL1-Blue competent cells (Stratagene) were used for plasmid expression and E.
coli BL21 (DE3) competent cells (Novagen) were used to express the recombinant protein.

53

Table 4. Enrichment broths and their selective agents.
Broth

Selectivity

Selective
Agents

Supplier

Modiﬁed Tryptone Soya
Broth (mTSB)

Selective

Bile salts No. 3

Oxoid Limited (Basingstoke, Hampshire,
UK)

RapidCultTM E. coli

Selective

Sodium
thioglycolate

EMD Chemicals (Darmstadt, Germany)

BBLTM TripticaseTM Soy
Broth+ Novobiocin
(TSBN)

Selective

Novobiocin

Becton, Dickinson and Company (Sparks,
MD, USA)/ Sigma-Aldrich Co. LLC (St.
Louis, MO, USA)

BBLTM TripticaseTM Soy
Broth (TSB)

Nonselective

N/A

Becton, Dickinson and Company (Sparks,
MD, USA)
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Both strains were grown aerobically at either 37°C or RT in Luria Broth (LB) (BD, USA)
or on LB with 1.5% agar (BioShop, Burlington, ON, Canada). To maintain plasmid
selectivity, the LB broth or agar was supplemented with ampicillin (20 µg/ml) and/or
chloramphenicol (10 µg/ml), both from Sigma-Aldrich, USA. For long-term storage,
bacterial strains were frozen in LB broth with 20% glycerol and kept at -80°C. Table 5
summarizes the main characteristics of the two strains used within this part of the study.
3.2. Development of a Lateral Flow Immunoassay (LFIA) for Detection of E. coli
O157
Assembling of the LFIA
The LFIA devices used during this project were manufactured at the International Point of
Care Inc. (IPOC) facilities in Toronto, ON, Canada following their internal specifications
and protocols (Garth Styba, president IPOC, 2016, pers. comm.). Standard LFIA devices
were stored at RT, while bovine serum albumin (BSA) blocked devices were stored at 4°C
upon arrival at our facilities.
The standard LFIA device consists of one or two (tandem) plastic backed nitrocellulose
membrane strips coated with streptavidin on the test line and a polyclonal goat anti-mouse
antibody on the control line. A 28 mm polyester sample pad is adhered at one extreme of
the membrane, while a cellulose membrane is attached as an absorption pad on the opposite
side. The assembled LFIA strip(s) is (are) encased on a plastic cartridge, either a single or
tandem unit, as shown in Figure 5.
In-Tube Sandwich Immunoassay
An in-tube sandwich immunoassay was developed using three antibodies: a biotinylated
capture polyclonal antibody (pAb-b), a primary detection monoclonal antibody (mAb) and
a secondary antibody conjugated with colloidal gold (CGC) (Table 6). Briefly, the three
antibodies were mixed, either in solution or lyophilized, in an Eppendorf tube with 200 µl
of the sample assessed. Tubes were incubated for 30 min at RT. Furthermore, 150 µl of the
suspension was then pipetted onto the sample window of the LFIA device and allowed to

55

Table 5. Cloning and expression E. coli competent cells.
Bacterial
Strain

Characteristic

Purpose

Source

E. coli BL21
(DE3)

FompT hsdSB(rB -, mB -) gal dcm (DE3)

Protein
Expression

Novagen

E. coli XL1
Blue

recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac
[F’ proAB lacIqZΔM15 Tn10 (TetR)]

Cloning

Stratagene
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Figure 5. Schematic representation of the LFIA. A) The LFIA device with the
nitrocellulose strip(s) encased in either a single or tandem plastic cartridge. B) Diagram
of the assembled nitrocellulose strip with the sample and absorbent pad on each extreme.
The control line is formed by an immobilized polyclonal goat anti-mouse antibody, while
the test line contains streptavidin.
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Table 6. Antibodies used for the development of the LFIA Test Kit.
Antibody

Clonality

Host/
Isotype

Application

Specificity

Supplier

Primary,
detection

13B3 antiE. coli
O157
(mAb)1

Monoclonal

Mouse/
IgG3

ELISA, IF,
Agglutination

O157 LPS
antigen

USDA
Agricultural
Research Service,
Meat Safety and
Quality Research
Unit, NE

Capture

biotin
conjugate
(pAb-b)

Polyclonal

Goat

ELISA

E. coli

Pierce
Biotechnology,
IL, USA

Secondary

DGMGPolyclonal
Goat
Lateral Flow mouse IgG
BioAssay
B001,
Assay
(heavy and
Works®, MD,
colloidal
light chains) USA
gold
conjugate
(CGC)1
1The mAb ascites and colloidal gold conjugate were further produced by International Point of Care
(IPOC), Toronto, ON, Canada.
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flow through the membrane for 15 min before reading. Table 6 summarizes the main
characteristics of each antibody used.
Optimization of Reagents and Blocking Conditions
Optimization of the LFIA Test Kit was focused on membrane blocking, antibody
concentrations and enhancement of the positive signals. The standard LFIA and the in-tube
sandwich immunoassay described earlier were used throughout this process. Elimination
of non-specific binding, involved common strategies using a wide variety of proteins or
polymers, such as BSA, casein, fish serum, polyvinyl acetate (PVA), polyethylene glycol
(PEG) or polyvinylpyrrolidone (PVP), which can be adsorbed by the nitrocellulose
(114,133,134). Their main effect relies on interfering or competing with binding of the
target reagents (226). Three sequential approaches were undertaken. The first approach
involved using only a working culture of E. coli O157 DSM 17076 as positive control.
Cells were harvested by centrifuging at 5,000 ×g for 10 min at RT and re-suspending the
pellet in a blocking buffer consisting of 1% BSA (BioShop, Canada) and 0.05% Tween 20
(Sigma-Aldrich, USA) in 1×PBS. As a negative control, blocking buffer was used. For the
in-tube sandwich immunoassay, an aliquot of each sample was mixed with the capture and
detection antibodies at a final concentration of 3 µg/ml respectively, while the CGC was
used at 0.5 µg/ml throughout these experiments. The second approach consisted of pretreating the LFIA membrane with 50 µl of blocking buffer, allowing it to flow through the
device before loading the sample. The in-tube sandwich immunoassay composition and
procedure were kept the same. The final approach substituted the pre-treatment with the
incorporation of the blocking agents during the manufacture of the LFIA device. For this
purpose, various ratios of BSA and Tween 20 were sprayed onto the nitrocellulose
membrane and/or the sample pad during assembly. In addition, different volumes of
blocking solution per mm2 of nitrocellulose membrane were tested and compared. An
overnight E. coli O157:H7 DSM17076 working culture was always used as positive
control, while the blocking buffer or culture broth wwas used as a negative control,
depending on the experiment. At a later stage, working cultures of other non-E. coli O157
strains were tested for cross-reaction evaluation. Once potential prototypes of the LFIA
device were selected, their performance was assessed not only with pure cultures, but also
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using food samples prepared as per Section 3.1.4 and enriched using the selected
enrichment protocols.
The antibody concentrations were kept constant to compare the performance of all the
different LFIA device prototypes. However, after the potential prototypes were chosen,
antibody concentrations were fine-tuned for signal enhancement. Adjustments were made
by preparing antibody suspensions using either 1×PBS or blocking buffer as the diluent. In
order to extend the shelf life of the antibodies and facilitate their handling, potential
working concentrations for the different antibodies were used to produced lyophilized
beads at IPOC facilities following their standard manufacturing process (Garth Styba,
president IPOC, 2016, pers. comm.). Although antibody beads eventually replaced the
antibody suspension during the in-tube sandwich immunoassay, the procedure did not
change. Because the beads were sensitive to humidity, they were stored in Eppendorf tubes
inside a sealed metallic pouch with a desiccant and kept at 4°C until used.
Biochemical and microbiological sample composition played a key role in signal intensity.
Thus, to counterbalance the effect of such variations, it was necessary to standardize the
LFIA Test Kit procedure. Two alternatives were evaluated, pH adjustment and dilution of
sample matrix after enrichment. The final LFIA prototype and antibody beads for the intube sandwich immunoassay were used throughout these experiments. Pure working
cultures and food samples were prepared as before and enriched according to the final
protocol. Before enrichment, the pH of the homogenized sample was measured. After
enrichment, the sample was cooled to RT and 200 µl aliquots were pipetted into different
Eppendorf tubes containing the three lyophilized beads used for the in-tube sandwich
immunoassay. Different volumes of 1M HEPES buffer were added to each tube to adjust
the pH, except for one that was used as a control. After 30 min incubation at RT, the sample
was loaded into the LFIA device and the pH was measured using the remaining sample.
pH values were compared before and after adjustment and correlated to the results obtained
in the LFIA devices. All pH measurements were taken using a pHTestr®20 (Oakton®
Instruments, Il, USA) and/or pH strips (VWR International, Radnor, PA, USA).
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Finally, to evaluate the effect of sample composition and bacterial cell concentration, a
tandem test was developed. Right after enrichment, a 200 µl aliquot was pipetted directly
to an Eppendorf tube containing the antibody beads, named sample (A). A second aliquot
was taken from the enriched sample and diluted 1:100 using BPW, which was called
sample (B). An aliquot of 200 µl of this dilution was pipetted into a second tube containing
beads. Both tubes were incubated in parallel according to the in-tube sandwich
immunoassay protocol before 150 µl were loaded into the appropriate window in the
tandem LFIA device. All samples were run through the nitrocellulose membrane for 15 min
before the signal intensity was assessed.
Assessment of LFIA Device Signal
All LFIA devices were assessed 15 min after sample loading. During the initial
development stage, devices were only visually examined using the following criteria:
1) well-defined control lines in both positive and negative controls, 2) clear presence of
test line in positive controls and total absence in negative controls, and 3) absence of red
smear across the nitrocellulose stripe in both positive and negative controls (Figure 6).
Pictures were taken using an 8-megapixel iSight camera (Apple Inc., Ca, USA) and
representative images were evaluated by an independent team of at least four people.
Selection of potential prototypes was determined by consensus.
During fine-tuning of the LFIA Test Kit, the intensity of the control and test line was
measured using an optical reader, the i-Lynx™ system (Spectral Diagnostics Inc., Toronto,
ON, Canada), for comparison to the results obtained during visual evaluation.
Measurements were mostly performed in duplicate or triplicate and reported as the mean
± standard error of the mean (SEM).
Determination of the Limit of Detection (LOD)
During the development phase, the LOD was determined to establish the sensitivity of the
potential LFIA device prototypes. Therefore, only a working culture of E. coli O157
DSM17076 was used. Serial 10-fold dilutions were prepared using the appropriate broth
up to a concentration of 10 CFU/ml. Aliquots of 200 µl of each dilution were incubated
with the antibodies following the in-tube sandwich immunoassay protocol and 150 µl were
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Figure 6. LFIA standard results. Positive Standard: result obtained with an in-tube
sandwich immunoassay using a 107 CFU/ml E. coli O157 DSM 17076 working culture.
Negative Standard: result obtained using TSB. Both samples were incubated 30 min at
RT before they were loaded onto the device. Pictures were taken 15 min after loading.
Both devices complied with the three criteria established for visual evaluation: clear
control lines, defined test line with the positive control and complete absence on the
negative, and no red smear along the nitrocellulose membrane.
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loaded into the LFIA devices. After 15 min, results were evaluated as described in Section
3.2.4.
3.3. Relative Validation of a LFIA Test Kit for Detection of E. coli O157 in Raw Meat
Products
This section focuses on the methodologies performed to generate the data necessary for
requesting the inclusion of the ADx™ Decision Point™ test kit for E. coli O157 (also
referred as LFIA Test Kit in this document) in the Health Products and Food Branch
Compendium of Analytical Methods from Health Canada. For this purpose, the guidelines
outlined in the Procedure for the Development and Management of Food Microbiological
Methods, Part 4 (March, 2011) from the Compendium of Analytical Methods were
followed (174). The initial submission required a pre-collaborative study, also known as
preliminary study, which consisted of comparing the alternative method (AM), in this case
the LFIA Test Kit, to an approved reference method (RM). For this study, the reference
method followed was the MFHPB-10 Isolation of E. coli O157:H7/NM from foods and
environmental surface samples (October, 2014), which can also be found in the
Compendium of Analytical Methods and is included in Appendix B. Furthermore, the
relative validation not only involved the comparison of the AM to the RM, but also
considered the results obtained with the RM as the true values, which were the basis for
estimating the performance parameters of the LFIA Test Kit. Because the AM was
developed using a different enrichment procedure than that suggested in the RM, the
validation study followed an experimental layout for unpaired samples. This approach
requires that each sample evaluated with the AM must be diverted to follow the RM path
at the earliest stage possible to confirm the AM results. Figure 7 summarizes the protocol
for the relative validation using unpaired samples that was followed to assess the
performance of the LFIA Test Kit at Laboratory Services Division, University of Guelph,
ON, Canada.
Experiments in Section 3.3.1 were performed at Robarts Research Institute, London, ON,
Canada; while the submission report was prepared in collaboration with IPOC, Canada.
The relative validation had to be performed by an accredited laboratory for Test Method
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Figure 7. Workflow diagram for the relative validation of unpaired samples for the
LFIA Test Kit. Sample preparation, inoculation levels and distribution between the
alternative method (AM) and the reference method (RM) are depicted as the top of the
workflow. The left path shows the alternative method procedure, which includes the
divergence of samples to the reference method for confirmation of results. The right path
describes the procedure of the 45 samples allocated to the reference method for
comparison.
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Development and Evaluation and Non-Routine Testing under ISO/IEC 17025. Thus, the
experiments explained in Sections 3.3.2 and 3.3.3 were done by the Laboratory Services
Division, University of Guelph, ON, Canada, who also provided an extensive report.
Hence, information contained in both reports (Garth Styba, president IPOC, 2016, pers.
comm.) was used in preparation of this section.
Inclusivity and Exclusivity Study
The 50 E. coli O157 strains and the 37 non-E. coli O157 strains listed in Appendix A were
used. In both cases, working cultures were prepared as described in Section 3.1.1 and
coded using random numbering. Cultures were blindly run by an analyst using the LFIA
Test Kit instructions found in Appendix C. All samples were run in triplicate to assess the
consistency and reliability of the results.
If false positives were found during the exclusivity study, the bacterial strains were retested
by streaking a loop of the overnight culture on TSA plates and incubating at 37°C for 24 h.
A single isolated colony was selected and inoculated using TSBN at 42°C for 22 h, which
is the enrichment protocol suggested in the LFIA Test Kit. Then, the culture was evaluated
using the LFIA device. In addition, these strains were biochemically characterized to rule
out any cross-contamination, following the methodology described in Appendix A.
Relative Validation of the LFIA Test Kit Using a Protocol for Unpaired Samples
3.3.2.1 Sample preparation
The validation study comprised two food types within the Raw Meat Food Category, which
were Raw Meat (unprocessed) and Raw Meat (processed), as suggested in the
Compendium of Analytical Methods. The main aim of performing a relative validation
study was to demonstrate that the LFIA Test Kit could detect E. coli O157 equally or better
than the cultural reference method (RM), MFHPB-10. Four food items per food type were
evaluated; each one with twenty replicates that were equally split between the AM and the
RM. In addition, ten more samples from each food type were included as negative controls
(uninoculated) and were similarly split between AM and RM. A total of 180 samples, both
unprocessed and processed raw meat products, were used. For each food type, Health
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Canada’s guidelines require that food items chosen for evaluation must be as different as
possible (174). Thus, raw ground beef, raw ground veal, raw beef trim and carpaccio were
chosen as representatives of unprocessed raw meat products. Raw sausage, raw hamburger
patty, raw meatballs and raw kebabs were selected for representing processed raw meat
products. Each food item had 10 high (H), 10 low (L) and 2 uninoculated (U) samples, with
the exception of ground beef and raw sausage, which had 4 uninoculated samples each one.
All food samples used in this study were obtained by Laboratory Services Division,
University of Guelph, from local retail stores in Guelph, ON, Canada. Figure 8 depicts the
distribution of samples evaluated.
3.3.2.2 Preparation of inocula for processed and unprocessed food samples
The E. coli O157:H7 strains were procured from the Agriculture and Food Laboratory from
the University of Guelph culture collection. For inoculation of Raw Meat (unprocessed)
food items, strain E. coli O157:H7 ATCC 43889 from human origin was used. Briefly, an
isolated colony, taken from a blood agar plate incubated overnight at 37°C, was used to
inoculate 10 ml of BHI broth and further incubated 18-22 h with shaking at 35°C. Cells
were harvested by centrifugation at 8,000 rpm for 10 min at 4°C. Moreover, the pellet was
re-suspended and washed once using 10 ml of 0.1% peptone water for further use.
Raw Meat (processed) food items must be inoculated with a stressed culture, which was
prepared using E. coli O157:H7 strain 380-94 from unknown origin. The culture was
prepared as above and further incubated in a water bath at 50°C for 1 h (heat stress) before
proceeding with sample inoculation. The % of sub-lethal injury was calculated as described
in Section 3.1.3 by plating in triplicate using non-selective (TSA) and selective
(CHROMagar O157) agars, which were incubated at 35°C for 18-24 h. The % of sub-lethal
injury achieved was reported as the average of the triplicates.
Once both inocula were prepared and equilibrated for 18-24 h at 4°C, they were serially
diluted 10-fold using 0.1% peptone water. Two inoculation levels were needed: a “low
inoculum level (L)”, based on the likelihood of having a fractional recovery (a target
inoculum level of <5 CFU/25g), and a “high inoculum level (H)”, calculated at
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Figure 8. Scheme of the distribution of samples for the unpaired validation study. A
total of 90 samples were evaluated for each food type (Raw Meat Unprocessed and
Processed) distributed among four different Food Items respectively. Each Food Item had
24 or 22 replicates, which were equally split between the alternative method (AM) and
the reference method (RM).
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approximately 1 log higher than (L). The definite culture titers were estimated using
standard plate counts on TSA incubated at 35°C for 18-24 h.
3.3.2.3 Food sample inoculation
Firstly, TVC for each food item was estimated according to the method MFHPB-33
Enumeration of Total Aerobic Bacteria in Food Products and Food Ingredients Using
3M™ Petrifilm™ Aerobic Count Plates from the Compendium of Analytical Methods
(Appendix D). To ensure sample homogeneity, all food items were initially kept in bulk
before splitting them. The equivalent of 20 replicates of each food item was split into 2
primary groups for low (L) and high (H) inoculation levels. The rest of the replicates were
assigned to the uninoculated group (U). Each primary group was inoculated in bulk with
the correspondent E. coli O157 strain, either (L) or (H) inocula prepared as previously
described.
Inoculated bulk samples were mixed and equilibrated at 4°C for 48 h before splitting into
25 g portions and randomly assigned to either of the methods described in Figure 8. This
procedure assured that the true inoculation status of the samples is unknown and thus the
number of true positives within each method could be considered as statistically equal. In
addition, an unpaired samples protocol is performed whenever an alternative method has a
different enrichment than the reference method used for comparison. Therefore, the final
sample distribution consisted of 20 (L), 20 (H) and 5 (U) per food type and method of
analysis respectively.
3.3.2.4 Most Probable Number (MPN) determination of inoculated bulk samples
To determine E. coli O157 concentration after the 48 h equilibration at 4°C before
enrichment, the MPN was determined using a remaining portion of the primary inoculated
bulk samples of each food item evaluated. Portions of 50 g were taken in triplicate from
each high and low inoculation level. Each replicate was mixed with 450 ml of mTSBN
(1:10 dilution). Then, 10% (50 ml) was taken and mixed with another 450 ml of mTSBN
(1:100 dilution). A third dilution was performed in the same way to yield a 1:1000 dilution.
Finally, 50 ml were removed from this last sample to maintain the same volume as the
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previous samples. The final result was a 3×3 (three replicates, three dilution-levels) MPN
preparations, equivalent to having 45 g, 4.5 g and 0.45 g sample sizes. Samples were
incubated at 42°C for 22-24 h before they were further processed using immunomagnetic
separation (IMS) as per MFHPB-10. Furthermore, suspect colonies grown on CHROMagar
O157 and cefixime tellurite sorbitol MacConkey (CT-SMAC) were confirmed as described
in

Section

6.8

of

the

MFHPB-10

method.

Finally,

the

MPN

calculator

(http://members.ync.net/mcuriale/mpn/index.html) was used to estimate the MPN, based
on the number of confirmed positives and reported as MPN/25g.
3.3.2.5 LFIA Test Kit alternative method
The 90 inoculated test portions of 25 g that were randomly assigned to the AM were placed
in Stomacher® bags and homogenized in 225 ml of TSBN for 60 s using a Stomacher®.
Sample bags were loosely closed to allow air exchange for E. coli O157 growth and
incubated at 42±1°C for 16-24 h. After 16 h of enrichment, samples were analyzed using
the LFIA Test Kit Method. Briefly, 200 µl of the sample were pipetted directly into tube
A, while another aliquot of 10 µl of the enriched sample was diluted 1:100 with sample
diluent before pipetting 200 µl into Vial B. Furthermore, 10 µl of the sample buffer were
added to each vial, which were mixed thoroughly and incubated 30 min at RT.
Subsequently, 150 µl from each vial were loaded into their correspondent sample port in
the LFIA device. Results were visually assessed after 15 min according to the following
pattern: a positive result would show control lines in both A and B result windows and test
lines in either A and/or B. On the other hand, negative test results would show control lines
in both A and B result windows, but no test lines in neither A nor B. These results were
recorded as the Alternative Presumptive Result (AP). The complete LFIA Test Kit
methodology and schemes for the proper interpretation of results are shown in Appendix
C.
Because the validation study required an unpaired sample protocol due to different
enrichments used for the AM and RM, the AM enriched samples were re-incubated until
completing 22 h at 42°C. Afterwards, samples were analyzed as described in the MFHPB10 using concentration by IMS followed by selective isolation and ending with
confirmation of suspected colonies (Appendix B). The results obtained were recorded as
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the Alternative Confirmation Result (AC). Figure 9 summarizes the process path followed
to analyze the samples assigned to the alternative method.
3.3.2.6 Reference method MFHPB-10
The 90 samples assigned to the RM were tested following the RM MFHPB-10, which is
found in Appendix B. Briefly, 225 ml of mTSB with 20 µg/ml Novobiocin (mTSBN) were
mixed with each 25 g sample and homogenized for 2 min in a Stomacher®. Samples were
incubated at 42±1°C for 22 h, before they were analyzed as described above, starting with
IMS and finishing with confirmation of suspected colonies following the MFHPB-10
method (Appendix B). The results obtained were recorded as the MFHPB-10 reference
method result (RM).
3.3.2.7 LOD
For the determination of the LOD, only one food item was sufficient; thus ground beef was
chosen. The methodology described in Annex 4.5, Supplement to the Procedure for the
Development and Management of Food Microbiological Methods, Determination of the
Limit of Detection found in the Compendium of Analytical Methods (174) was followed.
Briefly, five spiking levels with six replicates each of artificially inoculated samples at a
range of known inoculum, were analyzed using the AM. In order to determine the inoculum
levels, a 3×3 MPN was performed using the highest inoculation level and following the
methodology described in Section 3.3.2.4. The lowest cell concentrations were
extrapolated from the results obtained from the MPN, while the LOD was estimated within
the two levels that gave respectively more and less than 50% (3/6) positives. A scheme
summarizing the LOD determination is found in Figure 10.
Evaluation of Probability of Detection (POD) and Performance Parameters
For calculating the performance parameters of an AM using a relative validation procedure,
the Compendium of Analytical Methods contains the statistical analyses for assessing the
data generated experimentally. Annex 4.1 Performance Parameters of Microbiological
Methods - Note on Sensitivity and Specificity and Annex 4.4 Supplement to the Procedure
for the Development and Management of Food Microbiological Methods, Procedure for
the Statistical Evaluation and Calculation of Performance Parameters of a New Alternative
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Figure 9. Flow chart of the LFIA Test Kit alternative method. The enriched sample
was evaluated at 16 h of enrichment using the alternative method. The results obtained
were considered the Alternative Presumptive Results (AP) (right). Furthermore, samples
were re-incubated up to 22 h and analyzed following the reference method starting at the
immunomagnetic separation (IMS) procedure. These results were considered the
Alternative Confirmation Results (AC) (left).
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Figure 10. LOD sample preparation scheme. The first row represents the number of
samples and inoculation level needed for calculating the MPN. Second to sixth rows show
the sequence of dilutions needed to estimate the LOD of the LFIA Test Kit.
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Qualitative Method Compared to a Reference Cultural Method (174), were followed
accordingly for presentation and analysis of data. Based on these guidelines, raw data were
summarized in separate tables comprising the AM results and the RM results for each food
type, due to the fact that an unpaired sample study was required. For the AM the
Presumptive Result (AP) and the Confirmation Result (AC) were combined to obtain the
Alternative Final Result (AF). Moreover, the Reference Method was considered to be
100% sensitive and specific because it was based on traditional culturing techniques. Thus,
it could not produce false positives nor false negatives. These raw data were used to
conduct a Probability of Detection (POD) analysis, which included estimating the POD for
the alternative method presumptive results (PODAP), the POD for the alternative method
final results (PODAF) and the POD for the reference method results (PODR) with a 95%
confidence interval. The POD is calculated by dividing the number of positives (!) by the
number of samples analyzed (N). Thus, the POD is calculated for each spiking level per
food type evaluated. Moreover, the comparative performance of the two methods was
estimated by the differences in the POD values according to the following formulas:
"#$% &',) = #$%&' − #$%)
"#$% &,,&' = #$%&, − #$%&'
If the 95% confidence interval associated with each difference included the value zero (0),
the results of the AM were considered equivalent to those of the RM, and the range of false
positive for that specific inoculation level and food item were considered acceptable,
respectively. Finally, data from the AP and AF were used to calculate the performance
parameters of the AM. When the AP result was confirmed by the RM, the AF was
considered a true positive (TP); however, if the confirmation resulted as negative, then the
final result was considered a false positive (FP). On the other hand, if the AP was negative
and confirmed by the AF, it was considered a true negative (TN), but if the confirmation
was positive, the result was a false negative (FN). This final evaluation was used:
-./01213124 =

567. #901213.0
!100
567. #901213.0 + ;<=0. >.?<213.0
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3.4. Development of a Humanized Single-Chain Variable Fragment (scFv) Against
the O-antigen of E. coli O157
Hybridoma Cell Line Growth Conditions, Screening and Propagation
The 13B3 hybridoma cell line used in this study was kindly provided by Dr. James Bono
from the Agricultural Research Service, U.S. Meat Animal Research Center, USDA, in
Nebraska, USA (227). Cryopreserved cells were thawed in a water bath at 37°C and
quickly diluted 1:10 in pre-warmed Gibco® Hybridoma-serum free medium (SFM)
(Gibco®, Life Technologies Inc., Carlsbad, CA, USA). Cells were harvested by
centrifugation at 200 ×g for 5 min at 4°C, and the supernatant removed. The pellet was resuspended in 5 ml of Hybridoma-SFM supplemented with 10% fetal bovine serum (FBS;
Gibco®, Life Technologies Inc., USA) and placed in T25-flasks and incubated at 37°C in
5% CO2. After 24 h, 5 ml of Hybridoma-SFM with 10% FBS were added to the T25-flasks
and returned to the incubator. Cell viability was checked using an haemocytometer and the
Trypan Blue Exclusion Method (228,229). When the cell density reached 105–106 cells/ml
and the viability was above 90%, cells were subcloned following the 96-well plate Limiting
Dilution Method, using a theoretical final concentration of 1 cell/well (228,230–233). After
one week, 100 µl of Hybridoma-SFM were added to those wells with single colonies. The
96-well plates were re-incubated until single colony wells reached 30–50% confluence and
the medium turned yellow (228,231). At this point, the supernatants of single colony wells
were screened for antibody production using a sandwich ELISA against E. coli O157:H7.
To ensure the stability and monoclonality of the hybridoma cell-line, one of the positive
clones was randomly selected and subcloned for a second time, as described above. After
this second subcloning, the three clones with the highest antibody titre were sequentially
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expanded to a 12-well plate, then a 6-well plate, and finally to a T75-flask. When cells
reached >90% viability and a density of 106 cells/ml, they were harvested for
cryopreservation by centrifugation at 200 ×g for 5 min at 4°C, and the supernatant
discarded. The pellet was re-suspended in freshly made FBS with 10% dimethyl sulfoxide
(DMSO; Sigma Aldrich, USA) and quickly transferred into cryopreservation vials for
storage at -20°C overnight. Subsequently, cryovials were moved to a -80°C freezer for a
maximum of one week before they were placed in a liquid nitrogen tank for long-term
storage.
For antibody production and RNA extraction, cells were harvested from a cryopreserved
sample as previously described. This time, the pellet was re-suspended in 2 ml of
Hybridoma-SFM with 10% FBS and transferred to the first well (#1) of a 24-well plate,
with 7 more wells filled with 1 ml of Hybridoma-SFM with 10% FBS. A serial dilution
was performed by transferring 1 ml from well #1 to well #2. Then, 1 ml of well #2 was
transferred to well #3, and followed the same sequence until well #7 was reached. Cultures
were mixed thoroughly in the well before proceeding with each dilution. The plate was
incubated at 37°C in 5% CO2 for 1–2 d until the initial wells reached 70% confluence. At
that point, cells were collected and placed in 15 ml conical tubes with 10 ml of fresh
Hybridoma-SFM. Cells were harvested by centrifugation at 200 ×g for 10 min at RT and
the supernatant was replaced with 2 ml of Hybridoma-SFM for pellet resuspension. The
cells were transferred to a 6-well plate containing 4 ml of the same medium, and incubated
at 37°C in 5% CO2. Plates were checked daily for cell viability and overcrowding. When
wells in the 6-well plate reached 60–70% confluence, cells were transferred to a T75-flask
containing 14 ml of Hybridoma-SFM. Cells were subcultured in T75-flasks in a 1:10 ratio
for a maximum of three passages. When cell viability was >90%, an aliquot was taken for
RNA extraction. The rest of the culture was re-incubated for antibody production until the
medium turned yellow and the cell viability decreased to approximately 50%. Finally, the
supernatant was collected by centrifugation at 200 ×g for 10 min at 4°C for antibody
purification.
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Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) and
Western Blotting (WB) for Protein Visualization
A 10 or 12% polyacrylamide resolving gel with 5% stacking gel was prepared using TrisGlycine Running Buffer, then 1D vertical SDS-PAGE was performed for 1.7 h at 110 V
using a Mini-PROTEAN System (Bio-Rad Laboratories Inc., Hercules, CA, USA).
Samples were mixed in a 3:1 ratio with Laemmli buffer (4×) and boiled for 10 min before
loading into the gel. The gel was fixed and stained with Coomassie Blue staining solution
for 10 min followed by destaining until the background of the gel was clear. For size
determination, the BLUeye Prestained Protein Ladder (FroggaBio Inc., Toronto, ON,
Canada) was used for comparison.
For Western Blotting analysis, protein samples were separated on a 12% polyacrylamide
resolving gel prepared as described above, without end-stage staining. Instead, proteins
were immobilized for detection by transferring the samples from the gel matrix to a
nitrocellulose membrane, 0.45 µm (Bio-Rad Laboratories Inc., USA) using electroblotting
with a Trans-Blot® SD semi-dry transfer cell (Bio-Rad Laboratories Inc, USA) for 1.2 h
at 16 V, 0.26 limit for one gel. Prior to transfer, both the resolving gel and the membrane
were equilibrated with Towbin Semi-Dry Transfer Buffer for 20 min with gentle shaking.
After transfer, the membrane was blocked using 5% (w/v) non-fat dry milk in 1×TBST
overnight at RT with shaking. For protein detection the biotinylated tag was probed for 2
h at RT with conjugated streptavidin-IRDye800 (1:10,000 in 1×TBST with 0.5% (w/v)
non-fat dry milk). The membrane was washed 3 times with 1×TBST for 5, 7 and 10 min,
respectively, and a last wash of 5 min with 1×TBS prior to viewing using a LI-COR
Odyssey® Infrared Imaging System (LI-COR, Lincoln, NE, USA). The composition of all
buffers and reagents is described in Appendix E.
Enzyme-Linked Immunosorbent Assay (ELISA) and Fluorescent-Antibody
Microscopy for Antibody Functionality Assessment
An ELISA was performed for hybridoma screening and to determine the functionality of
both the purified murine monoclonal anti-O157 and its derived single-chain variable
fragment (scFvO157). The procedure was adapted from Westerman et al. (227). Briefly,
microtiter plates were coated with 0.1 ml of an overnight working culture diluted to
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approximately 5×108 CFU/ml in Coating Buffer. The plates were sealed with Saran wrap
and incubated overnight at 4°C. E. coli O157 DSM 17076 was used as a positive control,
while E. coli ATCC 25922, S. enterica ser. Typhimurium and L. monocytogenes were used
as negative controls. Plates were washed 3 times with 1×PBST before adding 200 µl of
Blocking Buffer and incubated for 1 h at RT. Washing was repeated as before and the
appropriate sample (hybridoma supernatant, purified mAb or scFvO157) or controls
(Hybridoma-SFM or protein diluent) was added to the wells. This time, plates were
incubated for 2 h at RT. For hybridoma screening, the supernatant was undiluted, however,
the mAb and scFvO157 samples were diluted in Blocking Buffer and assessed at different
concentrations. Furthermore, the plates were washed 6 times as described above, blocked
again with 200 µl of Blocking Buffer and incubated for 17 min or 1 h at RT then washed
again. When evaluating the mAb functionality, plates were incubated 1 h at RT with 100 µl
of

peroxidase-conjugated

anti-mouse

IgG

heavy

and

light

chains

(Jackson

ImmunoResearch Inc., PA, USA) diluted 1:5,000 in Blocking Buffer. On the other hand,
horseradish peroxidase conjugated streptavidin (Streptavidin-HRP; Moss, Inc., Maryland,
USA) was used for scFvO157. Finally, plates were washed 6 times and 100 µl of 3,3',5,5'tetramethylbenzidine (TMB) ELISA peroxidase substrate (Rockland Immunochemicals
Inc., USA) were added to each well. After 20 min at RT, plates were read using a VMax
Kinetic ELISA Microplate Reader (Molecular Devices, LLC., CA, USA) at a wavelength
of 650 nm. The absorbance of control samples was used to determine the cut-off value as
established by the formula:
F72 − 9DD G<=7. = H3.6<?. I=</J + 3(-%)
Absorbance values above the cut-off were considered positive, while values below it were
considered negative.
For fluorescent microscopy, a loop from an overnight working culture was streaked onto a
TSA plate and incubated at 37°C for 24 h. A colony was picked and spread onto a glass
slide using a drop of water. Slides were allowed to air dry before they were fixed in cold
( -20°C) acetone (Sigma-Aldrich, USA) for 10 min and air dried again. Two circles were
drawn on each slide using a wax pencil to keep the reagents from spreading and drying out
during incubation. As a negative control, 100 µl of 1×PBS were added to one circle, while
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100 µl of either scFvO157 or mAb dilution were added to the other circles. After incubation
at 37°C for 30 min in a moisture chamber, the slides were washed 3 times in 1×PBS and
dried at RT before 100 µl of Streptavidin-fluorescein isothiocyanate conjugate
(Streptavidin-FITC; BioLegend, San Diego, CA, USA) or anti-mouse IgG (whole
molecule)-FITC (Sigma-Aldrich, USA) diluted 1:40 in 1×PBS with 5% BSA were added
to each circle. The slides were re-incubated for 30 min at 37°C and washed as before with
a final 2 min wash in distilled water. Slides were air dried and coverslips were mounted by
using a drop of AquaPerm mounting medium (Life Technologies Inc., Carlsbad, CA,
USA). The slides were then examined with an Olympus IX71 Inverted Micropscope
(Olympus Canada Inc., Richmond Hill, ON, Canada).
Murine mAb Characterization and Purification
The supernatant collected from the T75-flasks was initially isotyped using the Mouse
Immunoglobulin Isotyping ELISA Kit from BD Pharmigen™ (BD Biosciences, San Jose,
CA, USA). Eight different mouse immunoglobulin isotype-specific rat monoclonal
antibodies (IgG1, IgG2a, IgG2b, IgG3, IgM, IgA, Ig κ, and Ig λ) were coated in each row
of a 96-well plate. The positive control was an antigen mixture provided with the kit, while
the negative control was the Hybridoma-SFM medium. As the detection antibody, a HRPlabeled rat anti-mouse Ig monoclonal antibody was used. Preparation of reagents and assay
conditions were according to the manufacturer’s instructions.
The supernatant was concentrated 10 times using the Amicon® Ultra-15 Centrifugal Filter
Units NMWL 30 kDa (EMD Millipore, Germany) at 4000 ×g before purification using the
Nab™ Spin Kit for Antibody Purification (Thermo Scientific, IL, USA). A gravity-flow
procedure was followed as per the manufacturer’s instructions. In brief, the sample was
equilibrated with binding buffer in a 1:1 ratio and applied to the column. The column was
washed using 15 ml of binding buffer, then the elution buffer (12 ml) was applied. The
eluted antibody was collected in 3 ml fractions in tubes containing the appropriate volume
of neutralization buffer. Purified fractions were analyzed by SDS-PAGE; those that stained
positive pooled together, concentrated and dialyzed against 1×PBS pH 7.4 using the
Amicon® Ultra-15 Centrifugal Filter Units NMWL 30 kDa. The antibody was assessed for
homogeneity and purity by SDS-PAGE, and quantified using a NanoDrop 1000
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Spectrophotometer (Thermo Fisher Scientific Inc., Waltham, MA, USA). Finally, aliquots
were prepared and stored at 4°C for short-term use and at -20°C for long-term (up to 6
months).
The isoelectric point (pI) of the mAb was also determined with Ettan IPGphor II Isoelectric
Focusing (IEF; Amersham Bioscience AB, Uppsala, Sweden) equipment. An aliquot of the
purified mAb in 1×PBS, pH 7.4 was buffer exchanged using only water and the Amicon®
Ultra-15 Centrifugal Filter Units NMWL 30 kDa. The sample was washed three times to
remove 99% of the buffer. The appropriate sample volume was mixed with rehydration
buffer stock solution (RBSS) and IPG buffer (GE Healthcare Life Sciences, Piscataway,
NJ, USA). The mixture was spread evenly along the groove of each sample boat.
Furthermore, the 13 cm gel strip (Immobiline DryStrip, GE Healthcare Life Sciences,
USA) was placed with the gel facing down into each boat. For this assay, linear pH 3-10
range strips were used. The strips were covered with Dry Strip Cover Fluid (GE Healthcare
Life Sciences, USA) and then covered with the lid. The following step-n-hold protocol was
used to run the samples: 20 V for 12 h, 100 V for 20 min, 500 V for 500 Vh, 1000 V for
1000 Vh, 2000 V for 4000 Vh, 4000 V for 8000 Vh, 6000 V for 12000 Vh, and 8000 V for
30000 Vh, for a total running time of 24 h. The gels were taken out of the boat, fixed with
20% trichloroacetic acid (TCA; BDH Chemicals, VWR International, LLC) for 30 min,
then washed with 40% methanol (Caledon Laboratories, ON, Canada) and 7% acetic acid
(Sigma-Aldrich, USA) for 3 min, and used for direct staining with Gelcode™ Blue
(Thermo Fisher Scientific Inc., USA) for 1 h. Strips were destained twice for 15 min with
distilled water before distinct bands were visualized. The approximate distance for the
bands with respect to the beginning of the gel strip was measured in cm and the pI was
determined using the DryStrip gradient data provided by the gel strip supplier.
Hybridoma RNA Isolation
Between 1×106 and 5×106 hybridoma cells from an expanded ELISA-positive clone were
harvested for RNA extraction. Hybridoma cells were centrifuged for 5 min at 200 ×g at
4°C, the supernatant was discarded and the cells were washed with 1×PBS. The PureLink®
RNA Mini Kit (Life Technologies, USA) was used following the manufacturer’s protocol
for RNA purification from animal and plant cells. To ensure that total RNA was DNA-free,
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an on-column DNase digestion was performed using a RNase-Free DNase Set (Qiagen
Gmbh, Hilden, Germany) before washing the column. Total RNA elution was achieved
with 50 µl of Dnase/RNase/Protease-free water (BioShop, Canada) and quantified using a
NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific Inc., USA).
mAb Variable Regions Reverse Transcription (RT) and Polymerase Chain Reaction
(PCR)
The primers used for the RT-PCR were synthesized by Invitrogen® (Life Technologies,
USA) based on the sequences published by Wang et al. (196), shown in Table 7. The
highly degenerate 5’ primers for both variable heavy (VH) and light (VL) chains were
designed to start at the first nucleotide of the framework region 1 (FR1). For the VH, a
combination of two high degeneracy primers was used to cover the majority of possible
sequences, ensuring amplification of the VH gene. On the other hand, the 3’ primers were
complementary to the first constant region of each of the heavy and light kappa chains (CH1
and CκL). In addition, to be chain specific, the CH1 primer used in this study was isotypespecific for IgG3. All primers were rehydrated with the appropriate volume of Tris-EDTA
(TE) buffer (Thermo Fisher Scientific Inc., USA) to obtain 100 µM stock solutions that
were stored at -20°C. They were diluted 1:10 in TE buffer for preparation of working
solutions that were stored at 4°C for short-term use.
The QuantiTect Reverse Transcription Kit (Qiagen, Germany) was used to synthesize
cDNA from 2 µg of total RNA. Two reactions were carried out, each one containing a final
concentration of 0.7 µM of either the CH1 or CκL gene-specific primer. The rest of the
procedure was followed as per the manufacturer’s protocol. The resultant cDNA was
amplified by PCR (T100™ Thermal Cycler, Bio-Rad Laboratories, USA) using 1.25 U of
Taq Polymerase (Life Technologies Inc., USA), 0.2 mM deoxyribonucleotide
triphosphates (dNTP; Life Technologies Inc., USA), 1.5 mM MgCl2, 0.2 µM of each
primer (CH1 and MH1/MH2 for VH reaction; CκL and Mκ for VL), 1×PCR buffer and 2 µl of
the respective cDNA. The thermal cycling conditions for the amplification of the VH were
as follows: denaturation at 94°C for 3 min, followed by 30 cycles of 95°C for 45 s, 45°C
for 45 s, and 72°C for 1 min. The VL amplification was performed under the following
conditions: initial denaturation at 94°C for 3 min, followed by 10 cycles of 95°C for 45 s,
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Table 7. Sequences of primers for mAb VH and VL chains RT-PCR.
Primer
Name

Sequence (5’-3’)1

Description

C H1

gga aga tct AGG GAC CAA GGG
ATA GAC AGA TGG

Mouse heavy chain ﬁrst constant region primer.
IgG3 isotype speciﬁc (196)

CκL

ggt gca tgc GGA TAC AGT TGG
TGC AGC ATC

Mouse kappa chain constant region primer (196)

M H1

ctt ccg gaa ttc SAR GTN MAG CTG
SAG SAG TC

Mouse heavy chain FR1 high degeneracy
primers (196)

M H2

ctt ccg gaa ttc SAR GTN MAG CTG
SAG SAG TCW GG

Mκ

gg gag ctc GAY ATT GTG MTS
ACM CAR WCT MCA

1Underlined

Mouse kappa chain FR1 universal degenerate
primer (196)

nucleotides represent restriction enzyme recognition site.

87

45°C for 45 s, and 72°C for 1 min. Then, 10 cycles of 95°C for 45 s, 47°C for 45 s, and
72°C for 1 min. Finally, 10 cycles of 95°C for 45 s, 50°C for 45 s, and 72°C for 1 min. In
both cases, the final extension was achieved at 72°C for 7 min and the reaction cooled to
4°C. Both of these amplification thermal cycling conditions were previously published by
Koren et al. (195).
Plasmid DNA Isolation
Plasmid DNA was isolated and purified from E. coli XL1 Blue or BL21 (DE3) cells in
stationary phase (O/N aerobic growth at 37°C) with a QIAprep Spin Miniprep Kit (Qiagen,
Venlo, Limburg, Netherlands) as per the manufacturer’s microcentrifuge protocol. Plasmid
DNA was eluted with 50 µl of EB buffer (Qiagen, Netherlands) and stored no longer than
one month at -20°C for further use.
DNA Visualization and Gel Extraction
DNA was resolved by electrophoresis on 1%, 1.5% or 2% agarose DNA grade high-melt
gels (Thermo Fisher Scientific Inc, USA) in 1×TBE buffer at 85 V using a Mini-Sub Cell®
GT Agarose Gel Electrophoresis System (Bio-Rad Laboratories Inc., USA). Samples were
mixed 2:1 with gel loading buffer for nucleic acids (Sigma-Aldrich, USA), stained with
ethidium bromide (EtBr; MO BIO Laboratories, Inc., Qiagen, USA) and visualized under
ultraviolet light (UV; EpiChemi3 with 3UVTM Transilluminator, UVP, LLC., CA, USA).
For DNA fragment size determination, bands were compared against a 1 Kb Plus DNA
ladder (Invitrogen, Life Technologies Inc., USA). The DNA bands of interest were excised
and purified using a QIAquick Gel Extraction Kit (Qiagen, Netherlands) following the
manufacturer’s protocol. Purified DNA was eluted with 30 µl of EB buffer (Qiagen,
Netherlands) and the final concentration measured using a NanoDrop 1000
Spectrophotometer (Thermo Fisher Scientific Inc., USA).
DNA Sequencing
Sequencing of the VH, VL chains and plasmid DNA was performed at Robarts Research
Institute Sequencing Facility (Western University, London, ON, Canada) using either the
specific primers in Table 7 or the standard primers provided by the Sequencing Facility,
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which are described in Table 8. All samples were prepared following the standard
operating procedures of the Sequencing Facility (www.robarts.ca/sample-preparation).
Construction of the Humanized scFvO157
The VH and VL nucleotide sequences were translated into amino acids using the ExPASy
online

translation

tool

from

the

Swiss

Institute

of

Bioinformatics

(SIB;

http://web.expasy.org/translate/). To confirm that both sequences were new and
corresponded to VH and VL murine domains, each one was submitted to the BLASTP
program (http://blast.ncbi.nlm.nih.gov/Blast.cgi), where the non-redundant protein
database was selected to perform a multiple sequence alignment (MSA) using the
Constraint-Based Multiple Alignment Tool (COBALT). This helped to determine the
degree of conservation of each residue based on the Identity Conservation Setting.
Moreover, the specific CDR boundaries were defined based on predicted topological 3D
modeling. Briefly, the VH and VL sequences were submitted to SWISS-MODEL
(www.swissmodel.expasy.org) to obtain a structure homology model based on the template
with the highest sequence identity found in the Protein Database (PDB). Using the
COBALT results, the regions with more variability were used to define the
complementarity determining region (CDR) loops in the 3D model. Predicted CDR loops
and the immediate amino acids flanking them were finally grafted into a consensus
humanized backbone previously described by Patterson et al. (234). Finally, the humanized
scFvO157 construct was designed to have a Tobacco Etch Virus (TEV) cleavable site at
the N-terminal and a C-terminal biotin tag, as well as KpnI and BamHI restriction enzyme
sites, respectively, for strategic cloning purposes (Figure 11). The final humanized
scFvO157 was codon optimized for cloning and expression in E. coli cells, synthesized and
cloned into pUC57 plasmid by GenScript Corp (Piscataway, NJ, USA).
Further along the process, the humanized scFvO157 sequence was reanalyzed using
antibody informatics tools such as the Prediction of ImmunoGlobulin Structure (PIGS)
web-based server (http://circe.med.uniroma1.it/pigs/)(235) and Maestro Software
(Schrödinger, New York, NY, USA). The former was used to re-design the mAb. Briefly,
the single sequence submission was chosen, which allowed for the prediction of a single
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Table 8. Sequences of standard primers provided by the Sequencing Facility at
Robarts Research Institute, Western University.
Primer Name

Sequence (5’ - 3’)

Description

M13/pUC forward

CGC CAG GGT TTT CCC AGT
CAC GAC

Primers for sequencing inserts into pUC
plasmids.

M13/pUC reverse

TCA CAC AGG AAA CAG CTA
TGA C

T7 promoter

TAA TAC GAC TCA CTA TAG
GG

T7 terminator

GCT AGT TAT TGC TCA GCG
G

Primers for sequencing inserts into pET
plasmids.
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Figure 11. Humanized scFvO157 construct. Complete humanized scFvO157 construct
used for further cloning and expression. KpnI and BamHI restriction enzyme sites are
shown at the N- and C-terminal respectively. TEV cleavable site is found at the N-terminal
(orange) followed by the VH chain (blue) joined by a (G4S)3 linker (red) to the VL chain
(green). The biotin tag (yellow) found in the extreme C-terminal was attached to the VL
by a SG3 linker.
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antibody by uploading the sequences of the VH and VL chains from the mAb. For template
selection, the default number of results shown, which is 20, was used. Moreover, the “Best
H and L chains” method was chosen and the VH and VL chain structure templates with the
highest percentage of identity were selected for the prediction step. The Loop Grafting
Method and Side Chain Modeling Method were kept as default. The predicted structure in
PDB format was visualized with Maestro Software for subsequent structure analysis. On
the other hand, the amino acid sequence of the consensus humanized scFv used as
backbone for CDR grafting was submitted to SWISS-MODEL to obtain a 3D model and
further imported into Maestro Software for analysis. 3D models were superimposed using
the Protein Structure Alignment tool and the alignment score and root-mean-square
deviations (RMSD) were calculated to quantify the similarity between the two models.
Finally, the Multiple Sequence Viewer was used to compare some of the intrinsic
properties such as hydrophobicity between both proteins.
Molecular Cloning of the scFvO157
3.4.11.1 Restriction digestion
The gene encoding the TEV::scFvO157::biotin tag was excised from pUC57 using the
restriction enzymes KpnI and BamHI (New England BioLabs Inc., Ipswich, MA, USA)
following the manufacturer’s instructions. Briefly, the double digestion reaction consisted
of the target DNA plasmid, 1 U of each enzyme/µg DNA, 1×enzyme specific buffer and if
necessary, 1×BSA (New England BioLabs Inc., USA). Then, the reaction was incubated
for 1-2 h in a water bath at 37°C. As controls, single digestion reactions were prepared and
compared by visualization in a 1% agarose gel. The construct was purified from the gel
using a Qiaquick PCR Purification kit (Qiagen, Netherlands) and eluted with 50 µl of EB
Buffer as per the manufacturer’s instructions. The same procedure was followed for
preparing the digested pET32a(+) vector used for insertion of the TEV::scFvO157::biotin
tag construct.
3.4.11.2 DNA ligation
Ligation of the TEV::scFvO157::biotin tag and the digested pET32a (+) plasmid was
performed for 1 h in a water bath at 16°C. The reaction contained 40 U T4 DNA Ligase
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(New England BioLabs Inc., USA), 1×T4 Ligase Buffer (New England BioLabs Inc.,
USA), and appropriate concentrations of both scFv construct and pET32a(+) digested
plasmid, based on a sticky-ends ligation.
All vectors used and obtained in this study are summarized in Table 9. In addition, all
plasmid inserts were sequenced at the Robarts Research Institute Sequencing Facility
(London, ON, Canada).
3.4.11.3 Transformation of chemical competent E. coli cells
A 100 µl aliquot of chemical competent E. coli cells was thawed and incubated with 10 µl
of the appropriate plasmid DNA for 30 min on ice. Heat shock was induced by incubating
the cell at 42°C for 45 s and immediately placing it on ice for 2 min. Subsequently, 900 µl
of LB broth were added to the cells, which were incubated for 1 h at 37°C with shaking.
Finally, the transformed cells were spread plated on LB agar containing the appropriate
antibiotics and incubated overnight at 37°C for 18 h.
3.4.11.4 E. coli clone selection
Individual colonies taken from the spread plates were picked and inoculated into 4 ml of
LB with the appropriate antibiotics. Tubes were incubated overnight for 18 h with shaking.
Plasmid DNA was isolated as previously described and visualized using a 1% agarose gel.
The insert size was also verified by restriction digestion and by sequencing for final
confirmation. Cultures that were confirmed to be successfully transformed with the
appropriate plasmid were prepared for storage at -80°C as described in Section 3.1.7.
Expression of scFvO157
The E. coli BL21 (DE3) transformed with pBirACm (containing the birA gene coding for
biotin ligase), and the pET32a(+) TEV scFvO157:biotin tag plasmids was used to express
the recombinant protein of interest (TrxA His•Tag® TEV scFvO157 biotin). Cells were
grown aerobically at 37°C in LB medium with the appropriate antibiotics to an OD600=
0.1- 0.5 (early log phase). For optimization of protein expression, induction was performed
under different isopropyl-D-thiogalactopyranoside (IPTG; Bio Basic Canada Inc.,
Markham, ON, Canada) concentrations (1, 0.5, 0.3, 0.2, 0.1 mM), temperatures (4°C, 37°C
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Table 9. Plasmids used in this study.
Plasmid Name

Relevant Characteristic

Source
r

pET32a(+)

Protein expression vector; Ap ; 109aa Trx•Tag™
thioredoxin protein (TrxA) and His•Tag®
sequences

Novagen

pBirACm

pACYC184 with inducible biotin ligase; Cmr

Avidity

pUC57::TEV:: scFvO157:: biotin
tag

Codon optimized scFvO157 sequence with KpnI
and BamHI sites; Tobacco Etch Virus (TEV)
protease cleavage site; C-terminal biotin tag; Apr

GenScript

pET32a(+)::TEV::scFvO157::biotin
tag

TEV:: scFvO157:: biotin from pUC57:: TEV::
scFvO157:: biotin inserted into KpnI and BamHI
sites of pET32a (+)

This
study

Apr, Ampicillin resistance; Cmr, Chloramphenicol resistance
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and RT) and incubation times (3, 6, 48 h, and overnight). In addition, protein biotinylation
was achieved by adding 50 mM D-biotin (BioBasic Inc., Canada). Cells were harvested by
centrifugation at 5,000 ×g for 7 min at 4°C and the pellet re-suspended in cold Native
Buffer (20 mM Tris-HCl, pH 7.4, 200 mM NaCl). For cell lysis, the pellet was treated with
0.25 mg/ml lysozyme (Sigma-Aldrich, USA) and 0.02 mg/ml DNase I (Sigma-Aldrich,
USA) and incubated on ice for 1 h prior to sonication (Branson Sonifier 450, Branson
Ultrasonics Corporation, USA) with output 5, 3 cycles of 30 pulses each. The soluble and
insoluble fractions were separated by centrifugation at 4°C at 4,000 ×g for 15 min and both
fractions stored at -20°C for further analysis.
Purification and Refolding of scFvO157
The recombinant protein expressed was purified using nickel-nitrilotriacetic acid (NiNTA) His•Bind® resin (Novagen, EMD Millipore, USA) under three different conditions,
which were adapted from Akbari et al. (203) and are described below.
3.4.13.1 Native conditions
The soluble fraction was applied to a Ni2+-charged Ni-NTA affinity column and incubated
at RT for 1 h with agitation using a rotator wheel. The column was washed with Native
Buffer and eluted with increasing concentrations of imidazole (5 ml each of 15 mM,
30 mM, 60 mM, and 200 mM imidazole in Native Buffer).
3.4.13.2 Denaturing conditions
The pellet containing the scFvO157 inclusion bodies was re-suspended in Denaturing
Buffer pre-warmed at 37°C and gently rocked for 10 min at RT to ensure lysis.
Furthermore, the cell lysate was sonicated on ice (3 cycles of 10 pulses using output 5).
Cell debris was removed by centrifugation at 4,000 ×g for 15 min. Then, the supernatant
was pipetted into a Ni2+-charged Ni-NTA affinity column and incubated at RT for 30 min
with gentle agitation. The column was washed twice with Denaturing Binding Buffer and
eluted using the Denaturing Elution Buffer. For refolding, the eluted recombinant protein
was dialyzed (dialysis membrane, 12,000 Da MWCO; Sigma-Aldrich, USA) against
10 mM Tris, 0.1 % Triton X-100, pH 5.5 buffer at 4°C to eliminate urea.
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3.4.13.3 Hybrid conditions
This protocol combined the previous denaturing and native methods. First, a bacterial pellet
was lysed following the denaturing protocol. The supernatant was applied to a Ni2+-charged
Ni-NTA affinity column and incubated at RT for 30 min with gentle agitation. The column
was washed twice with Denaturing Binding Buffer and four times with Native Wash
Buffer. Finally, the protein was eluted using Native Elution Buffer.
All purified fractions were dialyzed 3 times, 1 h each, against 200-400 times the volume
of Native Buffer at RT. Afterwards, the N-terminal tag (TrxA His•Tag® TEV) was
cleaved by autoinactivation-resistant His7::TEV protease (30 µl/ml sample) incubated 2 d
at RT. Cleaved proteins were purified using a second Ni-NTA affinity column following
the native conditions protocol. The fraction containing the pure scFvO157 biotin was
dialyzed against Native Buffer as described above, assessed for homogeneity by SDSPAGE and quantified using a Pierce™ BCA Protein Assay Kit and/or a NanoDrop 1000
Spectrophotometer, both from Thermo Fisher Scientific Inc., USA.
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CHAPTER 4 RESULTS
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4.1. Development of a LFIA for Detection of E. coli O157
Preparation and Evaluation of Bacterial Cultures
4.1.1.1 Preparation of healthy bacterial cultures
During the LFIA Test Kit development phase, five bacterial strains were frequently used
throughout the process: E. coli O157 DSM 17076 served as the positive control, while S.
enterica ser. Typhimurium LT-2, Shigella flexneri ATCC 25929, E. coli ATCC 25922 and
Listeria monocytogenes ATCC 19115 were used as cross-reaction controls. S. enterica ser.
Typhimurium, S. flexneri and E. coli ATCC 25922 are Gram negative bacteria belonging
to the Enterobacteriaceae family and thus closely related to E. coli O157 (24,236). These
bacteria represented ideal candidates for assessment of antibody cross-reactivity as they
also possess the O-antigen as part of their outer membrane, although with structural
variations that distinguish them from E. coli O157 (149). L. monocytogenes, a welldescribed human pathogen, was used as a representative of the Gram positive group. All
healthy cultures reached 109 CFU/ml after an 18-24 h incubation period, with the exception
of S. enterica ser. Typhimurium, which was approximately 108 CFU/ml, as confirmed by
plate counts.
4.1.1.2 Preparation of stressed E. coli O157 cells
Healthy cells, prepared as previously described, were used when assessing the performance
of the LFIA Test Kit under unprocessed raw meat conditions. However, when evaluating
processed raw meat conditions, it was necessary to mimic realistic situations, where
bacterial replication may be impaired due to exposure of meat to physical or chemical
treatments (170,225). Therefore, a “food stress” treatment, which consisted of incubating
an E. coli O157 culture for 10 d at 4°C with conditions similar to real processed raw meat
samples (TSB, 0.6% yeast extract, pH 4.9, and 130 g/L NaCl), was chosen for preparing
stressed cells that could be used for artificial inoculation (225). After treatment, E. coli
O157 cells were plated in parallel on non-selective (TSAYE) and selective (CR-SMAC)
media and the difference in growth was further compared to obtain the % of sub-lethal
injury. Therefore, to ensure the proper performance of both TSAYE and CR-SMAC media,
they were initially evaluated with a healthy E. coli O157 control. Plate counts were further
compared using a two-sided t-test (α=0.05). The results showed that cells plated on
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selective media (CR-SMAC) produced significantly lower CFUs compared with nonselective media (TSAYE) (p<0.05, Figure 12A). Hence, it was necessary to establish a %
of sub-lethal injury, or threshold value, attributed to the media performance in order to
distinguish from the true effect of the “food stress” treatment. The threshold value was
estimated as one standard deviation above the mean of % of sub-lethal injury calculated
for the eight healthy control samples assessed (225), which resulted in 21.7%. This
threshold value was further used to assess whether the % of sub-lethal injury was truly
caused by the “food stress” treatment or was simply an effect of the media performance.
Furthermore, five different E. coli O157 strains were treated following the “food stress”
protocol and the % of sub-lethal injury was compared with the threshold value previously
obtained using a one-sample t-test (α=0.05). Two of them, EC20001018 and EC19970515,
did not differ from the threshold value estimated (p=0.1426 and p=0.1385, respectively).
Therefore, the % of sub-lethal injury for both of them was assumed to be due to the media
performance rather than the effect of the “food stress” treatment. On the other hand, three
strains showed a difference in % of sub-lethal injury (p<0.05), which was attributed to the
effect of the “food stress” treatment (Figure 12B). These data demonstrated that although
all strains evaluated belong to the same species, E. coli O157, there was an inherent cellto-cell variation that could be reflected in the response to stress. Finally, despite the fact
that there was an intrinsic effect caused by the performance of the media, three strains
showed an adequate % of sub-lethal injury, which was optimal for their further use in the
artificial inoculation of meat samples.
Optimization of the LFIA Device Blocking Conditions
In order to improve the visualization of the test line in the positive control while eliminating
background signals, the first phase of the LFIA Test Kit development process focused on
reducing the non-specific binding. Although different combinations of proteins and
polymers were initially assessed, BSA, which is frequently reported to block non-specific
binding in nitrocellulose strips (237–239), was selected as the best alternative for further
optimization, based on our evaluation. In addition, Tween 20 was preferred over Triton X100 as a nonionic detergent for improvements in sample flow through wettability. Using a
blocking buffer either as a sample diluent or pre-treatment decreased the red smear along
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Figure 12. Preparation and assessment of stressed E. coli O157 cells. A) Bar graph
shows the difference in CFUs between the non-selective (TSAYE) and selective (CRSMAC) media performance using an E. coli O157 control culture. CFUs were
significantly lower on CR-SMAC compared with TSAYE (1.41×109 ± 1.57×108 and
1.57×109 ± 1.77×108, respectively). The p-value is from a two-sided paired t-test (p=
0.0254, n=8). Values represent mean ± SEM. B) Bar graph representing the % of sublethal injury of 5 different E. coli O157 strains subjected to a “food stress” treatment. Each
bar represents the mean value of % of sub-lethal injury ± SEM (n=3-5). A one sample ttest, using the threshold value (21.7%), was performed to determine whether the % of sublethal injury was truly caused by the “food stress” treatment or was mainly due to the
performance of the media (*p ≤0.05)
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the membrane and improved the flow of the sample through the nitrocellulose membrane,
as indicated by a well-defined control line when compared with the device without
blocking buffer (Table 10). In addition, positive samples showed a clearly defined test line
within the 15 min window established for reading, while negative samples remained clear
(Table 10). Despite the improved performance, the two approaches required additional
steps, increasing the complexity of the assay. Thus, it was necessary to assess additional
blocking strategies.
4.1.2.1 Assessment of different nitrocellulose blocking solutions
Prior work indicated that incorporating a blocking step increased the complexity of the
assay despite the improvement in the performance of the LFIA. Thus, an alternative
approach, where the blocking reagents were incorporated directly into the nitrocellulose
membrane during manufacture, was assessed.
The optimal concentration and type of blocking were determined by assessing different
ratios of BSA and/or Tween 20. The most representative prototypes of the blocking
optimization process are summarized in Table 11. The positive control was E. coli O157
DSM 17076 diluted to 107 CFU/ml using TSB, while the negative control was TSB alone.
Based on the criteria previously established for visual evaluation, LFIA devices A, E, and
F were ruled out because there was no control line either in the positive or the negative
control. Device B had twice the concentration of BSA and Tween 20 compared to A, which
slightly improved the development of control lines, however, it did not decrease the
formation of red smear along the membrane. This appearance was similar to device D,
which contained the same concentration of BSA only. Device B blocking treatment was
doubled in device C, causing better control lines and a slight decrease in the red smear.
However, the test line in the positive control was still unclear. Finally, device G was
blocked with a higher volume per mm2 of B treatment, resulting in an intense, well-defined
control line in the negative control. The positive control had a clear background with the
appearance of both the control and test lines, though the signal intensity was weak.
Based on these results, the volume of the B solution was optimized and three more
alternatives (1/2G, 1/4G, and 1/6G) were tested. The objective of using blocking post-

103

Table 10. Initial assessment of nitrocellulose blocking conditions.
Blocking

Positive Control

Negative Control

A) No blocking

B) Blocking buffer as
diluent

C) Blocking buffer as
pre-treatment

A) Standard LFIA with no blocking buffer used. B) Blocking buffer was used to re-suspend an overnight
culture of E. coli O157 DSM 17076 before mixing the reagents for the in-tube sandwich immunoassay. C)
Pre-treatment of the LFIA with 50 μl of blocking buffer before sample loading. The positive control
consisted of a 107 CFU/ml sample of E. coli O157 DSM 17076 while the negative control contained only
blocking buffer. Images of the LFIA devices were taken after 15 min after loading 150 μl of the
corresponding sample. The concentration of antibodies was kept constant throughout these experiments.
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Table 11. Screening of blocking conditions for the LFIA devices.
LFIA

Nitrocellulose Treatment

A

0.75% BSA and 0.019% Tween 20

B

2A

C

2B

D

2A-BSA only

E

2A-Tween 20 only

F

Unblocked control kits

G1

50 µl of B per 5.5 mm strip

1/2G1

25 µl of B per 5.5 mm strip

1/4G1

12.5 µl of B per 5.5 mm strip

1/6G1

9.375 µl of B per 5.5 mm strip

Visual Evaluation†
Positive Control

Negative Control
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Performance was evaluated for 9 different blocking solutions sprayed over nitrocellulose strips during
manufacture of the LFIA devices. All cassettes had a 28 mm sample polyester pad blocked with Tween 20.
1G devices were treated with different volumes of B blocking solution. †Images and visual evaluation of
the cassettes were performed after a prolonged incubation time of 15 min. Positive Control: E. coli
O157:H7 DSM 17076 (107 CFU/ml). Negative Control: TSB.
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treatment was to evenly coat the surface of the membrane, which becomes chemically
uneven due to different chemical species found in the capture reagents immobilized on the
control and test lines. This can cause irregular flow when the sample is applied (240).
However, the results in Table 11 demonstrate that post-treatment is only effective when a
balance between BSA and Tween 20 is reached, allowing for removal of nonspecific
adsorption, while maintaining the optimal activity of the capture reagents reflected on welldefined control and test lines with a clear background. Therefore, the optimal blocking
composition was achieved with the 1/6G device, which was selected for further studies.
Optimization of the In-Tube Sandwich Immunoassay
Once the optimal LFIA device prototype was selected, other parameters that influenced the
sensitivity and specificity of the LFIA Test Kit, such as concentration of antibodies, sample
pH and sample concentration, were evaluated. Hence, most of the optimization focused on
the in-tube sandwich immunoassay, which was based on noncompetitive indirect detection
of the antigen by using a secondary anti-mouse antibody conjugated with colloidal gold.
This format had the advantage of keeping intact the detection antibody because it was not
directly labeled and thus it was fully immunoreactive. The detection antibody used was a
mAb raised against the O-antigen of E. coli O157 previously described by Westerman
et al. (227). Its selection was based on reported ability to react with 47 E. coli O157:H7
strains and 17 O157:non-H7 strains. Moreover, this mAb did not cross-react with any of
38 non-E. coli enterobacteria tested by its developers (227). On the other hand, the
biotinylated polyclonal antibody (pAb-b) acted as the capture antibody, binding to the
streptavidin immobilized on the test line. This antibody was commercially available and
chosen due to its synergy when combined with the mAb.
The in-tube sandwich immunoassay optimizations were performed using checkerboard
titrations to identify the best combinations of the different reagents or conditions assessed.
In addition, fine-tuning involved supporting visual evaluation with the measurement of the
control and test lines’ intensity by using the i-Lynx system. Previous studies performed at
IPOC facilities using their standard LFIA commercial products have shown that values
below 0.055 reflective units (RU) were not visually detected by an untrained panel (Garth
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Styba, president IPOC, 2016, pers. comm.), therefore this value was adopted as the cut-off
for discriminating positive versus negative results during the optimization studies.
4.1.3.1 Optimization of the pH
Besides antibody pairing, determining the suitable concentration of antibodies used in the
in-tube sandwich immunoassay played a key role in the sensitivity and specificity of the
LFIA Test Kit. However, even when adequate concentrations are used, their interaction
with the antigen can be compromised by sample conditions, such as the pH. In fact, the
effect of pH on the LFIA performance was noticed due to the presence of false positives
with overnight cultures of non-target organisms, which were included as cross-reaction
controls during the optimization stage. Previous screening had shown that none of the
antibodies cross-reacted with these strains. Moreover, when the cultures were diluted
10 fold with culture broth, the false-positives were eliminated. A previous study, which
focused on the development of an immunochromatographic assay, reported that when the
pH of samples was <5, false positives were detected and thus maintaining the pH between
6 and 9 was recommended (241). Therefore, to assess the effect of pH on the LFIA Test
Kit, the pH of overnight grown cultures was determined and adjusted to neutral (pH 7)
using 1 M HEPES buffer. The normal pH of an E. coli O157 culture was estimated to be
6, similar to the non-pathogenic E. coli ATCC 25922. Conversely, S. enterica ser.
Typhimurium and S. flexneri cultures had a pH of 5, which resulted in high intensity falsepositive signals, as shown in Figure 13. However, pH neutralization reduced the
appearance of the false-positive signals, especially with S. enterica ser. Typhimurium and
S. flexneri. The effect of low pH on the development of false positives was confirmed when
TSB, which has a neutral pH, showed RU values around 0.135 when its pH was adjusted
to 5 (Figure 13). Overall, these data showed that, to maintain the optimal performance of
the LFIA Test Kit, it is necessary to adjust the sample pH during the in-tube sandwich
immunoassay.
4.1.3.2 Optimization of the colloidal gold conjugated secondary antibody (CGC)
In order to continue with the in-tube sandwich immunoassay optimization, different
concentrations of the colloidal gold conjugate were assessed. This type of secondary
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Figure 13. Optimization of the in-tube sandwich immunoassay pH conditions. Effect
of pH on the performance of the LFIA device using pure bacterial cultures. Graph
represents the intensity of the test lines before and after pH adjustment with 1 M HEPES
buffer. Normal pH values were 6 for E. coli O157 at a concentration of 109 CFU/ml and
E. coli ATCC 25922, while S. enterica ser. Typhimurium and S. flexneri cultures had a
pH of 5. E. coli O157 at a concentration of 105 and 104 CFU/ml, and TSB had a normal
pH of 7 similar to all sample after adjustment with 1 M HEPES. Data corresponds to the
mean ± SEM (n=2-5).
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labeled antibody is widely used in the development of immunochromatographic test strips
due to the visible red color produced by the gold nanoparticles (114,133,140,242,243).
CGC targets the mAb detection antibody which binds directly to the O157-antigen. A
checkerboard titration of four samples and three concentrations was used to determine a
suitable CGC concentration to continue with the optimization of the other two antibodies.
Early in the process, it was noticed that 109 CFU/ml overnight cultures of E. coli O157
presented a drastic decrease in intensity of the control and test lines, which could be
mistaken for a false negative. Hence, a 105 CFU/ml dilution was included as a true
representation of a positive result. In addition, S. enterica ser. Typhimurium was included
as a false positive control, representative of non-target organisms. Finally, TSB was used
as a negative control. Optimal conditions were determined based on the maximum color
intensity of the control and test lines that could be achieved without producing background
coloration or non-specific binding with the negative controls. Figure 14 shows a graphic
representation of the results obtained for the CGC optimization, where the E. coli O157
signal increased proportionally with the increase in CGC. However, there was also an
increase in the false positive with the S. enterica ser. Typhimurium culture. Therefore, it
was concluded that using the lowest CGC concentration assessed was optimal to further
optimize the concentrations of the mAb and pAb-b because it gave a clear positive read out
with E. coli O157 105 CFU/ml without producing false positive signals with either S.
enterica ser. Typhimurium or TSB.
4.1.3.3 Optimization of the antibodies
During CGC optimization it was noted that high levels of E. coli O157 produced weak
signals that were close to the cut-off value. Hence, different combinations of mAb and
pAb-b were assessed to tackle the “hook-effect” or prozone effect, seen with E. coli O157
at high concentrations. This effect occurs when the concentration of the target antigen
exceeds that of the antibodies, reducing the formation of the sandwich complex and
decreasing the intensity of the positive signal (143,244,245). Figure 15 represents the main
antibody combinations assessed, however, the intensity of the test line was not improved
when high levels of E. coli O157 were present. At this point, other modifications within
IPOC’s manufacturing protocols, such as the concentration of streptavidin in the test line,
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Figure 14. Optimization of the colloidal gold conjugate secondary antibody
concentration. Data represent the trend in the test line intensity with four different
samples and three main concentrations of CGC assessed during one checkerboard
titration. All cultures used in these experiments were grown in TSB and pH adjusted for
the in-tube sandwich immunoassay using 1 M HEPES buffer. For E. coli O157 105
CFU/ml dilution, BPW (pH 7) was used. The cut-off value (0.055 RU) is also represented
as a dotted line.
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Figure 15. Optimization of the mAb and pAb-b concentrations. The data represent the
three most relevant concentrations of the mAb in combination with the two main
concentrations of the pAb-b using the same four bacterial cultures as before. All cultures
used in these experiments were grown in TSB and pH adjusted for the in-tube sandwich
immunoassay using 1 M HEPES buffer. For E. coli O157 105 CFU/ml dilution, BPW (pH
7) was used. The cut-off value (0.055 RU) is also represented as a dotted line.
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membranes with faster capillary flow rate and increasing the reading time, were evaluated.
Nevertheless, none of these approaches decreased the prozone effect without affecting the
sensitivity and/or specificity of the LFIA Test Kit; thus other alternatives were further
investigated.
Development of a Tandem LFIA Test Kit
Besides the “hook-effect” previously described, it was hypothesized that matrix
interference was another factor involved in low signal intensity. Food matrices are complex
and contain high levels of contaminants that can hinder the ability of the detection method
to produce a reliable result. Therefore, in order to tackle both issues, the approach adopted
was to dilute the sample to an extent that matrix effect would be reduced, while the target
organisms would be at an optimal concentration to eliminate the “hook-effect” without
compromising specificity and sensitivity. In fact, this approach has been widely applied in
the development of detection techniques for toxins or pathogens in food (246,247).
A tandem LFIA device, containing two independent membranes was assembled, where the
neat or undiluted sample was loaded in one window (A), while a 100-fold dilution was
included in a second window (B). Figure 16 shows the results obtained for a concentration
curve for a pure culture of E. coli O157 using the tandem LFIA device. The prozone effect
was seen at 109 CFU/ml, where the RU value for both control and test lines in the (A)
window were decreased due to the high concentration of bacteria in the sample. However,
the 100-fold dilution in window (B) had an RU value that was almost doubled, allowing
the sample to be accurately detected as a positive instead of a false negative. When using
pure cultures, 104 CFU/ml was established as the limit of detection (LOD) of the LFIA,
because it was the lowest cell concentration with readings above the cut-off value and
confirmed by a visible test line detected by all members of the panel. Table 12 shows the
proper visual interpretation of results when using the tandem test based on the data from
Figure 16. Overall, these outcomes demonstrated that, by combining the test line results
in both windows of the tandem LFIA device, it was possible to overcome the “hook-effect”
obtaining positive results from samples containing 104-109 CFU/ml, with a maximum
signal intensity achieved at 106 CFU/ml.
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Figure 16. E. coli O157 concentration curve using the tandem LFIA device. Control
and test line curves for both neat (A) and 100-fold diluted (B) samples obtained using the
tandem LFIA device with serial dilutions of an E. coli O157 pure culture. Data represent
one experiment (mean ± SEM) of two independent experiments (n=2 performed in
triplicate) using pure cultures of E. coli O157 grown on TSB overnight. The visual cutoff value (0.055 RU) is shown in both graphs. CL: control line; TL: test line.
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Table 12. Visual interpretation of an E. coli O157 concentration curve using the
tandem LFIA device.
Sample

Neat (A)

1/100 (B)

Visual Interpretation

Mean RU ± SEM

Mean RU ± SEM

Neat (A)

1/100 (B)

Final Result

EC9

0.096±0.007

0.180±0.021

+

+

POS

EC8

0.127±0.013

0.537±0.049

+

+

POS

EC7

0.171±0.004

0.230±0.033

+

+

POS

EC6

0.558±0.048

0.040±0.014

+

-

POS

EC5

0.308±0.041

0.036±0.011

+

-

POS

EC4

0.090±0.009

0.039±0.001

+

-

POS

EC3

0.039±0.004

0.046±0.011

-

-

NEG

EC2

0.044±0.018

0.030±0.010

-

-

NEG

EC1
NEG
0.043±0.004
0.055±0.007
Data shown correspond to the i-Lynx readings of the test lines from serial dilutions of a pure E. coli O157
culture grown in TSB overnight. Results represent one experiment (mean ± SEM) of two independent
experiments (n=2 performed in triplicate). For visual interpretation values >0.055 RU are considered
positive (+) while values ≤0.055 are considered negative (-). The combination of (A) and (B) produced the
final result of the test. EC9-EC1: E. coli O157 109 CFU/ml – 101 CFU/ml. POS: positive result; NEG: negative
result.
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Pairing the Enrichment Procedure with the LFIA Test Kit
Previous data have demonstrated an optimal performance of the tandem LFIA device with
pure cultures. Thus, the following stage consisted in proving the effectiveness of sample
dilution to overcome matrix interference by combining the tandem test with the selected
enrichment broth to detect E. coli O157 in artificially inoculated food samples.
Bacterial pathogens are often found in low concentrations in food, hence an enrichment
step is often necessary to increase the number of E. coli O157 cells to a detectable level,
notably when stressed cells must be recovered. Extensive studies, which compared and
assessed the performance of a variety of enrichment media and incubation conditions in
order to recover E. coli O157 as fast and efficiently as possible, have been done by others
(170,248–250). Therefore, this information was taken into consideration while selecting
potential enrichment broths and conditions that could improve the performance of the LFIA
device.
4.1.5.1 Assessment of the RapidCult™ enrichment medium
Although most of the selective enrichment media require the presence of antibiotics to
inhibit the growth of competing microbiota, some antibiotics, such as cefixime and
cefsulodin, have been reported to affect the growth rate of E. coli O157 (249,251,252). For
this reason, RapidCult™ enrichment medium, which is a relatively new broth, was
evaluated and selected for the LFIA Test Kit. This medium was the only commercially
available medium that claimed to recover E. coli O157 from meat samples in 8 h at 42°C.
Although its specific composition is not publicly available, one of the ingredients reported,
sodium thioglycolate, has been used as a selective agent that maintains reducing conditions
by lowering the oxygen concentration in the liquid medium and hence inhibiting the growth
of most of the organisms found in certain types of food (253). When RapidCult™ was
combined with the LFIA device, it became possible to detect 106 CFU/g in artificially
inoculated ground beef samples and 105 CFU/ml when using pure cultures. In both cases,
we started the procedure with 10 CFU/25g or ml of either healthy or stressed E. coli O157
cells after an 8 h incubation time (data not shown). Regrettably, RapidCult™ had to be
replaced during the development process as the manufacturer withdrew it from the market.
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4.1.5.2 Assessment of mTSBN and mTSB enrichment media
In order to replace the RapidCult™ enrichment medium, mTSBN and TSBN were further
evaluated in combination with incubation at 42°C, which was earlier shown to yield higher
recovery rates by acting as a selective factor for non-target organisms that commonly grow
at 37°C (249,251,254). mTSBN was selected for the kit because it is the recommended
enrichment broth in Health Canada’s reference method for isolation of E. coli O157 (255).
The performance of enrichment was assessed in combination with the LFIA device using
ground beef samples inoculated with 5 CFU/25g of non-stressed E. coli O157 cells. After
2

12 h enrichment, E. coli O157 counts reached 1.6×107 CFU/ml , however, the LFIA device
failed to detect them. In order to investigate further, pure cultures of E. coli O157 were
used to eliminate the influence of the food matrix. Samples of E. coli O157 cultures
enriched in TSB, mTSB and mTSBN were tested. For these experiments, it was necessary
to increase the cell concentration approximately 100 times because bacterial counts in
3

mTSB and mTSBN only reached 3.63×104 and 3.44×103 CFU/ml , respectively, after 12 h
of enrichment. The results with mTSBN were consistent with those obtained with the
ground beef samples, where it was not possible to detect the presence of E. coli O157
despite reaching >108 CFU/ml after 12 h enrichment. Figure 17A compares the results of
12 h enrichment using TSB, mTSB or mTSBN. After a 100-fold dilution, cells grown in
TSB media gave a positive signal, while the other selective enrichments failed, even after
dilution. As well as reducing the growth approximately 0.5 log10, with and without
novobiocin, the presence of bile salts in mTSB and mTSBN appeared to inhibit the
antibody-antigen interaction. mTSB contains 1.5 g/L of bile salts No. 3, which is a mixture
of sodium cholate and sodium deoxycholate. The latter, which is considered an anionic
salt, has proven to have a concentration-dependent inhibitory effect on the antigenantibody interaction (256). To test the hypothesis that bile salts inhibited the assay,
different enriched samples grown in TSB, mTSB or ½ mTSB, where the concentration of

2
3

Average of E. coli O157 counts obtained in two experiments.
Average of E. coli O157 counts obtained in three experiments
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Figure 17. Effect of bile salts on the LFIA Test Kit performance. A) Comparison of
TSB, mTSB, or mTSBN enrichment media effect on the intensity of LFIA signals using
undiluted samples (1×) and a 100-fold dilutions (1/100×) using each enrichment broths as
diluent. B) Intensity of LFIA signals using 100-fold dilutions of enriched samples in TSB,
mTSB or ½ mTSB, with either BPW or ½ mTSB. Graphs represent the mean ± SEM of
one experiment measured in triplicate using 102 CFU/ml of non-stressed E. coli O157
cells prior to enrichment. The cut-off value of 0.055 is also represented. The CFU/ml
calculated for each sample is also included. These experiments were run with the 1/6G
single LFIA device. CL: control line; TL: test line.
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bile salts was diluted with either BPW or ½ mTSB just before the assessment with the
LFIA Test Kit, were tested (Figure 17B) The intensity of the signals increased when TSB
or ½ mTSB enriched samples were diluted with BPW, while the ½ mTSB sample diluted
with the same enrichment broth failed to produce a positive signal. Despite the dilution,
the intensity was still lower when compared with the TSB sample, perhaps also due to the
approximately 0.5 log10 growth reduction in the presence of bile salts. These results are
consistent with those from the previous experiment; thus both mTSBN and mTSB were
eliminated as potential enrichment media.
4.1.5.3 Assessment of TSBN enrichment medium
Due to the previous findings, where the presence of bile salts interfered with the
performance of the LFIA Test Kit, TSBN medium was further evaluated in combination
with the LFIA. Novobiocin-containing medium has been reported to have better
performance when compared against other antibiotics used as selective reagents for
recovery of E. coli O157 (251,252). In addition, Novobiocin is described as the most
common antibiotic used for selective enrichment (250), making it readily available and
affordable from a commercial perspective.
Using TSBN in combination with the tandem LFIA Test Kit failed to detect low
concentrations of stressed E. coli O157 cells after 8 h of enrichment at 42°C (data not
shown). Hence, after performing time-course studies, the enrichment time was increased
to 16 h at 42°C to reach detectable levels. Samples inoculated with healthy or stressed, low
or high inoculation levels produced visually positive results after 16 h of enrichment, an
observation confirmed by further measuring the intensity of the test lines (Figure 18). In
addition, both the presence of E. coli O157 and its concentration were confirmed by plate
counts in CR-SMAC and CHROMagar. After 16 h, samples inoculated with healthy cells,
regardless of the initial concentration, reached >7×108 CFU/ml, while samples inoculated
with high levels of stressed cells reached approximately 1×108 CFU/ml. However, after
20 h each of the samples had a concentration close to 1×109 CFU/ml. On the other hand,
stressed cells inoculated at low concentrations reached approximately 2×108 CFU/ml and
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Figure 18. TSBN enrichment medium time-course combined with the tandem LFIA
Test Kit using artificial inoculated ground beef samples. Results from two different
sets of ground beef samples inoculated with a low E. coli O157 cell concentration (<5
CFU/25g): stressed cells (left) and healthy cells (right). Both control and test lines (CL
and TL) are shown in each graph corresponding to either the A or the B window,
respectively. Samples were assessed at 16, 18, and 20 h of enrichment using TSBN at
42°C and plated on CR-SMAC and CHROMagar for confirmation and enumeration.
Results represent one experiment of 5 different time-courses that were performed under
similar conditions.
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plateaued even after 20 h. Nevertheless, the results suggested that TSBN enrichment
conditions were adequate for establishing the final LFIA Test Kit instructions for use.
Assessing the LOD Using Meat Samples
Previously, the LOD of the LFIA Test Kit was determined using pure cultures. However,
the food matrix and microbiota are known to interfere with the signal intensity. Thus, the
LOD was re-assessed using an uninoculated ground beef sample previously enriched and
used as a diluent for preparing serial dilutions of E. coli O157 culture. Results showed that
the LOD of the LFIA device was ~2×105 CFU/ml (Figure 19), which is approximately
10 fold higher than the LOD obtained with pure cultures. This increase is attributed to the
influence of the food matrix mainly in the binding of the antigen-antibody complex to the
test line and of the free mAb to the control line.
Moreover, as shown in Figure 16, as the concentration of E. coli O157 increased, the
intensity of the control line began to decrease, especially with the undiluted sample (A).
This is believed to be due to a lower concentration of free mAb as more antibody-antigen
sandwich complex is formed, augmenting the intensity of the test line proportionally.
However, when the prozone effect starts, at around 107-108 CFU/ml, the intensity of both
lines in the (A) window decreases. Window (B) showed the same effect, although in a
delayed manner. This trend in signal intensity is also seen in Figure 19. Hence, besides
providing an estimated LOD of the tandem LFIA Test Kit when using meat samples, these
data also revealed an alternative to further investigate the relation between the
concentration of E. coli O157 in meat samples and the intensity trends of both the control
and test lines of the tandem device.
Estimating E. coli O157 Content in Artificially Inoculated Meat Samples Using the
Tandem LFIA Test Kit
Although the LFIA Test Kit is intended to obtain qualitative information regarding the
presence/absence of E. coli O157 in meat samples, previous data showed that the
combination of control and test line intensities within the tandem LFIA device could be
used as an indicator of E. coli O157 concentration. Therefore, to investigate this further,
six additional artificially inoculated meat samples were evaluated. Samples were

127

Figure 19. Assessment of the LOD of the LFIA Test Kit using food samples.
Concentration curves for both neat (A) and 100-fold diluted (B) samples from a serial
dilution of an overnight E. coli O157 culture (9.42×108 CFU/ml)) using an enriched
ground beef sample as diluent. Data represent the mean ± SEM of one experiment
measured in duplicate. The visual cut-off value (0.055 RU) is shown in both graphs. CL:
control line; TL: test line.
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inoculated with 5 CFU/25g and incubated for 12-24 h using TSBN enrichment conditions.
All samples were assessed with the tandem LFIA device at different time-points. Tandem
LFIA device results and their respective cell counts for each time-point were assessed
individually to establish the criteria in Table 13. Even though a wide time for incubation
range was assessed (12-24 h) to obtain a broad spectrum of E. coli O157 concentrations
within the detectable levels of the tandem LFIA device, only one sample had its initial
time-point enumeration within the lowest range. Six time-points were used to determine
the upper and lower limits of the mid-range by calculating the mean value ± SD.
Furthermore, 15 time-points were considered within the maximum level (Figure 20). In
addition, an intensity score was linked to each criterion to account for the intensity of the
four lines into one single result. A one-way analysis of variance (ANOVA) using SPSS
v.23 (IMB Corporation, Armonk, NY, USA) was performed to examine the effect of the
concentration of E. coli O157 in meat samples on the intensity score. Results showed that
there was an effect of the E. coli O157 concentration levels on the intensity scores
[F(2,63)=27.61, p<0.001]. Bonferroni post-hoc tests showed that there was a significant
difference in mean concentration values between scores 1 and 3 (2×106 vs 3.62×108 ±
2.06×108; p= <0.003), and 2 and 3 (2.72×107 ± 1.98×107 vs 3.62×108 ± 2.06×108;
p=<0.001). This suggested that the combination of line intensities established for score 3
is a good indicator of a high concentration of E. coli O157 in a sample. Despite the fact
that scores 1 and 2 indicated low cell concentrations, with score 1 suggesting a lower mean
concentration than score 2, the difference between these was not significant. The latter
might have been due to the small number of time-points that had cell concentrations within
the low range (5×105- 5×106), being underrepresented in score 1. Therefore, further studies
must be performed to determine whether or not lower concentration ranges can be better
differentiated. Overall, the data obtained demonstrated that the prozone effect, which
showed an intensity inversely proportional to the concentration of the target antigen (E.
coli O157), in combination with the relationship between control and test line intensities,
can be a good indicator of target antigen concentration whenever a positive sample is
obtained using the tandem LFIA Test Kit.
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Table 13. E. coli O157 concentrations and intensity scores using the tandem LFIA
Test Kit with meat samples.
Sample
Estimated
Concentration
(CFU/ml)

Visual Interpretation
Food Samples
Tandem LFIA Device Image

Neat (A)

1/100 (B)

Intensity
Score

CL

TL

CL

TL

6

LI

LI

HI

-

1

~6×106- 5×107

LI

LI

HI

LI

2

>5×107

LI

-

HI

LI

3

5

~5×10 - 6×10

Different combinations of control and test line intensities obtained with the tandem LFIA device when
analyzing meat samples. These combinations were linked to three different E. coli O157 concentrations,
where the lower and upper limits of the mid-range were used to establish the low and high concentration
levels, respectively. In addition to visual evaluation, the line intensities were linked to i-Lynx readings as
follows: high intensity (HI) >1.000 RU, low intensity (LI) <1.000 RU, and negative (-) <0.055 RU. To
perform the statistical analysis, intensity scores were assigned to each set of line combinations. Results
were obtained from six different time-courses run independently with 3-5 time-points, each one assessed
in triplicate (n=66).
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Figure 20. Relationship between the tandem LFIA device control and test line
intensities with E. coli O157 concentrations in meat samples. Graphs represent the
general trend of the relationship between cell concentration and intensity (RU) of the
control and test lines obtained by curve fitting using a total of 22 time-points. The limits
of the three intensity scores (1, 2, and 3) are also defined by red lines. Data correspond to
the mean ± SEM (n=3) obtained for each timepoint.
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4.2. Relative Validation of a LFIA Test Kit for Detection of E. coli O157 in Raw Meat
Products
Prior results demonstrated that the tandem LFIA Test Kit was optimized to detect E. coli
O157 in meat samples containing < 5 CFU/25g by using TSBN as the enrichment medium
in combination with incubation for 16 h at 42°C. Therefore, the method was considered
completely prepared for the relative validation of the pre-collaborative study. In order to
be recognized as an alternative method (AM) by Health Canada’s Microbiological Methods
Committee (MMC), the guidelines for the relative validation of indirect qualitative food
microbiological methods found in Part 4 of the Procedure for the Development and
Management of Food Microbiological Methods from the Compendium of Analytical
Methods had to be followed (174). The LFIA Test Kit was considered to be an indirect
qualitative method because it is based on the detection of the O157-antigen, which is a
physical characteristic, found in the membrane of the target pathogen. In addition, it is
considered qualitative due to the fact that it solely determines the presence or absence of
E. coli O157.
For the LFIA Test Kit validation study, two food types within the Raw Meat Food Category
were considered, based on the classification of food categories found in the Compendium
of Analytical Methods. These were Raw Meat (unprocessed) and Raw Meat (processed).
All data presented in this section were generated in two facilities: Robarts Research
Institute, Western University (Section 4.2.1) and Laboratory Services Division, University
of Guelph (Section 4.2.2) and are adapted from the reports prepared for the submission
package sent to Health Canada’s Microbiological Methods Committee. Detailed raw data
are found in Appendix F, which are presented in the format required by the MMC for its
evaluation.
Inclusivity and Exclusivity Study
Inclusivity results using 50 E. coli O157 strains (including H7 and non-motile) tested
positive with the LFIA Test Kit. Five strains had negative (-) A strips, but positive (+) B
strips, which occurs when high cell concentrations are present in a sample (>107 CFU/ml).
Moreover, two samples showed a positive (+) A strip, but a negative (-) B strip, which
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occurs when the sample has a lower cell concentration (<106 CFU/ml). Six strains had at
least one replicate differing from the rest, but without compromising the final result, which
was positive (strains 6, 10, 35, 42, 44 and 47). The rest of the samples were consistent
within the replicates, showing a positive signal (+) in both strips, suggesting that the cell
concentration was between 106 and 107 CFU/ml. Overall, the inclusivity rate obtained was
100%.
Exclusivity results showed that 31 E. coli non-O157 strains included in this study were
negative with the LFIA Test Kit. Six strains showed at least one weak positive replicate;
thus they were retested by obtaining isolated colonies on TSA plates and then using LFIA
Test Kit enrichment (TSBN at 42°C) incubated up to 24h. Four strains (E. coli O78:H11,
E. coli O3:H2, S. flexneri, S. enterica ser. Typhimurium) were negative and only two E. coli
strains, 044:H18 and O124:NM, remained weakly positive. These results represented an
exclusivity rate of 94.6%.
Sample and Inocula Preparation
For each food item used, the APC or TVC was first determined as it is required to be at
least 10 times higher than the E. coli O157 inoculum. Results presented in Table 14
confirmed that the APC and E. coli O157 ratio complied with the requirements. Moreover,
the inoculation levels for both (H) and (L) were initially determined by calculating the
culture titers using the plate counts of each culture. These values were confirmed after
equilibration by the most probable number (MPN) method, as shown in Table 14. In the
case of the E. coli O157 strain 380-94 inoculum used for raw processed meat, the average
percentage of sub-lethal injury achieved after stress treatment was 63.5%, considered
sufficient for the purpose of the study. Together, these data demonstrated that samples and
inocula were properly prepared in accordance with the requirements established by the
Compendium of Analytical Methods for further evaluation.
Artificial Inoculation and Experimental Layout Using an Unpaired Samples Protocol
Using an unpaired samples protocol, two sets of data for each food type were obtained, one
corresponding to the presumptive alternative method (AP) with its confirmation and the
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Table 14. Estimation of TVC and inoculation levels for each food item.

Food Item

Raw ground
beef

TVC
(CFU/g)

Target
Level

Estimated
Inoculation Level
(CFU/25g)

3.20×103

Low

Raw ground
beef
Raw ground
veal

1.05×104

Raw ground
veal
Raw beef
trim

3.4×104

Raw beef
trim
Carpaccio

7.7×103

Carpaccio
Raw
sausage*

1.35×10

Raw
sausage*
Raw burger
patty*

3.5×106

Raw burger
patty*
Raw
meatballs*

4.6×103

Raw
meatballs*
Raw kebabs*
Raw kebabs*

6.2×105

4

MPN Results Post-spiking
MPN
Index
Value

Estimated
Inoculation Level
(MPN/25g)

1.26

3-0-0

1.2

High

15

3-3-1

25

Low

1.26

2-0-0

0.5

High

15

3-3-0

13.3

Low

1.26

3-0-0

1.3

High

15

3-3-0

13.3

Low

1.26

3-0-0

1.3

High

15

3-2-1

8.3

Low

0.96

3-0-0

1.3

High

9.6

3-3-0

13.3

Low

0.96

2-0-0

0.5

High

9.6

3-3-0

13.3

Low

0.96

3-0-0

1.3

High

9.6

3-2-1

8.3

Low

0.96

3-0-0

1.3

High

9.6

3-3-1

25

*These food items were inoculated with strain 380-94, which was stressed as described in the Inoculum
Preparation Section.
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results from the RM. Table 15 and Table 16 summarize the data obtained for both food
types, unprocessed and processed raw meat. For (H) samples, all 20 were presumptive
positives and agreed with the confirmation results, while (L) samples, with a fractional
inoculation, showed only 6 and 8 positives, respectively, from the 20 samples. The rest of
(L) samples, 14 unprocessed and 12 processed, were neither detected with the AM nor the
RM. Finally, all (U) samples were negative with the AM, which fully agreed with the
confirmation results. Hence, based on the results presented, it was concluded that there
were no discordant results (false positives/false negatives) when confirming the AM with
the RM, with a total of 54 true positives and 36 true negatives in the complete study.
Evaluation of Probability of Detection (POD)
Using the previous results, the performance parameters and POD were calculated for each
spiking level of each food type. The results for the POD calculation, which is the proportion
of positive results for a specific food type and level of inoculation (257) are shown in Table
17, which confirmed that all 95% confidence intervals encompass the value zero (0). Thus,
the AM was considered equivalent to the RM for all spiking levels of the two food types
evaluated. In addition, the 95% confidence interval from the !"#$ %&,%( also included
the value zero (0), suggesting that the rate of false positives obtained was acceptable.
Evaluation of Performance Parameters
Previous results showed that all combinations of spiking level and food type passed the
POD analysis. Hence, they were all considered for the calculation of the performance
parameters using only the results from the AM, which were the alternative presumptive
(AP) and the alternative final (AF) together with the formulas previously described in
Section 3.3.3. Overall, the AM complies with the criteria established by the MMC for each
performance parameter evaluated. It achieved 100% sensitivity, which means that all
positives confirmed by the RM were correctly identified by the AM and no false negatives
were obtained. In addition, the LFIA Test Kit had 100% specificity with no false positives,
suggesting that it only detected the target organism. Finally, it was considered 100%
efficient because the presumptive results matched their confirmation (Table 18).
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Table 15. Summary of the alternative method (AM) and reference method (RM)
unpaired samples results for the unprocessed raw meat food type.
Alternative Method
AP

Reference Method
AF1

AC

RM

Total Samples
POS

NEG

POS

NEG

TP

TN

FP

FN

POS

NEG

20

0

20

0

20

0

0

0

20

0

(L)

6

14

6

14

6

14

0

0

8

12

(U)

0

5

0

5

0

5

0

0

0

5

TOTAL

26

19

26

19

26

19

0

0

28

17

(H)

1Alternative Final Results (AF) are defined as True Positives (TP), True Negatives (TN), false positives (FP)

or false negatives (FN).
AP: Alternative Presumptive; AC: Alternative Confirmation; RM: Reference Method; POS: positive result;
NEG: negative result.
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Table 16. Summary of the alternative method (AM) and reference method (RM)
unpaired samples results for the processed raw meat food type.
Alternative Method
AP

Reference Method
AF1

AC

RM

Total Samples
POS

NEG

POS

NEG

TP

TN

FP

FN

POS

NEG

20

0

20

0

20

0

0

0

20

0

(L)

8

12

8

12

8

12

0

0

9

11

(U)

0

5

0

5

0

5

0

0

0

5

TOTAL

28

17

28

17

28

17

0

0

29

16

(H)

1Alternative

Final Results (AF) are defined as True Positives (TP), True Negatives (TN), FP: false positives,
or FN: false negatives.
AP: Alternative Presumptive; AC: Alternative Confirmation; RM: Reference Method; POS: positive result;
NEG: negative result.
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Table 17. POD analysis for unprocessed and processed raw meat food types.
Unprocessed raw meat
Level

Alternative Presumptive (AP)

Alternative Final
(AF)

!"#$%&,(

Reference (R)

MMC

!"#$%",%&

POD1

LCL

UCL

POD

LCL

UCL

POD

LCL

UCL

dPOD

LCL

UCL

dPOD

LCL

UCL

Pass/
Fail

(L)

1.00

0.88

1.00

1.00

0.88

1.00

1.00

0.88

1.00

0.00

-0.12

0.12

0.00

-0.12

0.12

Pass

(H)

0.30

0.16

0.48

0.30

0.16

0.48

0.40

0.24

0.58

-0.10

-0.33

0.14

0.00

-0.23

0.23

Pass

(U)

0.00

0.00

0.35

0.00

0.00

0.35

0.00

0.00

0.35

0.00

-0.35

0.35

0.00

-0.35

0.35

Pass

Processed raw meat
Alternative Presumptive
(AP)

Level

Alternative Final (AF)

!"#$%&,(

Reference (R)

!"#$%",%&

MMC

POD1

LCL

UCL

POD

LCL

UCL

POD

LCL

UCL

dPOD

LCL

UCL

dPOD

LCL

UCL

Pass /
Fail

(L)

0.40

0.24

0.58

0.40

0.24

0.58

0.45

0.28

0.63

-0.05

-0.29

0.20

0.00

-0.24

0.24

Pass

(H)

1.00

0.88

1.00

1.00

0.88

1.00

1.00

0.88

1.00

0.00

-0.12

0.12

0.00

-0.12

0.12

Pass

(U)

0.00
0.00
0.35
0.00
0.00
0.35
0.00 0.00 0.35 0.00
-0.35 0.35 0.00
-0.35 0.35 Pass
of Detection (POD) was calculated as POD= x/N, where x represents the number of positives and N the number of samples evaluated.
LCL: lower confidence limit; UCL: upper confidence limit; MMC: Microbiological Methods Committee.
1Probability
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Table 18. Performance parameters for the Alternative Method.
Performance Parameters
Food Type

Relative
Sensitivity

Relative
Speciﬁcity

FP
Rate

FN
Rate

Test
Eﬃcacy

MMC Criteria

>98%

≥90.4%

<9.6%

<2%

≥94%

Raw meat-unprocessed25g

100%

100%

0%

0%

100%

Ready-to-cook-processed25g

100%

100%

0%

0%

100%

Total

100%

100%

0%

0%

100%

Pass/Fail
Pass
Pass
Pass
Pass
Pass
The results showed were achieved at 16 h of enrichment following the LFIA Test Kit procedure.

141

Determination of the LOD
The last criterion assessed for the AM was the LOD, which is defined in the Compendium
of Analytical Methods as the smallest amount of culturable microorganisms that can be
detected by a specific method in 50% of the samples evaluated (174). For this study, five
spiking levels were included with six replicates each. All samples were analyzed with the
AM, but confirmed with the RM. Moreover, to determine the proper cell concentration
used for inoculation, a 3×3 MPN was also performed using a different set of samples
inoculated with the highest level used for the LOD. Thus, the highest inoculation was
estimated to be 2.35 MPN/25g with a confidence limit between 0.575 and 9.5 MPN/25g,
obtained from the MPN Index Value of 3-1-0. Using this result, the lower cell
concentrations included in the LOD study were extrapolated and included in Table 19.
Finally, the LOD was between the two levels that give respectively more and less than 50%
positives. Thus, based on the recorded number of positive and negative replicates for each
inoculum level, the LOD was 0.588-1.175 MPN/25g (level 2-3).
Based on the results presented in this section, it was concluded that the LFIA Test Kit
exceeded the performance parameters criteria established by the MMC after 16 h of
enrichment as shown in Table 18. In addition, considering the MPN range obtained for the
LOD as an estimate of CFUs (258), it was lower than the range settled by the
Microbiological Methods Committee, which is 3-5 CFU/25g (174); thus, its performance
was considered comparable to that of the RM. Therefore, it represents a faster and simpler
alternative for pre-screening of raw meat samples. Moreover, these outcomes resulted in
an official submission of the LFIA Test Kit to the MMC requesting its evaluation for
inclusion into Health Canada’s Compendium of Analytical Methods.
4.3. Development of the scFvO157
Stability of the Hybridoma Cell Line
The hybridoma cell line (13B3) that produced a monoclonal antibody specific for the
O157-antigen that was used throughout this study was first reported in 1997 by Westerman
et al. from the U.S. Meat Animal Research Center, USDA (227). Because stocks were
stored for an extended period of time, it was necessary to ensure that proper antibody
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Table 19. Determination of the LOD for the raw meat products category using MPN.
Level

No. Positives/ No. Negatives

Level 1, 2.35 MPN/25g1

6/6

Level 2, 1.175 MPN/25g

4/6

Level 3, 0.588 MPN/25g

1/6

Level 4, 0.294 MPN/25g

1/6

Level 5, 0.147 MPN/25g 0/6
highest inoculation level was estimated using a 3×3 MPN and used to determine the lower
inoculation levels.
1The
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specificity was retained. Once the hybridoma was recovered from liquid nitrogen, it was
cloned twice using the limiting dilution method, resulting in 97.8% of positive clones when
screened using ELISA (data not shown). Previous studies have shown that hybridomas,
which yield >90% of positive clones after repeated subcloning, can be considered as stable
(183,228,231,232,259). Thus, once ensuring that cells were healthy and stable, three clones
were further expanded for antibody production and RNA extraction.
Anti-O157 mAb Characterization
Antibody characterization had two main objectives within this study: 1) to guarantee that
the hybridoma cell line was producing the mAb of interest before proceeding with RNA
extraction and genetic sequencing; and 2) to determine the main features and properties
necessary for their optimal performance as a diagnostic reagent. For this purpose, the mAb
was produced by incubating the hybridoma cell cultures until the cells reached a saturated
density (viability <50%). At this point, the medium turned yellow and the supernatant was
collected. The supernatant of three expanded clones was initially assessed for the mAb
isotype. This isotyping analysis indicated that the anti-O157 mAb was an IgG3 isotype
with kappa light chains (Figure 21), thus confirming the outcome reported by Westerman
et al. for this specific cell line (227).
4.3.2.1 Anti-O157 mAb purification and ELISA
Further characterization of the anti-O157 mAb required the mAb to be pure in order to
eliminate potential interference effects of non-Ig components found in the hybridoma
supernatant. Thus, the mAb was affinity purified using immobilized protein G resin. The
presence of the pure mAb in the eluted fraction was confirmed by SDS-PAGE, where the
50 kDa and 25 kDa bands characteristic of the heavy and light chains were visualized
(Figure 22A). Furthermore, the functionality of the mAb was determined by ELISA using
E. coli O157 and three other non-target strains (E. coli ATCC 25922, S. enterica ser.
Typhimurium and L. monocytogenes) at a concentration of 107 CFU/well. The absorbance
obtained with the mAb in the presence of E. coli O157 was 0.606 ± 0.058, while all nontarget organisms were below the average cut-off value estimated for each individual strain
(Figure 22B). Based on these results, it was confirmed that the mAb produced by the
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Figure 21. Anti-O157 mAb isotyping results. The supernatant of three selected positive
clones (3A5, 3C4, and 1B3) was used for antibody isotyping using an isotyping ELISA
kit. The positive control was an antigen reference mixture provided with the isotyping kit,
while the negative control was the Hybridoma-SFM. The positive reaction wells
developed a yellow color after the addition of stop solution demonstrating the IgG3
isotype and kappa light chain for the anti-O157 mAb.
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Figure 22. Overview of the anti-O157 mAb purification steps and ELISA results. A)
Representative image of the affinity purification steps of the mAb using 10% SDS-PAGE
gel stained with Coomasie blue. 1) Molecular Weight Marker (kDa); 2) Column flow
through; 3) Pure mAb; 4) Crude supernatant before purification. B) ELISA results
obtained with the positive control (E. coli O157) and 3 negative controls (S. enterica ser.
Typhimurium, E. coli ATCC 25922 and L. monocytogenes). Data was obtained using 1.25
µg/ml of the mAb and 107 CFU/well of each culture. Bars represent the mean ± SEM
(n=6). The cut-off value was calculated for each sample as the blank mean ± 3SD (n=46), represented as a dotted line.
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hybridoma cell line had the expected specificity towards E. coli O157 when used in an
ELISA.
4.3.2.2 Determination of the anti-O157 mAb isoelectric point (pI)
In addition to isotyping and functional ELISA characterization, there are other relevant
features that can help to predict the performance of an antibody in a particular assay or
technique. As an example, the pI of antibodies is infrequently available despite its effect
on proper folding, solubility and thus antigen-antibody interaction. The pI, by definition,
is the pH at which the net charge equals zero and thus the antibody may precipitate (260–
262). In addition, knowledge of the pI increases the success rate of labelling techniques
because most of them depend on the presence of charged amino acids (123). Therefore,
knowledge of an antibody pI can help to predict its behavior in an assay and, if necessary,
improve the conditions to ensure its proper function. For these reasons, the pI of the antiO157 mAb was determined by using isoelectric focusing (IEF) and immobilized pH
gradient gel strips. Figure 23A shows the stained gel strips with a defined band
approximately at 7.9 cm when urea was present in the sample mixture and at 7.7 cm when
urea was absent (native). The pH gradient data provided by the supplier was graphed in
order to interpolate the pI values, which were estimated to be 6.75 and 6.63, respectively
(Figure 23B). This slight shift between native and denaturing conditions can be explained
by the effect of urea, which causes a conformational change and hence alters the total
charge of the antibody. This effect has been previously reported by comparing the pI values
of denaturing and native proteins using IEF (263). Moreover, a previous study measuring
the pI of around 50 different hybridoma mAb, found that >90% were within a pH of 6-8
(262). Therefore, the pI obtained under native conditions, which was approximately 6.63,
was considered acceptable for the anti-O157 mAb.
RT-PCR and Sequencing of the Variable Heavy and Light (VH and VL) Chains of the
Anti-O157 mAb
Besides the previous characteristics that were obtained for the anti-O157 mAb, the most
important, considered as the “fingerprint” of an antibody, is the amino acid sequence of the
complementarity determining regions (CDRs). CDRs represent the specific antigen
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Figure 23. pI determination of the anti-O157 mAb using IEF. A) Linear pH 3-10
Immobiline DryStrip gels showing the mAb band after IEF. Sample containing urea (U)
showed a band at approximately 7.9 cm, while the sample without urea (NU) has a band
at approximately 7.7 cm. Strips were stained with GelCode™ Blue after IEF. B) Graph
represents the DryStrip gradient data provided by the supplier, which was used to estimate
the pI of the anti-O157 mAb by interpolation. Both pIs, with and without urea, are shown.
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binding sites; hence knowing these boundaries allows for the understanding of the
antibody-antigen interactions while permitting further bioengineering of alternative
recombinant antibodies with potentially improved features. The approach adopted for the
anti-O157 mAb was to use its VH and VL chains amino acid sequences to synthesize a
single-chain variable fragment (scFv) that could be used for targeting the O157-antigen.
For this purpose, it was necessary to sequence the antigen binding site of the mAb. The
PCR products corresponding to both VH and VL chains of the mAb were obtained by using
the primers described by Wang et al. (196) and the thermal cycling conditions stated by
Koren et al. (195). The length of the amplicons obtained after sequencing corresponded to
409 and 381bp, for the murine VH and VL chains, respectively (Figure 24). Hence, these
data were in agreement with previous studies that have shown that VH and VL chains’ PCR
products can vary between 400-470 and 360-390 bp, respectively, depending on the
primers degeneracy and conditions used (192,195).
Characterization of the Anti-O157 mAb VH and VL Chains
In order to continue with the development of the scFvO157, the nucleotide sequences of
the murine VH and VL chains were translated into amino acids. Then, each individual
sequence was submitted to the BLASTP program to search for possible identical sequences
that had been reported to date. The analysis provided us with the 100 amino acid sequences
that produced a significant alignment with the query. Table 20 summarizes the results into
two representative sequences for each variable chain, the one with the highest percentage
of identity regardless of the sequence coverage and the one with the highest sequence
coverage despite the level of identity. This analysis demonstrated that there was no
characterized sequence 100% identical to the anti-O157 mAb in the database. Antibody
variable domains are highly conserved, especially in the framework regions (FRs), which
was reflected in the high percentages of identity achieved. In particular, VL chains tend to
be more conserved than VH chains, consistent with the higher percentage of identity we
found among the query sequences for the VL than for the VH chain. Moreover, the analysis
of the conserved domains suggested that both sequences, obtained experimentally,
belonged to a murine-heavy chain and a murine kappa-light chain variable region, which
were the results expected.
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Figure 24. Gel electrophoresis of VH and VL chains PCR products. The correctly
amplified VH and VL of the mAb expressed by the hybridoma cell-line were
approximately 409 and 381 bp, respectively. The PCR products were analyzed on a 2%
agarose gel stained with ethidium bromide.
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Table 20. anti-O157 mAb VH and VL chains BLASTP results.
BLAST MSA Result

Murine
Variable
Region

Accesion

Sequence

VH

AJG06889.1

VL

%Query
Coverage

%Identity

immunoglobulin heavy chain variable
region [Mus musculus]

98

77

AAO18783.1

immunoglobulin heavy chain variable
region [Mus musculus]

86

92

ADE80875

anti-botulism toxin B immunoglobulin
kappa light chain variable region, partial
[Mus musculus]

99

90

AAC13704

Ig kappa light chain variable region,
90
98
partial [Mus musculus]
For each variable sequence query, the results with the highest sequence coverage and identity,
respectively, were selected among the 100 hits.
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To supplement the results obtained with BLASTP, a COBALT analysis was performed to
pre-screen the VH and VL chains for FRs and CDRs. Figure 25 presents a preliminary
overview of the conserved and variable residues, which mainly shaped the FRs and CDRs,
respectively. The most noticeable CDR detected was H3, which corresponds to the most
diverse loop among the six that formed the variable domain or V-domain. Although it was
possible to outline the other five CDRs, the COBALT analysis did not provide concise
information to allow us to determine the exact boundaries of the CDR. Therefore, this
information was further evaluated using 3D modelling.
Construction of the Humanized scFvO157
After the experimental sequences were confirmed to belong to murine VH and VL domains,
they were used to create 3D models for estimating the CDR loops based on topological
predicting modeling. For this purpose, SWISS-MODEL was used to find the template with
the highest identity within the Protein Database (PDB). Table 21 summarizes the relevant
characteristics for each of the models created. Besides the sequence identity and coverage,
the Global Model Quality Estimation (GMQE) was also reported. It combines properties
from the target and the template alignment reflecting the accuracy of the model built.
Values closer to one indicated higher reliability in the result. For the VH and VL, the GMQE
values were 0.93 and 0.98, respectively, suggesting that models obtained were good
enough to determine the CDR loops. Figure 26A and Figure 26B shows the 3D models
with the CDR loops outlined by refining the COBALT results with the topology of the
model.
Once CDR loops were defined, both murine VH and VL sequences could have been used
for constructing the scFv. However, previous studies have shown that recombinant
proteins, including scFv, tend to aggregate when expressed in E. coli (215,264,265).
Therefore, the murine VH and VL sequences were aligned with a humanized consensus
scFv (234) and adjusted for loop grafting into the humanized backbone. Loop grafting,
especially murine loops into humanized backbone, has been shown to improve the stability
of scFv synthesized for therapeutic purposes (218,220). The final amino acid sequence of
the humanized scFvO157, described in Figure 26D, was submitted to SWISS-MODEL to
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Figure 25. anti-O157 mAb VH and VL chain amino acid sequences and COBALT
analysis results. The 121 and 116 amino acid sequences are shown with a color code
representing the degree of conservation of each residue based on the alignment with the
100 most significant sequences found in the literature. RED: highly conserved residues
within that position. BLUE: less conserved residues, but without gaps in that position
when aligned. GREY: residues which position had gaps at least in one sequence aligned.
For the latter, upper case residues mean that less than 50% of the analyzed sequences
contain gaps and lowercase, greater than 50%. Underlined regions were found to be the
most variable within each chain. Heavy chain CDRs: H1, H2, and H3; Light chain CDRs:
L1, L2, and L3.
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VH
lpefQVKLEESGGGLVKPGGSLKLSCAASGFAFSSYDMSWVRQTPEKRLEWVAFISSG
H1
H2
GGRTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDSGMHYCART---------EWY----H3
FDVWGAGTTVTVSSa

VL

welDIVITQSPSSLAVSAGEKVTMSCKSSQSVLYSSNQKNYLAWYQQKPGQSPKLLIY
L1
WASTRESGVPDRFTGSGSGTDFTLTINSVQAEDLAVYYCHQYLSS--WTFGGGTKLEI
L2
L3
KR
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Table 21. SWISS-MODEL homology modeling results used for the construction of
the scFvO157.
SWISS-MODEL Homology Modeling Results
Sequence

Template
(PDB)

Description

Seq.
Identity

Seq.
Similarity

Seq.
Coverage

GMQE1

Murine VH

2zuq.1.C

Fab fragment
heavy chain, Xray

86.32

0.57

0.97

0.93

Murine VL

4m61.2.A

Fab A52 light
chain, X-ray

95.58

0.60

0.97

0.98

Humanized
2ghw.1.B
anti-sars scFv
78.39
0.54
1.00
0.83
scFvO157
antibody, 80R
Templates with the highest identity were chosen to create the 3D-model for each variable chain and the
final humanized scFvO157. The characteristics that are relevant to assess the quality and reliability of the
model created are included for each sequence. 1GMQE stands for Global Model Quality Estimation and is
expressed as a number between zero and one. The highest the value, the higher the reliability in the model.
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Figure 26. Construction of the humanized scFvO157 based on 3D modeling. Ribbon
representation of 3D models obtained for the A) murine VH, B) murine VL, and C)
humanized scFvO157. D) The final humanized scFvO157 amino acid sequence, with the
grafted murine CDRs underlined in their corresponding VH and VL human backbone. The
polylinker is shown in purple. Murine VH CDRs are represented as follows: dark green,
H1; blue, H1; light green, H3. On the other hand, murine VL CDRs are as followed:
yellow, L1; orange, L2; red, L3.
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D) Humanized scFvO157
EVQLVESGGGLVQPGGSLRLSCAASGFAFSSY
DMSWVRQAPGKGLEWVAFISSGGGRTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCARTEWYFDVWGQGTLVTVSSGGGGSGG
GGSGGGGSDIVMTQSPSTLSASVGDRVTITCL
YSSNQKNYLAWYQQKPGKAPKLLIYWASTR
ESGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CHQYLSSWTFGQGTKLEIK
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obtain the 3D model, as shown in Figure 26C. The humanized scFvO157 was
complemented with two more sequences: a tobacco etch virus (TEV) protease cleavable
site on the N-terminus and a biotin tag on the C-terminus. Once completed, the amino acid
sequence was reverse translated into a DNA sequence, with KpnI and BamHI restriction
enzyme sites incorporated onto the 5’ and 3’ ends, respectively (Figure 27). This sequence
was codon optimized in order to improve translational efficiency in E. coli, synthesized
and cloned into the pUC57 plasmid for further processing.
Molecular Cloning of the Humanized scFvO157
Besides using loop grafting as an approach for increasing protein solubility, the humanized
scFvO157 was also fused, at the N-terminal, with thioredoxin (TrxA). The latter has the
ability to confer translation efficiency and solubility to fused proteins (265,266). TrxA is a
protein feature included in pET32a(+) plasmid, which was selected for expression of the
scFvO157 construct. In addition, pET32a(+) contains a His6tag, commonly used for protein
purification with Ni-NTA affinity resin columns.
Because the scFvO157 was to be used as a detection reagent, the construct was designed
to carry a biotin tag sequence at the C-terminal, which consisted of 15 amino acids
(AviTag™ Technology, Avidity). Biotinylation was proved to be successful through the
insertion of the pBirAcm plasmid, which contains the gene that codes for the BirA enzyme
and is also induced by the presence of IPTG. The AviTag™ sequence was recognized by
the BirA enzyme for an in vivo addition of biotin, which was combined with the culture
medium during induction. Therefore, the final protein expressed in E. coli BL21(DE3) was
TrxA His6 tag TEV scFvO157 biotin. Figure 28C depicts the pET32a(+) cloned map
with the most relevant features.
After the cloning process, the presence of the 801 bp scFvO157 construct was initially
assessed by agarose gel electrophoresis. Figure 28A shows the shift in gel bands when the
scFvO157 construct was successfully cloned into pET32a(+). A restriction enzyme
digestion was performed to corroborate the presence of the construct by its size. Figure
28B shows a ~800 bp band, which corresponds to the size of the scFvO157 construct, while
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Figure 27. Deduced amino acid and DNA sequences used for scFvO157 expression.
A) scFvO157 amino acid sequence including the TEV cleavable site on the N-terminal
(bold) and the biotin tag (red) in the C-terminal. B) Reverse translated and codon
optimized nucleotide sequence with the KpnI (blue) and BamHI (green) restriction
enzyme sites at 5’ and 3’ ends respectively.
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A)
ENLYFQâGEVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLE
WVAFISSGGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTEW
YFDVWGQGTLVTVSSGGGGSGGGGSGGGGSDIVMTQSPSTLSASVGDRVTITCLYS
SNQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDF
ATYYCHQYLSSWTFGQGTKLEIKSGGGLNDIFEAQKIEWHE
B)
GGT ACC GAA AAC CTG TAT TTC CAA GGC GAA GTC CAA CTG GTC GAA TCG
GGT GGC GGT CTG GTC CAA CCG GGC GGC TCC CTG CGT CTG TCC TGC GCG
GCC AGC GGC TTT GCA TTC AGC TCT TAT GAT ATG TCC TGG GTT CGT CAG
GCA CCG GGT AAA GGC CTG GAA TGG GTC GCT TTT ATT AGT TCC GGC GGT
GGC CGC ACC TAT TAC GCT GAT TCT GTG AAA GGT CGT TTC ACC ATC TCT CGC
GAC AAC AGT AAA AAT ACG CTG TAT CTG CAG ATG AAC AGC CTG CGT GCA
GAA GAT ACC GCT GTG TAT TAC TGC GCG CGC ACG GAA TGG TAC TTT GAC
GTT TGG GGT CAA GGC ACC CTG GTG ACG GTT TCA TCG GGT GGC GGT GGC
AGC GGT GGC GGT GGC TCT GGT GGC GGT GGC AGT GAT ATT GTC ATG ACC
CAG AGC CCG TCT ACC CTG AGT GCG TCC GTC GGT GAC CGT GTG ACC ATC
ACG TGT CTG TAT AGC TCT AAC CAG AAA AAC TAT CTG GCC TGG TAT CAG
CAA AAA CCG GGC AAA GCG CCG AAA CTG CTG ATT TAC TGG GCC TCC ACC
CGT GAA TCA GGT GTT CCG TCG CGC TTT TCA GGT TCG GGC AGC GGC ACC
GAT TTC ACC CTG ACG ATC AGT TCC CTG CAG CCG GAA GAC TTT GCC ACC
TAT TAC TGC CAT CAG TAT CTG TCA TCG TGG ACC TTC GGC CAG GGT ACG
AAA CTG GAA ATT AAA TCG GGC GGT GGC CTG AAC GAC ATC TTT GAA GCA
CAG AAA ATT GAA TGG CAC GAA TAA GGA TCC
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Figure 28. Cloning of the scFvO157 construct into pET32a(+) expression plasmid.A)
Image comparing the empty pET32a(+) (lane 1) with the pET32a(+) scFvO157 construct
(lane 2). B) Image of restriction digests, where lane 1 and 2 include KpnI or BamHI alone
resulting in single bands of the full size empty plasmid. Lane 3 corresponds to a double
digested KpnI/ BamHI empty plasmid, which produced a single band of slightly lower
size. Lane 4 shows the products of a double digested KpnI/ BamHI cloned pET32a(+),
matching the size of the backbone (~5858 bp) and the released insert of ~800 bp. Both
images correspond to 1% w/v agarose gels stained with EtBr. C) pET32a(+) map
containing the 801 bp scFvO157 gene (red) cloned using KpnI and BamHI. The
TrxA His6tag is situated where protein translation starts.
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C)
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no smaller bands were seen when empty plasmids were also cut. In addition, the plasmid
was sequenced to confirm that the construct sequence was correct after the cloning process.
Expression of the Humanized scFvO157
Despite the efforts made during the design of the scFvO157 construct to ensure protein
solubility, the initial trials for expression and purification resulted in poor yields of the
purified protein (Figure 29). Attempts were made to assess its functionality by ELISA
using E. coli O157 DSM 17076 as a positive control and E. coli ATCC25922 as a negative
control. However, the results obtained with E. coli O157 (0.035 ± 0.001) did not notably
surpass the cut-off value, besides, the negative control was also positive although with a
4

lower absorbance (0.013 ± 0.004) . Because these results were considered inconclusive,
immunofluorescence microscopy was also attempted to evaluate the scFvO157 specificity,
but did not result in an improved outcome that could serve as evidence of the proper
function of the scFvO157.
Due to the previous results, efforts to increase the expression of soluble protein were made.
It has been shown that overexpression of heterologous genes can promote protein
misfolding (217), which can lead to aggregation and consequently formation of
intracellular inclusion bodies (264,267). Taking this into consideration, different attempts
were made to modulate production rate through the induction step. Modification of
conditions, including induction time, temperature, and concentration of the inducer (IPTG),
were tried, however the SDS-PAGE analysis after cell disruption showed that none of the
variations succeeded in increasing the expression of soluble protein and thus the yield of
purified scFvO157 (Figure 30). The fact that optimization of process parameters improves
protein solubility has been well-established (197,203,267), however, their effects are still
unpredictable and dependent on the particular requirements of the protein expressed
(264,268).

4

Average of the absorbance obtained from duplicates± SEM. The cut-off value average was calculated from
a total of four blank replicates for each of the two strains assessed.
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Figure 29. Overview of the purification and cleavage of the scFvO157. SDS-PAGE
and Western Blot analysis of the purification steps including A) separation of the
TrxA His6tag TEV scFvO157 biotin protein (45 kDa) from the crude extract (flow) by
increasing imidazole concentrations (mM) using Ni2±affinity gravity chromatography, B)
removal of the TrxA 6×His tag using autoinactivation-resistent His7 TEV cleavage, and
C) purification of the scFvO157 using an imidazole gradient and Ni2±affinity gravity
chromatography. Schematic representations of the target protein throughout the process
are also included. Images correspond to 12% SDS-PAGE gels stained with Coomassie
blue or nitrocellulose membranes stained with Pierce™ Reversible Protein Stain Kit.
Western Blot images correspond to detection using streptavidin-IRDye800.
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Figure 30. Effect of temperature and induction time in the expression of soluble
scFvO157. SDS-PAGE and Western Blot analysis of soluble and insoluble fractions
showing the effect of different induction conditions on protein expression. Inductions
were carried out in small scale with (+) and without (-) 0.1 mM IPTG. SDS-PAGE images
correspond to 12% SDS-PAGE gels stained with Coomassie blue. Western Blot images
correspond to detection using streptavidin-IRDye800.
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As a final alternative, attempts were focused on recovering the cytoplasmic inclusion
bodies from the cell pellet by using denaturing conditions and solubilization in 8 M urea.
Although the advantage of this approach was that inclusion bodies were obtained mostly
unadulterated after cell disruption, in vitro refolding proved to be difficult due to
precipitation of the target protein. Therefore, a second alternative using a combination of
denaturing and native buffers was also tried, but it was not advantageous to the overall
yield. Both methods proved to increase the protein extraction yield when compared to the
previous results obtained from the soluble protein fraction. However, further in vitro
refolding and/or processing was particularly challenging due to constant precipitation.
Through all these efforts, it was concluded that obtaining sufficient yields of the pure
scFvO157 was and still is a challenge that requires a thorough study to adapt either the
induction or the in vitro refolding procedures to the particular characteristics of the
expressed protein.
Re-Design of the scFvO157 Structure
The major constraint in this study was the difficulty in obtaining an adequate yield of
purified scFvO157 to perform proper functional assessments. Two main challenges were
identified: a) low expression of soluble protein and b) precipitation of purified inclusion
bodies during in vitro refolding. Even though both limitations can be overcome by
adjusting conditions during induction or further refolding, whether a recombinant protein
is soluble or forms inclusion bodies relies mostly on its primary structure
(197,264,269,270). Protein sequence provides information regarding functional
conformation (268), thus minor changes in the primary amino acid sequence
(197,268,270,271), or in its length (271) may affect the expression of soluble protein or
affect the proper folding. In order to investigate the potential effect of the scFvO157
primary sequence in its soluble expression levels, a retrospective approach was adopted;
two of the most relevant intrinsic properties of the scFvO157 were compared against the
humanized scFv template used for its construction.
The initial alignment score between the humanized scFv0157 and its template was 0.015
with a RMSD of 0.609 Å as obtained with Maestro Software. The default settings were
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used, where all residues within both structures were considered for the alignment. Both
values were particularly small, confirming the high structural similarity and thus
meaningful alignment of the 3D models. One of the major intrinsic protein properties that
plays a key role in promoting aggregation is hydrophobicity, especially when clusters of
hydrophobic residues are exposed in the surface of the expressed protein (264,272). For
this reason, the primary sequences were aligned and compared using the Kyte-Dolittle
hydrophobicity color scheme in the Multiple Sequence Viewer, where minor amino acid
distinctions were found between the CDR loops of both sequences (Figure 31). To have a
better estimation of the effect of those residue variations, the amino acid sequences were
used to calculate the hydrophobicity index for each scFv using the GPMAW bioinformatics
tool (http://www.alphalyse.com/gpmaw_lite.html). The outcome was -0.28 and -0.34 for
the scFvO157 and the humanized scFv template, respectively, suggesting that the former
was slightly more hydrophobic. Formation of inclusion bodies has been assumed to be
favored by non-specific interactions among hydrophobic residues found in different
molecules (216,273). Therefore, the modifications in amino acid residues due to loop
grafting may have predisposed the aggregation of the expressed protein, when compared
with its humanized template.
To complement the hydrophobicity results, the theoretical pI of both scFv was also
obtained, using the GPMAW bioinformatics tool, with the result being 8.95 for the
scFvO157 and 9.22 for the humanized scFv template. Because the scFv were not expressed
alone, the hydrophobicity index and pI were also calculated for the protein including the
fusion partner, TrxA, cleavage sites and tags. The hydrophobicity index was similar to the
one obtained for the scFv alone however pI values were 6.05 for the scFvO157 and 5.65
for the humanized scFv template. As noted, there was a remarkable difference in pI values
between the humanized scFv template and the scFvO157, regardless of the presence of the
fusion partner and tags. These results support the hypothesis that even though the
humanized backbone was kept constant the differences in certain amino acid residues
found in the CDR loops can significantly change the protein properties. In addition, they
reinforce the fact that extraction and processing conditions need to be tailor made for each
particular protein taking into consideration such characteristics.
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Figure 31. Hydrophobicity comparison of the scFvO157 and scFv humanized
template CDR loops. The six CDR loops were aligned and compared using the KyteDolittle hydrophobicity color scheme in the Multiple Sequence Viewer of Maestro
Software. Hydrophobic residues are red, hydrophilic residues are blue, and residues
without hydrophobicity are white. The first line represents the CDR loops of the scFv
humanized template (1) while the second line represents the CDR loops of the scFvO157
(2). Blue arrows represent beta sheet secondary structures.
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CHAPTER 5 DISCUSSION
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Safe food and water are crucial elements of a healthy society. However, given current food
processing techniques and practices, it is not reasonable to guarantee that all food will be
safe; however, it is possible to ensure, that all food will be free of hazards to an acceptable
level of risk (3). In pursuit of this, initiatives around the world have been implemented,
where one of the key elements to increase food safety relies on early detection of potential
hazards and monitoring of food following a farm-to-fork approach (5,8). Of particular
interest has been the development of improved detection tools for targeting bacterial
pathogens in food, where research efforts have been focused in order to achieve the
following: a) identify microbial hazards (7) and b) decrease the burden of disease caused
by foodborne diseases and pathogens (8).
In this work, the focus was on E. coli O157, which is of particular interest due to its
relevance in food safety since this serotype was first described in 1982. Of importance, in
2015, the first Canadian study that focused on estimates of hospitalizations and deaths due
to foodborne illness considered E. coli O157 was among the top five foodborne pathogens
with the highest number of hospitalizations (246) and among the four pathogens with the
highest number of deaths (8) each year (15). Although it was not considered as one of the
pathogens that causes the greatest number of illnesses (15), either due to infrequent
reporting (62) or to a lower incidence (274), its contribution to the total number of
hospitalizations and deaths due to the severity of the illness and long-term negative
outcomes, including death, establishes this pathogen as a major public health concern. In
addition, a study published in 2014 estimated a significant annual cost of illness due to E.
coli O157 infections in Canada (62). Based on an estimate of 22,344 annual primary
infections and 37,867 on-going long-term cases, extrapolated from the incidence rate of
2008 (2.28 infections/100,000 persons) reported by the Public Health Agency of Canada
(PHAC), an annual cost of at least $403.9 million CAD was estimated due to primary cases
and long-term outcomes caused by E. coli O157 infections (62). Since 1990, verotoxigenic
E. coli (including E. coli O157) became a notifiable disease, meaning that any case has to
be reported by PHAC (66). In addition, due to the low infectious dose of E. coli O157 and
considering that meat, especially raw beef products, has been the most implicated in
outbreaks in Canada (31), a no detectable level policy for E. coli O157 was established
specifically for these food products (70). However, despite all these efforts made to control
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foodborne diseases, new challenges, including climate change (5,7), are having a huge
impact on microbial ecology with the emergence of foodborne diseases and unusual
outbreaks. These all have to be rapidly investigated (5). Together with Salmonella spp.,
E. coli O157 is considered of great concern due to its stress tolerance response (e.g. acid
resistance) that could potentially make it a strong survivor in the event of climate change
(7). In addition, with the globalization of the food market, the risks of spreading potential
foodborne diseases globally have also increased (7,8). For these reasons, it is evident that
E. coli O157 has been and still is one of the major foodborne pathogens upon which
research in Canada should be focused.
One of the tools that food producers use as part of their food safety surveillance system is
microbial testing for monitoring and early pathogen detection. Conventional bacterial
culture has most commonly been used, which, in practical terms, requires up to a week to
confirm the presence of E. coli O157 in contaminated food. Therefore, in the last decade,
there has been an increase in rapid detection methods (159) that can be used for fast
screening instead of the lengthy, laborious traditional culture method. These technologies
are allowing food producers to release safe products at an earlier stage instead of waiting
for the traditional cultural results that take several days. Numerous reviews have focused
on analyzing the advantages and disadvantages of emerging technologies that are being
used for developing rapid methods for the detection of foodborne pathogens (106,159,275).
In particular, the lateral flow immunoassay (LFIA) format has received significant
attention in food safety research (106,132,140) and commercial (106) sectors, as it is
considered an inexpensive, easy-to-use, and fast alternative for pre-screening (106).
Despite the fact that several LFIA were commercially available at the time of writing, for
example, MaxSignal® E. coli O157 Strip Test Kit (Bioo Scientific Corporation), DuPont™
Lateral Flow System for E. coli O157 (DuPont), FoodChek™ E. coli O157 test
(FoodChek™ Systems Inc.), Reveal 2.0 for E. coli O157:H7 (Neogen Corporation), and
VIP® Gold for EHEC (BioControl), not all of them were approved by Health Canada. In
fact, in the latest published version of the summary of methods found in Health Canada’s
Compendium of Analytical Methods for E. coli O157:H7, only one immunological
method, the Merck Singlepath® E. coli O157 Kit, has met the standards required for it to
be approved for screening purposes (276). In practice, essentially two methods are widely
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used in the Canadian food production system, conventional culture and PCR, thus a reliable
and validated point of care test that has regulatory authority would be a major advance in
food safety in Canada and potentially beyond.
Given the critical role that an alternative method plays in determining the reasonable level
of risk of food products, these tests must be subjected to a thorough evaluation before
commercialization and use for food analysis. Several standards have been developed
worldwide that provide protocols for the validation of new microbiological methods. The
most widely recognized are the AOAC International programs, the ISO 16140 Standard
(159), USDA-FSIS Guidance for Evaluating Test Kit Performance (277), and Health
Canada’s Guidelines for the Development and Management of Food Microbiological
Methods (174). As it is critical that the results obtained with the alternative method are
reliable and recognized by the government parties (159) involved in a food safety
management system, Health Canada’s guidelines were selected for the validation of the
LFIA Test Kit. In fact, food producers can determine which testing method to use based
on the fit for purpose. However, particularly in the case of raw beef products, the CFIA
based on the Meat Hygiene Manual of Procedures, which is under the Meat Inspection Act
and Meat Inspection Regulations, requires that the testing of products must be done using
an approved method listed under Health Canada’s Compendium of Analytical Methods
(176). Collectively, this information, in combination with the fact that Merck Singlepath®
was the only approved immunological method, brought up the possibility to proceed with
the validation process to seek the inclusion of the alternative LFIA Test Kit method in the
Compendium of Analytical Methods. It should be noted that the LFIA Test Kit developed
during this study for the detection of E. coli O157 is currently undergoing the assessment
by the Technical Group of the Microbiological Methods Committee for its inclusion in the
Compendium of Analytical Methods (174).
In general terms, the validation of an alternative method can be defined as the process of
confirming its “fitness for purpose” by providing and examining objective evidence that
will lead to the establishment of the method’s performance parameters (159,172).
Regardless of the validation standard used, the initial stage involves the comparison of the
alternative method against a reference method (105,159,173). In most cases, the reference
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method is represented by the conventional culture method, which is internationally
recognized by the standard agencies or governmental authorities.
Focusing on the LFIA Test Kit validation, this procedure is defined in the Compendium as
a Relative Validation, where the performance of the Test Kit was assessed in comparison
with the reference method MFHPB-10 as shown in Table 15 and Table 16. Although these
results showed that the LFIA Test Kit was able to detect the same number of positives as
the reference method (true positives), it does not provide evidence of an equivalency
between both methods. Therefore, the POD analysis had to be performed, which is a model
that helps to determine equivalency between two methods particularly in cases where
different sample portions are evaluated with each method due to different enrichments. As
shown in Table 17, the POD is calculated for each inoculation level, which makes the
qualitative data conditional on the concentration of E. coli O157 present in the sample
(278). In addition, the POD compares the response of the alternative and the reference
method by the mathematical difference of their POD values (dPOD), while the statistical
significance is given by the calculation of its confidence interval (278). These final results
were further used to determine the performance parameters in Table 18. Overall, the
relevance of the POD analysis is that it allows one to determine the compliance of an
alternative method with established performance parameters, as stated in Table 17, based
on concentration. It also determines the equivalence between two methods (278). In
addition to the POD and performance parameters analysis, an effective alternative method
should have a LOD comparable to the standard method or ≤3 CFU/g (174). In the case of
alternative methods for detection of E. coli O157 in raw meat products, this is critical due
to the total absence of established criteria (176), which implies that 1 CFU/25g sample
should be detectable. Indeed, the results obtained for the LOD evaluation (Table 19)
demonstrated that the LFIA Test Kit was able to comply with this requirement. The LFIA
Test Kit was able to deliver presumptive results in 17 h of total assessment time compared
with the 2 days that it takes to obtain isolated presumptive colonies with the culture
reference method (255). Therefore, it proved to be faster but was still sensitive enough to
meet the required criteria. In addition, the validation results were similar to the Merck
Singlepath® results reported in the AOAC Research Institute certificate for raw ground
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beef (169), but with the great advantage of providing results in <25 h, which is the reported
total analysis time found in the AOAC® Performance TestedSM Certificate.
The principle of the LFIA relies on a sandwich immunoassay, where the monoclonal
antibody confers the specificity necessary to detect E coli O157. In fact, Westerman et al.
reported that the mAb selected for this assay reacted with 47 E. coli O157:H7 strains and
17 O157:non-H7 strains (227). This was further supported by the results obtained with the
inclusivity study performed for the validation of the LFIA Test Kit (Section 4.2.1 and
Appendix A), where all E. coli strains expressing the O157 somatic antigen were detected,
regardless of the H antigen they possessed. Although two strains, E. coli O44:H18 and
E. coli O124:NM belonging to the enteroaggregative (EAEC) and enteroinvasive (EIEC)
pathotypes, respectively, produced weakly positive results during the exclusivity study,
they were not considered as a critical cross-reaction issue due to the nature of the strains
and the overall result obtained during the exclusivity study. Further analysis using an
ELISA suggested that the mAb did not cross-react with these strains. In addition, no
evidence was found that could structurally link the O44 and O124 antigens with the O157.
Therefore, this represents an opportunity to further investigate these results and potentially
improve the performance of the LFIA Test Kit.
The concept of sandwich immunoassays has been known for some time and has been
widely used in pathogen detection because bacteria have many different epitopes that can
be targeted by different antibodies without interfering with each other (140). Frequently
used formats are based on immobilized captured antibody on a nitrocellulose membrane
(140) or by using conjugation pads, where the immune complex is formed (239). However,
the former technology has proven to alter the binding site of the antibody by adsorptioninduced denaturation, which can cause non-specific interactions (279).
An ideal method for a sandwich immunoassay is one that can maintain the native structure
of the antibodies, which involves keeping the antibodies in solution and avoiding
immobilization. In addition, allowing a longer incubation time has proven to increase the
sensitivity of the assay, without a significant impact on the total assay time (132). To our
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knowledge, this is the first attempt to combine an in-tube-sandwich immunoassay with a
LFIA device for pathogen detection.
The main challenge that rapid methods, such as the LFIA Test Kit, normally face within
food safety, is the complexity and variability of the food samples (132,280) and the low
concentration of pathogens, which in combination decrease the sensitivity and specificity
of the assay. Therefore, over the course of the development process, several modifications
and optimization of reagents and assay conditions were evaluated to obtain an acceptable
LOD, while maintaining a clear difference between positive and negative samples
distinguishable by the naked eye. We can highlight the relevance of ensuring proper
nitrocellulose blocking to prevent non-specific binding (Table 10). Particularly, it was
noticed that over-blocking the membranes caused weak control and test lines, which might
have been due to an excess of BSA and/or Tween 20 that interfered with the binding of
complexes with the capture reagents immobilized in either the control or test line (134)
(Table 11). Importantly, however, it was also demonstrated that low sample pH promotes
the development of false positive results (Figure 13). Indeed, minor changes in pH can
alter the stability of any protein, not only of antibodies, by influencing their net charges
and thus their conformation (241,281,282). This can produce non-specific interactions with
either the immobilized streptavidin in the test line or with other ligands found in the sample
(241,281). In fact, Kim et al. reported false positives during the development of a dipstick
immunoassay used for detection of E. coli O157 in ground beef samples (283). They
attributed this effect to the possible denaturation or degradation of the polyclonal antibody,
which could then have non-specific interactions with the detection and/or conjugated
antibodies.
On the other hand, background microbiota, naturally present in food matrices, has proven
to act as a competitor to target pathogens, which normally are found in lower numbers. The
food microbiota can potentially inhibit the growth of the target microorganism and thus its
detection (248,257,284) when present in high concentrations, making it necessary to use
enrichment techniques frequently supplemented with growth inhibitors. However, some
inhibitors, such as cefixime, have also been shown to affect E. coli O157 growth. In fact,
this effect was demonstrated when comparing the performance of non-selective and
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selective media for preparation of stressed cells (Figure 12A). Ogden et al. have reported
that cefixime, a supplement found in CR-SMAC, can inhibit the growth of some E. coli
O157 strains (285), perhaps explaining the difference in counts. These findings agreed with
the results reported by Jasson et al., where using a combination of cefixime and tellurite
with MacConkey medium (CT-SMAC) as selective agar caused a significant difference in
performance with TSAYE (225). Therefore, for enrichment purposes, novobiocin was
preferred in combination with TSB. This enrichment medium proved to be compatible with
the LFIA device by detecting E. coli O157 from food samples after 16 h of enrichment at
42°C (Figure 18).
Particularly, in LFIA, matrix composition alters the capillary flow and thus the intensity of
the control and test lines (134). In addition, the matrix composition can also interfere with
the formation of antigen-antibodies complex (132). Indeed, this effect was noted when
comparing the results with the undiluted samples (window A) in Figure 16 and Figure 19,
where reduction of the control line intensities was approximately 7-fold in the presence of
food matrix, but without compromising the final qualitative result. The concept of sample
dilution has been reported for dealing with matrix effects in immunochromatographic
assays however this approach has the potential disadvantage of decreasing assay sensitivity
(132). Therefore, the adoption of a tandem device represented an opportunity to solve the
prozone and matrix effect, without altering the sensitivity of the assay, which was
approximately 104 CFU/ml when using pure cultures and 105 CFU/ml with meat samples.
The latter was an acceptable LOD, which agreed with data Shan et al. reported for six
different LFIA (140). These LFIAs were previously developed for detection of foodborne
pathogens using colloidal gold, showing LODs between 105 and 106 CFU/ml (140).
The initial objective of immunochromatographic assays is to deliver qualitative results
(132). However, lately, there has been more interest in developing quantitative assays for
food safety, especially for determination of toxic compounds such as mycotoxins
(134,135,144,286) and chemical contaminants (281), where more than a presence/absence
result is needed. Interestingly, few studies were found regarding quantitative applications
of LFIA for bacterial analysis (287). In these devices, to determine concentration, the
intensity of the test line is normally measured by using a photometric device. However,
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this is impractical for a point-of-care rapid test. The tandem LFIA, although focused only
on E. coli O157, demonstrated that it could be potentially useful in determining semiquantitatively the concentration of a target bacteria by measuring the intensity of the lines
in the two windows of the device (Figure 20). It was also possible to link the control and
test line intensity measurements with a simple visual evaluation of the tandem LFIA device
(Table 13). To our knowledge, the tandem LFIA device represents a new alternative, not
only for solving LFIA issues such as prozone and matrix effect, which are frequently faced
in food safety due to the complex nature of the samples, but also as a potential alternative
for transitioning from qualitative to semi-quantitative results without needing extra
equipment.
The application of immunochromatographic systems, such as LFIA, has shown great
potential in the food safety sector. Specifically, improvement in sensitivity and specificity
has been shown when they are combined with new detection schemes or novel reagents
(e.g. gold nanoparticles combined with enzymatic activity or thermal contrast
(125,126,246,288). Of importance is the application of single-chain antibody fragment
(scFv) in diagnostic tools such as LFIAs. Indeed, recent studies have introduced scFv as
novel alternatives (108,200,207,210,289) to monoclonal antibodies. Significant
advantages, such as large-scale (207,210) and more cost-effective production methods
(120,210,290) with enhanced or similar sensitivity and specificity than the parent
monoclonal antibody, have been demonstrated when scFv are used in ELISAs
(108,201,210). Within the food safety field, most of the scFv applications have been
reported for detection of mycotoxin (207,210). In addition, promising results have also
been reported for detection of antibiotics such as fluoroquinolones (209), enterotoxigenic
E. coli toxins (201), and for detection of S. enterica ser. Typhimurium using competitive
ELISA (213). Therefore, it is evident that scFv have not been fully exploited for detection
of foodborne pathogens. Within this study, a scFv recombinant antibody directed against
the O157-antigen expressed in the outer membrane of E. coli O157 (scFvO157), was
developed.
Although, monoclonal antibodies still represent the main alternative for high-sensitivity
reagents for immunoassays, it has been well-documented that cell culture supernatants tend
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to have low concentrations of mAb, ranging from 1-100 µg/ml (180,291) depending on the
cell line, culture medium, culture conditions and/or cell line stability. Thus, the
concentration of large volumes of supernatant before purification has become a common
practice (180), which can increase the complexity and cost of the production process.
Indeed, the average yield of the anti-O157 mAb obtained through hybridoma technology
5

was 11.58± 2.24 µg/ml of supernatant purified. The concentration of mAb was considered
sufficient for the purpose of this study, nevertheless, it may not be ideal for the downstream
processing requirements of the LFIA Test Kit manufacturing process. Hence, it was of
particular interest, not only from a manufacturing perspective, but also for the advancement
of food safety, to engineer a scFv that could target one of the major foodborne pathogens,
which is E. coli O157. The scFvO157 was derived from the anti-O157 mAb (227), which
was used as the capture antibody for the development of the LFIA Test Kit. This mAb was
confirmed to be an IgG3 isotype (Figure 21), which is the preferred immunoglobulin
isotype secreted against bacterial antigens (228,291). Moreover, after purification (Figure
22A) and functional characterization through ELISA (Figure 22B), it was confirmed that
the anti-O157 mAb was successfully produced by the 13B3 hybridoma cell line and
specific against E. coli O157.
The early development of the scFvO157 consisted of the molecular cloning and sequencing
of the anti-O157 mAb variable regions, which is formed by the variable heavy (VH) and
light (VL) chains (Figure 24). Monoclonal antibodies are considered unique molecules due
to their particular specificity, which, surprisingly, is only attributed to the genetic diversity
and length of six loops known as complementarity determining regions (CDRs) found
within the VH and VL (292,293). Such variability has led to a classification of 15 VH and
18 Vκ gene families (192), which makes amplification of murine Ig genes challenging.
Attempts to successfully amplify V-genes have led to the development of consensus or
degenerate primers that target the framework and constant conserved regions of both the
VH and VL chains (192,196,261,294). The translated amino acid sequences were further
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Average obtained from three different purifications± SEM.
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characterized using the BLASTP program and COBALT, which is a constraint-based
alignment tool (295). In combination, they compared the VH and VL chain sequences with
protein databases providing as an end-result a multiple sequence alignment where
conserved and significant variable residues within the sequences could be identified
(Figure 25) (296). In fact, it was possible to recognize the conserved residues of the
variable chains that mainly represent the framework regions. These conserved regions were
responsible for the identity percentage obtained on the sequence comparison (Table 20).
The difference between the target and the templates was due to the areas within the
sequences that outlined the CDR loops (Figure 25). Besides confirming that the variable
regions belonged to a murine antibody and corresponded to VH and VL chains, the analysis
demonstrated that at the time of writing no other murine antibody against the O157-antigen
was previously published in the database. A search performed in the protein database
(PDB) showed 207 results related to “O157”, but none of them were antibodies that could
target the O157-antigen. Overall, cloning and sequencing of the anti-O157 mAb variable
region represents a unique opportunity to preserve its particular specificity, which can be
relevant for extensive characterization or in the event of hybridoma loss. To our
knowledge, this may represent the first sequenced V-gene of a murine mAb against E. coli
O157.
Using the sequence information of the murine V-gene has been helpful in creating
molecular models for guiding the in vitro engineering of scFv (209). Homology modeling
is the most common computational tool used to predict 3D structures of proteins based on
the comparison of their primary amino acid sequence with a template protein
(209,297,298). For this purpose, SWISS-MODEL, which is considered one of the most
frequently used public modeling servers (298,299), was used. Overall, homology modeling
is efficient and reliable, however V-gene prediction, particularly CDR loops, may represent
a challenging and more laborious procedure. Reliable models generally can be obtained
when the target-template sequence identity is >40% (297,298). However, the second
requirement for homology modeling involves the correct target-template alignment (297),
which was represented by the GMQE score (300). The molecular modeling performed led
to the identification of the CDR loops using 3D models with a high GMQE score and
sequences with >80% identity (Figure 26A and Figure 26B, Table 21). This step was
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critical because minor modifications to the CDR loops sequence structure can lead to loss
of functionality.
As most of the development of scFvs has been focused on drug therapy development,
humanization of scFvs has become a common practice (301). A second benefit obtained
from loop grafting has been the achievement of a higher stability of the scFv structure when
compared to the original murine scFv (218). Therefore, the scFvO157 construct was
designed by loop grafting of murine CDRs onto a humanized consensus backbone
previously described to be successfully expressed in E. coli (234) (Figure 26C and Figure
26D). As a fact, scFvs have frequently been reported to be difficult to express as a soluble
protein in E. coli. Several strategies, such as codon optimization (203) and fusion with
highly soluble proteins (e.g. TrxA) (266), have been developed in order to overcome this
issue. In fact, both strategies were adopted during the design of the scFvO157 construct.
Expression of the recombinant protein was successful, however despite the efforts made to
ensure its solubility, it was mainly expressed as inclusion bodies found in the insoluble
fraction of the cell lysate (Figure 30). Several factors, such as use of strong promoters
(268,302), high inducer concentrations (268,302), or high temperatures during induction
(268), have been linked to the formation of these insoluble aggregates, which overall
increased overexpression of the recombinant protein (303). Throughout this study, several
attempts were made to improve the expression of soluble protein (Figure 30). Induction
was tried at different temperatures, such as 4°C, however it resulted in low yields of both
soluble and insoluble fractions mainly due to a reduced bacterial growth rate. The optimal
temperature range frequently reported for induction is 15-25°C (RT) (265,304), which
showed a slightly higher amount of soluble protein when induction was performed during
6 h (Figure 30). Induction was also started at early log phase because it promotes the
production of more soluble protein (265). Different concentrations of inducer (IPTG) were
also tried and showed a proportional increase of expressed protein with higher
concentrations of inducer, but mainly as inclusion bodies (data not shown).
Inclusion body formation is commonly reported in scFv synthesis; hence, isolation and
refolding of insoluble aggregates has become a common practice for recovery of functional
proteins (203,210,218,290,303). Within this study, isolation of inclusion bodies was
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proved to be successful under denaturing and hybrid conditions, however refolding
strategies were not ideal for recovery of a functional protein that could be used for
functional assessment. These results demonstrate that synthesis of recombinant proteins
using the E. coli expression system, in particular scFvs, still represents a challenging
process in order to fulfill the requirements of large-scale production, which is the end-stage
objective of their application.
Different approaches, such as expression in yeasts (217) or Gram-positive bacteria (e.g.
Bacillus brevis and Bacillus subtilis) (215), can be used in order to prevent inclusion bodies
formation. However, importantly, several studies have reported the relevance of protein
structure in the proper expression and folding. Fahnert et al. highlighted the fact that
specific structural characteristics, such as point mutations, can be critical in promoting
protein aggregation (268). In addition, Akbari et al. have shown that the order of the VH
and VL chains in scFv can affect the expression and stability (203), while Gu et al. have
reported that the functional cooperativity of both VH and VL chains can be influenced by
the length and sequence of the peptide linker (305). Overall, recombinant antibody design
is challenging and when loop grafting is performed, proper selection of the framework is
critical because it can affect the CDR conformation and also proper pairing of the VH and
VL chains (184). Potential substitution of specific residues from the murine backbone into
the new framework may affect the proper folding and functionality (180). In fact, these
backmutations can be recognized by homology modeling of the V-genes or by structure
analysis (180). In light of this evidence, it was speculated that expression of soluble
scFvO157 may be enhanced by a re-design of the primary scFvO157 structure using
computational tools to aid in predicting its properties and to overcome the obstacles faced
during the experimental stage.
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CHAPTER 6 CONCLUSIONS, LIMITATIONS AND FUTURE DIRECTIONS
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6.1. Overall Findings and Implications
The results obtained after the relative validation study clearly demonstrated that the LFIA
Test Kit was faster and sensitive enough to serve as an alternative detection method for
Canadian meat producers to rapidly detect E. coli O157 in contaminated samples, while
meeting the criteria required by the Microbiological Methods Committee (MMC)
described in Health Canada’s Compendium of Analytical Methods. In addition, these
findings suggested a reduction in total analysis time, requiring only 17 h from enrichmentto-result, as compared with 25 h reported in the Merck Singlepath® AOAC® Performance
TestedSM Certificate (169). The newly developed LFIA Test Kit is capable of detecting
E. coli O157 in contaminated processed and unprocessed meat samples, with a time-toresults advantage over its direct competitors (Merck Singlepath® and the MFHPB-10),
emphasizing its inherent commercial value as a potential E. coli O157 detection alternative
for meat producers.
Moreover, by assembling a tandem LFIA device, we devised a novel and simple alternative
to overcome one of the most common weaknesses of this type of immunoassay, which is
the prozone or “hook-effect” (143,244,245). Previous studies suggested using sample
dilution as the potential solution to the prozone effect (288). However, this directly
decreased assay sensitivity. Therefore, the novel design of the tandem LFIA device, which
allows analysis of both undiluted and diluted samples simultaneously, maintains the benefit
of sample dilution without compromising the sensitivity of the method. In addition, this
new LFIA design provides an opportunity to further develop a visual semi-quantitative
technique for estimating bacterial concentrations in complex matrices including food
samples. Although we were able to demonstrate the relationship between the intensities of
the control and test lines with E. coli O157 cell concentration in meat samples, further
research should focus on validating this approach using different food items, such as
produce. Overall, this tandem device advances LFIA performance by providing a feasible,
simple and easy-to-use alternative that effectively overcomes the “hook-effect”, while
concomitantly offering the possibility to transform a qualitative method into a semiquantitative LFIA without needing extra equipment for interpreting the results.
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Although the LFIA Test Kit successfully passed the relative validation for submission to
Health Canada’s Microbiological Methods Committee, we elected to try to further improve
the detection method by the synthesis of a scFv derived from the anti-O157 mAb used as
the immunochemical reagent.
Several advantages were foreseen with this approach, including the following a) potential
enhancement of the assay sensitivity, b) easy and cost-effective production of detection
reagents in bacterial hosts and c) positive proof of the application of a scFv as a detection
reagent for food pathogens. The use of scFv in food pathogen detection has not been wellexploited, with only a few publications focusing on the detection of enterotoxigenic E. coli
toxins (201) and S. enterica ser. Typhimurium membrane protein D (213). Hence, the
synthesis of a scFv that could target the antigen of a major food pathogen such as E. coli
O157 represents an innovative adaptation that could benefit the food sector. Moreover, we
can validate that no protein or nucleotide sequences related to antibodies or recombinant
proteins against E. coli O157 are publicly available at the time of writing. This is interesting
because this study might represent the first attempt to genetically characterize a mAb
targeting E. coli O157. Knowledge of the variable domain genetic sequence opens a wide
range of possibilities for in-depth antibody engineering research using bioinformatics that
could help to develop novel alternatives for tackling E. coli O157 food contamination.
Some examples of these approaches are predicting antigen-antibody interactions and
analyzing the effects of site-directed mutagenesis for improvement of the binding affinity,
among others.
Our results indicated correct sequencing of the target variable regions of the anti-O157
mAb was achieved. We were also able to express this scFvO157 in a cell-based E. coli host
system. Unfortunately, we were unable to completely evaluate the functionality of the
scFvO157 due to the limited yield of bioengineered soluble protein obtained, a result of
the formation of inclusion bodies. Many different conditions were explored in an attempt
to improve the solubility and yield of the E. coli expressed bioengineered protein. These
included testing different purification techniques to enhance the recovery of these inclusion
bodies.
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These experimental problems prompted us to reconsider the scFvO157 gene design
because modification of the primary scFv sequence could positively alter the folding and
stability properties of the expressed, bioengineered protein. Although we were able to
initiate this retrospective analysis by using novel bioinformatics tools for antibody and
protein design, this component of the study was not completed within the time available.
This last part of the study provided the foundation for improved scFv design with the help
of computational tools as the main thrust for future research.
6.2. Research Limitations
As mentioned previously, the LFIA Test Kit was successfully submitted for assessment by
the MMC. However, several limitations were noted during the development process. First,
that the enrichment broth RapidCult™ was no longer on the commercial market
represented a major setback. RapidCult™ broth was initially selected, among other broths
assessed, due to its ability to recover healthy and stressed E. coli O157 cells from
artificially inoculated meat samples in 8 h of incubation. Therefore, new readily available
enrichment broths were also evaluated. We evaluated commonly used alternatives such as
mTSB, mTSB+novobiocin, and TSB+novobiocin. The latter was the final enrichment
broth selected because the presence of bile salts in the other two alternatives interfered in
the detection of E. coli O157 using the LFIA device. Despite the successful results obtained
with the LFIA Test Kit, the presence of novobiocin seemed to delay the recovery of E. coli
O157 cells, especially when stressed. Thus, it was not feasible to replicate the results
obtained with RapidCult in the 8 h incubation time, forcing us to increase the enrichment
period to 16 h. Although other potential alternatives could also be evaluated, previous
comparison studies performed by others (87,170,248–250) were used to screen for the most
appropriate broths to evaluate with the LFIA Test Kit.
During the optimization phase, small lots of LFIA devices and/or reagents were
manufactured, limiting the number of duplicates and/or experimental replicates within each
experiment. To overcome this issue, the reagents and LFIA devices were strategically
allocated using primarily checkerboard titrations. We included experimental controls to
ensure that the screening and optimization data are representative, while achieving a robust
performance that could be confirmed during the relative validation process. Whereas this
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approach allowed us to determine the optimal conditions for a functional LFIA Test Kit, it
could present a source of bias due to the lack of sufficient replicates.
Sample preparation was also a main limitation for the performance of the LFIA Test Kit.
As noted, physicochemical properties of food samples, including pH and matrix
composition, interfered with specificity and the intensity of the control and test lines. As a
result, pH optimization was necessary when the pH of samples was below 5. Although
meat samples used during the development process demonstrated a consistent pH value of
6 after enrichment, they were less acidic than the S. enterica ser. Typhimurium and S.
flexneri pure cultures evaluated. Hence, it was necessary to create a general methodology
to account for the potential diversity of sample pH. Sample dilution was also necessary to
counteract the effect of sample composition and the prozone effect caused by an excess of
antigen. Consequently, the general procedure using the tandem LFIA Test Kit was
validated including a pH adjustment step. Both approaches resulted in a functional LFIA
Test Kit, although this compromised the simplicity of the test because it required the
incorporation of simple, but extra, pipetting steps. This represents an opportunity to further
assess the sample buffer as lyophilized beads included with the antibodies beads which,
due to time constraints and manufacturing limitations, it was not possible to continue the
optimization with this format.
Finally, during the production of the scFvO157 the major limitation faced was the inability
to obtain an appropriate yield of purified scFvO157. Initial attempts to demonstrate the
functionality of the scFvO157 through ELISA and immunofluorescence microscopy were
made, however, the results were inconclusive due to low signal magnitude. Expression of
the recombinant protein was successful as demonstrated by Western Blot analysis (Figure
29). However, despite cautionary efforts made during the design of the scFvO157 gene, it
was mainly expressed as inclusion bodies found in the insoluble fraction of the cell lysate.
It has been well-documented that expression of scFv as soluble protein represents a
challenging process (197,205,215). In fact, different approaches to tackling this limitation
have been published, including expression in a different host such as yeasts (217), Grampositive bacteria (e.g. Bacillus brevis and Bacillus subtilis) (215), or other E. coli strains
such as E. coli Origami B (DE3) (265,304). These approaches are designed to improve
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disulfide bond-dependent protein folding and may be more appropriate here. In addition,
the influence of induction conditions has been widely assessed (197,267,306). Because the
latter are considered to be easily modifiable as they are involved in the final stage of
scFvO157 synthesis, they were initially evaluated, as shown in Figure 30. The results
obtained confirmed only the fact that the scFvO157 was mainly produced as insoluble
protein regardless of the induction conditions used. Thus, the next approach used was
focused on the purification of the inclusion bodies, which showed promising results in
terms of purification but its further refolding step required further optimization. Therefore,
despite the fact that we were able to express the bioengineered scFvO157, the overall
results were considered inconclusive due to the lack of unambiguous evidence that could
support the successful production of the scFvO157 through functional assessment.
6.3. Future Directions
Extending the Application of the LFIA Test Kit
Due to an increasing awareness of healthy eating habits, trends are switching towards
higher consumption of sustainable, fresh produce (6,7). Thus, fresh products have been
recently recognized as an emerging source of foodborne pathogens because they are mainly
eaten raw (7,48,307). In fact, in the last decade, there have been several foodborne
outbreaks linked to consumption of fresh vegetables worldwide. These include an outbreak
related to iceberg lettuce and the well-known case of contaminated bagged spinach that
occurred in 2006 (308). In 2011, a multistate outbreak caused by contaminated romaine
lettuce was also reported (48). All three of these outbreaks occurred in the US. Thus, it will
be relevant to assess the applicability of the LFIA Test Kit on detection of E. coli O157 in
fresh produce. It is important to focus on leafy green vegetables, which are considered the
commodity with the highest microbiological safety concern because they are prone to
contamination with E. coli O157 from irrigation water, soil and/or manure used as fertilizer
(6). Therefore, demonstrating the suitability of the LFIA Test Kit and further validating its
performance against the reference method may represent a new possibility for expanding
the applicability of the LFIA Test Kit to fresh produce, a commodity that is emerging as a
high-risk carrier for E. coli O157.
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Collaborative Study
The study presented in this work focused on the first stage of the validation process for
alternative detection methods, namely a pre-collaborative study. It will be important to
continue with the second stage, which is a collaborative study comprising the comparison
of the alternative method against the reference method, but this time pursued in parallel by
multiple laboratories (174). The main objectives of this study will be as follow: a) to
determine the variability of the outcomes obtained when using the LFIA Test Kit in
different laboratories with similar samples, and b) to compare these results with the ones
obtained during the pre-collaborative study. The collaborative study will be performed
following the guidelines established in Health Canada’s Compendium of Analytical
Methods. Overall, these guidelines require a minimum of eight accredited laboratories,
evaluating at least one relevant food type with three contamination levels (negative control,
slightly above the alternative method detection level, and 10 times higher than the
alternative detection level). Each level should comprise 8 replicates for a total of 24
samples assessed by the LFIA Test Kit and the reference method (174). Although
artificially inoculated samples are accepted, including naturally contaminated samples is
preferred. Performing a collaborative study is highly recommended because it will generate
robust evidence to evaluate the performance of the LFIA Test Kit, especially if this method
is expected to aid regulatory activity as suggested through our submission of the precollaborative study to Health Canada’s Microbiological Methods Committee.
Tandem LFIA Test Kit as a Semi-Quantitative Assay
To date, most of the commercially available LFIAs have been developed for obtaining
qualitative results (presence/absence). However, research has been focusing lately on
adapting the LFIA format to provide semi-quantitative or even quantitative results.
Although, the focus has been mainly on measuring the intensity of the test line (130),
modification in the design of the traditional LFIA format has also been considered as a
feasible approach for developing more sensitive and quantitative formats (309,310). In this
work, the tandem LFIA device was adopted as a solution to the prozone and matrix effect
faced during the development of the alternative detection method. However, results
obtained with enriched meat samples suggested that it could potentially be used to estimate
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the concentration of E. coli O157 in contaminated samples. Future studies should focus on
proving the concept of a tandem LFIA as a visual semi-quantitative method. For this
purpose, the results obtained during this study should be confirmed by using a larger
number of samples with emphasis on the lower concentration ranges so that they are as
equally represented as the high concentration range. In addition, the subsequent visual
evaluation of the results should also be carried out using an untrained panel to ensure that
the combination of lines is easily interpreted and linked to the concentration levels
previously stipulated. Overall, the tandem LFIA design offers a technology with significant
advantages over the standard LFIA device once it if confirmed to consistently provide an
easy-to-interpret visual result linked to a level of contamination with E. coli O157.
Alternative Strategies for Improving the Synthesis of Soluble scFvO157
It is important to further study the expression of the humanized scFvO157 using different
expression hosts in order to avoid the necessity of isolating inclusion bodies and to obtain
a higher yield of soluble protein. Within E. coli expression hosts, there is a wide variety of
strains that have been developed to improve soluble protein expression. E. coli strains have
many advantages over other expression systems including fast and easy transformation,
and inexpensive culture broths with high cell density easily achievable due to rapid growth
rate (265,266,290,306). Hence, for future studies, it is recommended to initially evaluate
the expression in strains such as E. coli Origami B (DE3) or Novagen AD494, which are
designed to promote proper folding of proteins through the formation of disulfide bonds,
especially when the recombinant protein is fused to TrxA (216). Different vectors, which
aim at expressing soluble recombinant proteins using E. coli as an expression host
(271,306), have also been described. Other alternatives are represented by co-expression
of chaperones (216,306,311), and/or fusion of other protein carriers besides TrxA, such as
maltose binding protein (216,311) or the E. coli N-utilizing substance A (NusA) (216).
Both have shown to substantially increase the solubility of highly insoluble scFv when
expressed in E. coli (216).
Soluble protein expression in different hosts other than E. coli has also been suggested. As
an example, the Gram-positive Bacillus megaterium has been successfully used for
expression of a scFv, with the advantage of secreting the expressed protein directly into
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the growth medium, facilitating its further purification with superior yields than expression
in E. coli (215). Moreover, expression in eukaryotic cells such as yeasts also provides a
cost-effective alternative for expression of soluble recombinant proteins, which can be
easily purified from the culture supernatant (290). Due to the vast number of combinations
that can be assessed, microexpression incubator shakers have also been developed, which
allows screening of all possible conditions faster and cost-effectively in small, less
expensive reactions (271).
Alternative Strategies for in vitro Refolding of Inclusion Bodies
Within this study, purification and refolding of the scFvO157 inclusion bodies represented
a challenging process due to constant precipitation. Therefore, alternative protocols must
be assessed in order to increase the yield of purified protein. In vitro refolding can be
facilitated by dialysis (273,303,312), dilution (218,273) or solid phase (273,303). Dialysis
and solid-phase were the methods tried for the refolding step of the scFvO157; thus it is
strongly advisable to evaluate the dilution method. Something to be considered of the
refolding strategy is that buffer composition is strongly dependent on the inherent
characteristics of the recombinant protein. Hence, different buffer compositions should be
assessed regardless of the methodology chosen for refolding. An ideal screening method
for selecting the proper conditions for scFvO157 refolding is described by Vincentelli et al.
(273), where 96-well plates were used to assess the solubility of a target protein in a
selection of refolding conditions by measuring the turbidity of the solution as a result of
protein precipitation. Those conditions that showed absorbance values close to the
absorbance of the buffer alone were regarded as optimal for protein solubility and further
used to determine the proper folding of the protein through techniques such as circular
dichroism (204,273,303) and dynamic light scattering (273). Recovery of inclusion body
is becoming more common due to an increase in production of recombinant proteins mainly
for therapeutics. This has switched the perspective of looking at inclusion body as an
advantage rather than a problem needed to be solved. Inclusion body recovery allows for a
faster and more efficient purification, however efficient in vitro refolding strategies still
require careful optimization that can only be accomplished by proper knowledge of the
protein of interest.
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Re-Evaluation of the scFvO157 Using Bioinformatics
Besides assessing other expression and in vitro refolding strategies, re-evaluation of the
scFvO157 structure should also be pursued. Characteristics such as folding, solubility, and
stability can be predicted and improved once structural information is available and
properly analyzed. In recent years, several computational tools have been developed with
the main objective of assisting in the successful engineering of recombinant proteins,
including scFv. In fact, a field known as “antibody informatics” has evolved to tackle some
of the major obstacles faced during antibody drug discovery (313). A recent publication
from Shirai et al. highlighted many of the obstacles presented during the antibody
engineering experimental workflow and linked them to the ideal informatics tools that can
be used to overcome these problems (313). Hence, this approach could be easily adopted
to identify the major constraints and identify the necessary tools to improve the design of
scFv regardless of their future application.
Focusing on scFvO157, the main obstacle is the formation of inclusion body and
aggregation during expression, which may be attributed to unsuitable physicochemical
properties of the bioengineered protein and may be improved by an adequate in silico
design. Some of the scFvO157 re-evaluation was started by analyzing and comparing the
theoretical hydrophobicity and pI of both the humanized scFvO157 and the human scFv
acceptor primary sequences (Section 4.3.8). Findings suggested that differences found
between the scFvO157 and the human scFv acceptor are due to the loop grafting process
and could have influenced the improper folding of the scFvO157. These results support the
assertion that proper knowledge of the scFv characteristics could help to determine the
optimal conditions for its expression and purification.
During antibody engineering, there are three main structural characteristics that have to be
considered: a) the primary amino acid sequence, which is the result of V(D)J gene segment
and somatic mutations, b) the structure of the six CDR loops, which form the antigenbinding site, and c) the relative orientation of the VH and VL chains, which will partially
determine the interaction with the target antigen. Based on these, it is suggested to first
analyze the murine VH and VL chain sequences and further compare them with the
humanized scFvO157 initially designed. Kuroda et al. suggested a simple procedure that
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starts by using the VH and VL chain sequences for antibody modeling, followed by an
antibody-antigen docking simulation, which provides a prediction of potential mutations
for enhancing the desired antibody properties including solubility (314). For the first step,
which is antibody modeling, a web server named PIGS (prediction of immunoglobulin
structure) developed by Marcatili et al., is suggested to model the variable domain of the
anti-O157 mAb. This server takes into consideration not only the alignment of the primary
amino acid sequence, but also the canonical structures of the CDR loops and the final
packing (orientation) of the VH and VL chain in order to derive the quaternary structure that
best predicts the conformation of the antibody structure (315,316). The PIGS murine antiO157 mAb model can be further superimposed with the scFvO157 to determine if the latter
maintains the proper folding, secondary structure and VH and VL chain packing of the
original mAb. Furthermore, the anti-O157 mAb model can be subjected to a detailed
analysis of its primary and secondary structure to identify those residue positions that are
crucial for antigen recognition. Interestingly, some residues within the FRs have been
identified as crucial for antigen binding, while conserved residues within the CDRs have
been regarded as providing structural support rather than contributing directly to active
binding (219). Hence, discrimination among functional and structural residues will allow
the refinement of the CDR grafting process to potentially enhance biophysical properties
such as solubility. Finally, as an additional in silico analysis, the PIGS murine anti-O157
mAb model can be used to develop an antibody-antigen docking model using programs
such as Glide from Schrödinger Software (317,318). Besides providing supporting
information for enhancement of scFvO157 design, attempting to develop an antibodycarbohydrate docking model will further expand the knowledge regarding this type of
interaction because most of the research has focused on antibody-protein/ peptide binding
(319).
In conclusion, by using a combination of bioinformatics tools it is possible to undertake an
in silico modeling strategy to achieve the following a) understand the possible structural
cause(s) that underlie the formation of inclusion body and aggregation during recombinant
protein expression stage, and b) increase the knowledge of the murine anti-O157 mAb
sequence and tertiary structure to re-design the scFvO157 and potentially improve the
experimental design to enhance its solubility during expression.
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Appendices
Appendix A: Characterization of inclusivity and exclusivity strains
Both inclusivity and exclusivity panels were assembled by collecting strains from multiple reliable
contributors including the following: Public Health Agency of Canada, Guelph, ON, Canada (PHAC),
Western University, Department of Microbiology and Immunology, London, ON, Canada (UWO), Canadian
Research Institute for Food Safety, Guelph, ON, Canada (CRIFS), Leibniz Institute DSMZ- German
Collection of Microorganisms and Cell Cultures, Braunschweig, Germany (DSMZ), University of Manitoba,
Department of Food Science, Winnipeg, MN, Canada (UofM), American Type Culture Collection, VA, USA
(ATCC), and Health Canada, Listeriosis Reference Service, Ottawa, ON, Canada.
The characterization of the 50 E. coli O157 strains was done according to the confirmation assays described
in the MFHPB-10 Isolation of Escherichia coli O157:H7/NM from foods and environmental surface samples,
Section 6.8 (255), except for the presence of verotoxins, which was provided by the respective contributors.
Strains, taken from the frozen stocks, were grown in TSB at 37°C for 24 h. A loop was taken from each
culture and streaked into TSA plates to obtain isolated colonies. Plates were incubated at 37° for 18-24 h. A
grid was drawn in two selective agars: Oxoid CR-SMAC (Oxoid Limited, UK) and BBL CHROMagar O157
(BD, USA). For each strain, isolated colonies from the TSA plates were picked and inoculated in each grid
cell of both agars. Finally, plates were incubated at the appropriate time and temperature suggested by the
suppliers. After incubation, colonies were considered positive (+) if they presented the characteristic growth
being translucent, colorless or straw-colored edges, with a dark center ranging from grey to pink (non-sorbitol
fermenting) for the CR-SMAC and, mauve against white background for the CHROMagar. If they were red
in the CR-SMAC and/ or colorless, blue, green, or blue-green on the CHROMagar, they were considered
negative (-). For cellobiose fermentation, tubes containing 5ml of Purple Broth (Difco™, BD, USA) with 1%
cellobiose (Sigma-Aldrich, USA) were inoculated with one isolated colony of each strain obtained from the
TSA plates. Then, they were incubated at 37°C for 18-24 h. After incubation, positive (+) strains showed
color change from purple to yellow since they fermented cellobiose, while negative (-) strains showed no
color change. Furthermore, the API 20E Test rapid identification system was performed following the
manufacturer’s instructions (API 20E Identification system for Enterobacteriaceae and other non-fastidious
Gram-negative rods; bioMérieux, Inc.; 07584D-GB-2002/10). The numerical profiles obtained were used to
confirm the strains as E. coli according to their database. The presence of the O157 antigen was confirmed
by O157 antisera agglutination using an isolated colony from the TSA plates and re-suspended in a small
drop of saline solution on a glass slide. Then, a similar drop of E. coli O157 antiserum (BD, USA) was added.
Both drops were mixed with the needle. To promote agglutination, the slide was rocked back and forth for
1 min (320). Positive strains (+) showed the presence of white lumps, while negative (+) strains maintained
a homogeneous turbid solutions. Finally, H7 serotyping was done by immobilization. Briefly, columns of
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semi-solid agar (TSA/ 0.4% agar) were prepared containing H7 antiserum (BD, USA). Then, they were
stabbed with a needle containing an isolated colony taken from the TSA agar plates for each strain. Tubes
were incubated at 37°C for 18-24 h. After incubation, positive tubes (+) showed growth only along the stab
because they were immobilized due to the presence of the flagellar H7 antigen. Negative tubes (-) showed
growth (cloudiness) away from the stab line, which meant that E. coli cells were motile, but did not have the
H7 antigen. Finally, positive strains (+) were inoculated in agar columns without antigen to discriminate from
real H7 motile strains and non-motile ones (NM). Tubes were also incubated at 37°C for 18-24 h. E. coli H7
strains grew away from the stab line when no H7 antiserum was present (+), while non-motile strains
remained along the stab line (-) (320,321).
The results for the characterization of the fifty E. coli O157 strains collected are shown below. The O- and
H-antigen confirmation assays showed the expected results, where all strains were positive for the O157antigen agglutination and H7-antigen strains were immobilized with the H7 antiserum. Moreover, all strains
were negative for cellobiose fermentation. On the other hand, 84% of the strains were sorbitol negative, while
16% were sorbitol positive according to the results obtained with the CR-SMAC. From the latter, two were
H7, while the rest had a different flagellar H-antigen. CHROMagar results showed characteristic mauve
colonies for all O157:H7/ NM strains, while strains with different H-antigen did not grow or presented a
different color (negative). The API 20E results corresponded to an Escherichia coli 1 taxon with a percentage
of identity (ID) above 97.7% for all strains but one. The latter, E. coli O157:NM 02-1840, showed a mixed
taxon, Escherichia coli 1 and Escherichia coli 2, with an ID of 83.1 and 10.1% respectively.
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E. coli O157 strains and characterization results

Culture
Collection

Reference

1

CRIFS

C480

Escherichia
coli

O157:H7

2

CRIFS

C654,
EC20321

Escherichia
coli

3

CRIFS

C670,
EC960282

4

CRIFS

5

#

Strain

Serotype

Source/
Origin

Shiga
Toxin*

Confirmatory Tests

VT1

VT2

CRSMAC

CHROM
Agar

O157

H7

Cellobiose

API Test

N/A

N/I

N/I

+

+

+

+

-

Escherichia
coli 1

O157:H7

L.Goodridge

N/I

N/I

+

+

+

+

-

Escherichia
coli 1

Escherichia
coli

O157:H25

Bovine

N*

N*

-

-

+

-

-

Escherichia
coli 1

C671,
EC940076

Escherichia
coli

O157:H19

Bovine

N*

N*

-

-

+

-

-

Escherichia
coli 1

CRIFS

C677,
EC930195,
32511

Escherichia
coli

O157:NM

L.Goodridge

N/I

N/I

+

+

+

+

-

Escherichia
coli 1

6

CRIFS

C899, ATCC
43888

Escherichia
coli

O157:H7

Human ,
feces

N/I

N/I

+

+

+

+

-

Escherichia
coli 1

7

CRIFS

C901, ATCC
43894

Escherichia
coli

O157:H7

Human ,
feces

N/I

N/I

+

+

+

+

-

Escherichia
coli 1

8

CRIFS

C918, 380-94

Escherichia
coli

O157:H7

Bovine,
salami

N/I

N/I

+

+

+

+

-

Escherichia
coli 1

9

CRIFS

C919, 9490

Escherichia
coli

O157:H7

USDA

N/I

N/I

+

+

+

+

-

Escherichia
coli 1

10

CRIFS

C1264,
ATCC
700927

Escherichia
coli

O157:H7

Derived
from
ATCC43895

N/I

N/I

+

+

+

+

-

Escherichia
coli 1

11

DSMZ

DSM 17076,
NCTC 12900

Escherichia
coli

O157:H7

Human,
clinical

N

N

+

+

+

+

-

Escherichia
coli 1

12

PHAC

EC19920333

Escherichia
coli

O157:H7

Human,
clinical

N

Y

+

+

+

+

-

Escherichia
coli 1
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Reference

13

PHAC

EC19930038

Escherichia
coli

O157:H7

14

PHAC

EC19930553

Escherichia
coli

15

PHAC

EC19950095

16

PHAC

17

#

Strain

Serotype

Source/
Origin

Shiga
Toxin*

Confirmatory Tests

VT1

VT2

CRSMAC

CHROM
Agar

O157

H7

Cellobiose

API Test

Human,
clinical

N

Y

+

+

+

+

-

Escherichia
coli 1

O157:H7

Human,
clinical

Y

Y

+

+

+

+

-

Escherichia
coli 1

Escherichia
coli

O157:NM

Bovine,
meat

Y

Y

+

+

+

-

-

Escherichia
coli 1

EC19960266

Escherichia
coli

O157:H7

Human,
clinical

N

N

+

+

+

+

-

Escherichia
coli 1

PHAC

EC19960274

Escherichia
coli

O157:H7

Human,
clinical

N

N

+

+

+

+

-

Escherichia
coli 1

18

PHAC

EC19961016

Escherichia
coli

O157:H7

Human,
clinical

Y

N

+

+

+

+

-

Escherichia
coli 1

19

PHAC

EC19961025

Escherichia
coli

O157:H7

Human,
clinical

N

Y

+

+

+

+

-

Escherichia
coli 1

20

PHAC

EC19961027

Escherichia
coli

O157:H7

Human,
clinical

Y

Y

+

+

+

+

-

Escherichia
coli 1

21

PHAC

EC19961090

Escherichia
coli

O157:H7

Human,
clinical

Y

N

+

+

+

+

-

Escherichia
coli 1

22

PHAC

EC19970409

Escherichia
coli

O157:H7

Bovine,
meat

Y

Y

+

+

+

+

-

Escherichia
coli 1

23

PHAC

EC19970419

Escherichia
coli

O157:H7

Bovine,
meat

Y

Y

+

+

+

+

-

Escherichia
coli 1

24

PHAC

EC19970462

Escherichia
coli

O157:H7

Bovine,
meat

Y

N

+

+

+

+

-

Escherichia
coli 1

25

PHAC

EC199704651

Escherichia
coli

O157:H45

Bovine,
meat

N

N

-

-

+

-

-

Escherichia
coli 1

26

PHAC

EC19970515

Escherichia
coli

O157:H7

Bovine,
meat

Y

Y

+

+

+

+

-

Escherichia
coli 1
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Culture
Collection

Reference

27

PHAC

EC19970524

Escherichia
coli

O157:H42

28

PHAC

EC19990951

Escherichia
coli

29

PHAC

EC20000671

30

PHAC

31

#

Strain

Serotype

Source/
Origin

Shiga
Toxin*

Confirmatory Tests

VT1

VT2

CRSMAC

CHROM
Agar

O157

H7

Cellobiose

API Test

Bovine,
meat

N

N

-

-

+

-

-

Escherichia
coli 1

O157:H7

Bovine,
salami

Y

Y

+

+

+

+

-

Escherichia
coli 1

Escherichia
coli

O157:H7

Bovine,
ground

Y

Y

+

+

+

+

-

Escherichia
coli 1

EC20000673

Escherichia
coli

O157:H7

Bovine,
Meat

N

Y

+

+

+

+

-

Escherichia
coli 1

PHAC

EC20001018

Escherichia
coli

O157:H7

Bovine,
ground

Y

Y

+

+

+

+

-

Escherichia
coli 1

32

PHAC

EC20010294

Escherichia
coli

O157:H7

Bovine,
ground

Y

Y

+

+

+

+

-

Escherichia
coli 1

33

PHAC

EC20011231

Escherichia
coli

O157:H7

Bovine,
ground

Y

Y

+

+

+

+

-

Escherichia
coli 1

34

PHAC

EC20011236

Escherichia
coli

O157:H7

Bovine,
ground

Y

Y

+

+

+

+

-

Escherichia
coli 1

35

PHAC

EC20011244

Escherichia
coli

O157:H7

Bovine,
ground

Y

Y

+

+

+

+

-

Escherichia
coli 1

36

PHAC

EC20020335

Escherichia
coli

O157:H7

Human,
clinical

Y

Y

+

+

+

+

-

Escherichia
coli 1

37

PHAC

EC20040339

Escherichia
coli

O157:H7

Bovine,
meat

Y

Y

+

+

+

+

-

Escherichia
coli 1

38

PHAC

EC20050147

Escherichia
coli

O157:H12

Bovine,
feces

N

N

-

-

+

-

-

Escherichia
coli 1

39

PHAC

EC20060233

Escherichia
coli

O157:H7

Bovine,
ground

Y

Y

+

+

+

+

-

Escherichia
coli 1

40

PHAC

EC20060754

Escherichia
coli

O157:H29

Bovine,
feces

N

N

-

-

+

-

-

Escherichia
coli 1
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Culture
Collection

Reference

41

PHAC

EC20130376

Escherichia
coli

O157:H7

42

PHAC

EC20130378

Escherichia
coli

43

PHAC

EC20130390

44

PHAC

45

#

Strain

Serotype

Source/
Origin

Shiga
Toxin*

Confirmatory Tests

VT1

VT2

CRSMAC

CHROM
Agar

O157

H7

Cellobiose

API Test

Bovine,
feces

N

Y

+

+

+

+

-

Escherichia
coli 1

O157:H7

Bovine,
feces

N

Y

+

+

+

+

-

Escherichia
coli 1

Escherichia
coli

O157:NM

Bovine,
feces

Y

Y

+

+

+

-

-

Escherichia
coli 1

EC20130395

Escherichia
coli

O157:NM

Bovine,
feces

Y

Y

+

+

+

-

-

Escherichia
coli 1

PHAC

EC20132075

Escherichia
coli

O157:H7

Bovine,
feces

N

Y

+

+

+

+

-

Escherichia
coli 1

46

UofM

00-3581

Escherichia
coli

O157:H7

Human,
clinical

N

N

-

+

+

+

-

Escherichia
coli 1

47

UofM

02-0304

Escherichia
coli

O157:H7

Human,
clinical

N

N

-

+

+

+

-

Escherichia
coli 1

48

UofM

02-0627

Escherichia
coli

O157:H7

Human,
clinical

N

N

+

+

+

+

-

Escherichia
coli 1

49

UofM

02-0628

Escherichia
coli

O157:H7

Human,
clinical

N

N

+

+

+

+

-

Escherichia
coli 1

50

UofM

02-1840

Escherichia O157:NM Human,
N
N
+
+
Escherichia
coli
clinical
coli**
*Shiga toxin information was provided by the contributors. N:absence of Shiga Toxin; Y: presence of Shiga Toxin; +: positive results; -: negative results;
N/I: no information provided; N/A: not available. **This strain showed a percentage of identity of 83.1% corresponding to Escherichia coli 1 and a
10.1% corresponding to Eschericha coli 2.
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On the other hand, only the six strains that initially showed at least one positive replicate during the LFIA
Test Kit exclusivity study, were characterized following the methodology below.
Strains, taken from frozen stocks were grown in TSB at 37°C for 24 h. A loop was taken from each culture
and streaked into TSA plates to obtain isolated colonies. Plates were incubated at 37° for 18-24 h. The
cellobiose, API 20E Test and O157 antisera agglutination tests were performed as described in the inclusivity
studies. In addition, two more tests were included in order to characterize Shigella flexneri. Briefly, a lactose
fermentation test was prepared using tubes containing 5ml of Purple Broth with 1% lactose (J.T.Baker®
Chemicals, Avantor Performance Materials, PA, USA) inoculated with one isolated colony obtained from
TSA plates. Then they were incubated at 37°C for 18-24 h. After incubation, positive (+) strains showed
color change from purple to yellow because they fermented lactose, while negative (-) strains showed no
color change. As positive control we used E. coli ATCC 25922. Mobility was assessed using columns of
semisolid agar (TSA/ 0.4% agar) stabbed with a needle containing an isolated colony taken from TSA agar
plates. Tubes were incubated at 37°C for 18-24 h. After incubation, positive tubes showed growth
(cloudiness) away from the stab, which meant that the strain was motile. Negative tubes showed a delimited
growth along the stab meaning that the strain lack motility.
A summary of the results obtained from the biochemical characterization of the six strains that had at least
one replicate positive during the exclusivity study is found below. Strains with a percentage of identity (ID)
higher that 90% were no further evaluated. Strain EC20130473 had 85.5% ID corresponding to an E. coli 1,
however, the 14.4% ID missing was related to an E. coli 2 taxon thus, it was not considered either. On the
other hand, ATCC 25929 Shigella flexneri, had 68.8% ID corresponding to Shigella spp., while 17.5%
matching the E. coli 2 taxon. Therefore, this strain was subjected to two more biochemical tests: lactose
fermentation and motility following the methodology described above. The results obtained for this strain
showed a lack of ability to ferment lactose and no motility, which are typical from Shigella spp. when
compared against E. coli spp.
Non-E. coli O157 strains used within this study
#

Culture
Collection

Reference

Strain

Serotype

Origin/ Source

1

ATCC

ATCC 19114

Listeria
monocytogenes

4a

Animal, tissue

2

ATCC

ATCC 43886, CDC
E2539-C1

Escherichia coli

O25:K98:NM

Human, feces

3

ATCC

ATCC 43893, CDC
EDL 1284 [929-78]

Escherichia coli

O124:NM

Human, feces

4

CRIFS

C390

Salmonella
Heidenberg

N/A

N/A

5

CRIFS

C398

Salmonella newport

N/A

N/A

231

#

Culture
Collection

Reference

Strain

Serotype

Origin/ Source

6

CRIFS

C417

Salmonella
Enteritidis

N/A

N/A

7

CRIFS

C1116

Salmonella javiana

N/A

N/A

8

CRIFS

EC 910005

Escherichia coli

O111:NM

N/A

9

CRIFS

EC 910040

Escherichia coli

O145:NM

N/A

10

CRIFS

EC 910060

Escherichia coli

O121:H7

N/A

11

CRIFS

EC 920232

Escherichia coli

O2:H5

Bovine

12

CRIFS

EC 930004

Escherichia coli

O103:H2

N/A

13

HC

HPB 5949

Listeria
monocytogenes

1/2C

Food, ready-to-eat

14

PHAC

ATCC 6051

Bacillus subtilis

N/A

HJ Conn

15

PHAC

ATCC 7966

Aeromonas
hydrophila

N/A

From tin of milk
with a fishy odor

16

PHAC

ATCC 12014

Escherichia coli

O55:NM

CDC

17

PHAC

ATCC 13047

Enterobacter
cloacae

N/A

Spinal fluid

18

PHAC

ATCC 23715

Yersinia
enterocolitica

N/A

Human, blood

19

PHAC

ATCC 25922

Escherichia coli

O6

Human, clinical

20

PHAC

ATCC 25929

Shigella flexneri

N/A

Human, feces

21

PHAC

ATCC 25931

Shigella sonnei

N/A

Human, feces

22

PHAC

ATCC 33650

Escherichia
hermanii

N/A

Human, female
toe

23

PHAC

ATCC 43162

Citrobacter braakii
(freundii)

N/A

Clinical isolate,
California

24

PHAC

ATCC 43887

Escherichia coli

O111:NM

Human, feces

25

PHAC

ATCC 49149

Enterococcus
faecalis

N/A

Clinical isolate

26

PHAC

ATCC 700926

Escherichia coli

OR:H48:K-

Derived from
parent strain
W1485

27

PHAC

EC20130462

Escherichia coli

O75:H5

N/A

28

PHAC

EC20130463

Escherichia coli

O21:H4

N/A

29

PHAC

EC20130466

Escherichia coli

O44:H18

N/A

30

PHAC

EC20130467

Escherichia coli

O3:H2

N/A

31

PHAC

EC20130469

Escherichia coli

O28ac:NM

N/A

32

PHAC

EC20130473

Escherichia coli

O78:H11

N/A

33

PHAC

EC20130476

Escherichia coli

O25:NM

N/A
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#

Culture
Collection

Reference

Strain

Serotype

Origin/ Source

34

PHAC

MB1914

Hafnia alvei

N/A

N/A

35

PHAC

NO152388

Enterobacter
aerogenes

N/A

N/A

36

UWO

ATCC 13883,
UWO#479

Klebsiella
pneumoniae

N/A

NCTC

37

UWO

LT-2

S. enterica ser.
N/A
N/A
Typhimurium
PHAC: Public Health Agency of Canada, Guelph; UWO: Western University, Department of Microbiology
and Immunology; CRIFS: Canadian Research Institute for Food Safety, Guelph; ATCC: American Type
Culture Collection; HC: Health Canada, Listeriosis Reference Service; N/A: not available.
Characterization of non-target strains
Confirmatory Tests

#

Culture
Collection

Reference

Strain

Serotype

1

PHAC

EC20130473

Escherichia
coli

2

PHAC

EC20130467

3

PHAC

4

API Test
(%identity)

O157

Cellobiose

O78:H11

-

-

Escherichia
coli**

Escherichia
coli

O3:H2

-

-

Escherichia
coli 1 (98.1)

EC20130466

Escherichia
coli

O44:H18

-

-

Escherichia
coli (98.1)

ATCC

ATCC43893,
CDC EDL
1284 [92978]

Escherichia
coli

O124:NM

-

-

Escherichia
coli 1 (96.3)

5

PHAC

ATCC 25929

Shigella
flexneri

-

-

Shigella
spp. (68.8)

6

UWO

S. enterica
Salmonella
ser.
spp. (98.6)
Typhimurium
**This strain showed a percentage of identity of 85.5% corresponding to Escherichia coli 1 and a 14.4%
corresponding to Escherichia coli 2.
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Appendix C: LFIA Test Kit package insert
™

ADx
DECISION POINT™
Rapid Food Safety Testing Solutions

E. coli O157
Application
This method is applicable for the recovery and detection of Escherichia coli O157 (including H7 and non-motile) in
raw meat and ready-to-cook meat products.
Description
DECISION Point TM is a qualitative immunoassay that employs specific antibodies against target antigens found in
E. coli O157.
Assay Principles
The system uses a selective enrichment medium for the rapid recovery and growth of the target organism. After
enrichment, a portion of the sample is placed into a sample vial containing dried antibody reagents. The sample is
incubated with the reagents for 30 minutes at room temperature. If E.coli O157 is present in the sample, it will form
an antibody-antigen-antibody complex in solution. The sample is loaded onto the cassette, where it will flow through
the nitrocellulose membrane. Any complex formed will be captured in the test zone of the membrane, thus displaying
a visible red line. The rest of the sample will continue to migrate until it reaches the control line. The control line will
develop whether or not the sample contains E.coli O157, thereby ensuring that the test system is functioning properly.
Intended User
The test is designed to be used by personnel who are familiar with the aseptic techniques required in a microbiological
laboratory. Specialized training is not required; however, basic knowledge of food microbiology is recommended.
Materials Provided:
•
DECISION Point TM foiled test cassettes – single use
•
DECISION Point TM foiled test reagent vials – single use
•
DECISION Point TM Sample Diluent
•
DECISION Point TM Sample Buffer
•
Eppendorf tubes for dilutions
Materials Required But Not Provided:
•
Pipettes and tips for pipettes
•
Stomacher®-type filter bags
•
Sterile (deionized or distilled) water
•
Dried enrichment media: Tryptic Soy Broth + 20 mg/L Novobiocin
Equipment Required:
•
Autoclave
•
Analytical balance
•
Stomacher®
•
Timer
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•
•

Incubator capable of maintaining 42 ± 1ºC
Vortex (if available)

Storage and Handling
• Store DECISION Point TM test components at 2-8°C.
• Inspect the DECISION Point TM foiled test cassette and foiled test reagent vials for damage prior to use. Do not
use if the foil shows evidence of damage or perforation.
• Each DECISION Point TM test cassette and reagent vials is intended for single use only.
• DECISION Point TM test cassette and test reagent vials should remain in their sealed foil pouches until ready to
perform the test.
Sample Preparation and Cultivation:
1.

Sample Addition
• 25 g samples: Aseptically combine 25 g of sample with 225 mL of enrichment medium (1:10) in a
Stomacher® bag. Place the bag in a Stomacher® machine and mix for 60 seconds at normal speed.
• 325 g samples: Aseptically combine 325 g of sample with 2925 mL of enrichment medium (1:10) in a
Stomacher® bag. Place the bag in a Stomacher® machine and mix for 60 seconds at normal speed.

2. Incubation
Close the sample bag loosely to allow air exchange for E. coli O157 growth. Incubate at 42 ± 1ºC:
• 25 g samples: 16-24 hours.
• 325 g samples: 22–24 hours.
3. Cooling
After the appropriate incubation time has elapsed, allow the enriched sample to cool to room temperature prior to
testing.
4. Mixing
Hold the bag so that the bottom is supported and gently mix the contents using a side-to-side motion.
DECISION Point TM Test Procedure (FIGURE 1):
1. Remove the required number of foiled test cassettes, foiled test reagent vials, sample diluent bottles and sample
buffer bottles from 2-8°C storage.
Note: Allow the foiled test cassettes to equilibrate to room temperature during the 30 minutes sample
incubation.
2. Open up reagent vial pouch and label both vials with the sample number.
3. Pipette 1.0 mL of Sample Diluent into a clean Eppendorf tube, add 10 µL of the sample directly from the
Stomacher® bag (yielding 1/100 dilution) and mix thoroughly by vortexing or pipetting up and down several
times.
4. Transfer a 200 µL sample directly from the Stomacher® bag into Vial A.
5. Transfer a 200 µL of the diluted sample (from Step 3) into Vial B.
6. Add 10 µL of Sample Buffer into both vials, close caps and mix thoroughly by vortexing or inverting tubes several
times.
7. Let the samples incubate on the bench at room temperature for 30 minutes.
8. Open pouches containing the DECISION Point TM test cassettes 1-2 minutes before the end of the incubation
time and label the cassettes with the sample number.
9. When the incubation period is completed, load 150 µL of sample from vial A into sample port A (left) on the test
device and 150 µL of sample from vial B into sample port B (right).
10. Read the test results at 15 minutes. Observations after 17 minutes may be inaccurate due to overdevelopment of
the reaction. For results interpretation please see below.

241

Visual Interpretation of Results
Check for the presence of red lines in the Control (C) and Test (T) areas in result windows A and B at 15 minutes.
•
A positive test result is indicated by:
ü Control lines in both A and B result windows.
ü Test lines in either one or both A and B result windows.
•
A negative test result is indicated by:
ü Control lines in both A and B result windows.
ü Test lines in neither A and B result windows.
•
An invalid test result is indicated by:
ü No Control lines in either A and B result windows.
•
Notes:
ü Different intensities of Test and Control lines are acceptable.
ü The test is not quantitative and test line intensity does not reflect target antigen concentration.
ü If the test interpretation is invalid, the sample should be retested.
Possible Test Results
Positive Results

Negative Result

Invalid Results

Disposal
Decontaminate (autoclave, bleach, etc.) and dispose of used DECISION Point TM test cassettes, reagent vials, media,
and pipettes/tips in accordance with good laboratory practices and local and federal regulations.
FIGURE 1: Test Flow Chart
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Appendix D: MFHPB-33 Enumeration of total aerobic bacteria in food products and food ingredients using 3M™ Petrifilmt™ aerobic count
plates
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Appendix E: Buffer and reagents prepared for this study.
Buﬀer/ Reagent

Composition

Application

Blocking Buﬀer

137 mM NaCl, 10 mM Na2HPO4, 2.7 mM KCl, 1.8 mM
KH2PO4, pH 7.4, 10% BSA

ELISA

Coating Buﬀer

0.1 M sodium carbonate buﬀer pH 9.5

ELISA

Coomassie Blue
Staining Solution

45% (v/v) methanol, 10% (v/v) glacial acetic acid, 0.3% (w/v)
Coomassie brilliant blue R-250

Protein
Visualization

Denaturing Binding
Buffer

8 M urea, 20 mM sodium phosphate, 500 mM NaCl, pH 7.8

scFvO157
Purification

Denaturing Buffer

6M guanidine hydrochloride, 20 mM sodium phosphate, 500
mM NaCl, pH 7.8

scFvO157
Purification

Denaturing Elution
Buffer

8 M urea, 20 mM sodium phosphate, 500 mM NaCl, pH 4

scFvO157
Purification

Destaining Solution

40% (v/v) methanol, 10% (v/v) glacial acetic acid

Protein
Visualization

Laemmli Buﬀer (4×)

250 mM Tris-HCl pH 6.8, 8% (w/v) SDS, 40% (v/v) glycerol,
0.02% (w/v) bromophenol blue, 8% (v/v) β-mercaptoethanol

Protein
Visualization

Native Buffer

20 mM Tris-HCl, pH 7.4, 200 mM NaCl

scFvO157
Purification

Native Elution Buffer

50 mM NaH2PO4, 0.5 M NaCl and 250 mM imidazole, pH 8.0

scFvO157
Purification

Native Wash Buffer

50 mM NaH2PO4 and 0.5 M NaCl, pH 8.0

scFvO157
Purification

PBS (1×)

137 mM NaCl, 10 mM Na2HPO4, 2.7 mM KCl, 1.8 mM
KH2PO4, pH 7.4

Various

PBST (1×)

137 mM NaCl, 10 mM Na2HPO4, 2.7 mM KCl, 1.8 mM
KH2PO4, 0.05% (v/v) Tween-20

ELISA

Polyacrylamide
Resolving Gel (10%)

2.0 ml ddH2O, 1.7 ml 30% acrylamide/bisacrylamide (37.5:1)
aqueous solution, 1.3 ml 1.5 M Tris-HCl pH 8.8, 0.05 ml 10%
SDS, 0.05 ml 10% APS, 0.002 ml TEMED (5 ml Final
Volume)

Protein
Visualization
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Buﬀer/ Reagent

Composition

Application

Polyacrylamide
Resolving Gel (12%)

1.7 ml ddH2O, 2.0 ml 30% acrylamide/bisacrylamide (37.5:1)
aqueous solution, 1.3 ml 1.5 M Tris-HCl pH 8.8, 0.05 ml 10%
SDS, 0.05 ml 10% APS, 0.002 ml TEMED (5 ml Final
Volume)

Protein
Visualization

Polyacrylamide
Stacking Gel (5%)

0.01 ml 10% SDS, 0.13 ml 0.5 M Tris-HCl pH 6.8, 0.17 ml
acrylamide/bisacrylamide (37.5:1) aqueous solution, 0.01 ml
10% APS, 0.001 ml TEMED (1 ml Final Volume)

Protein
Visualization

Rehydration Buffer
Stock Solution
(RBSS)

48% urea (w/v), 2% CHAPS (w/v), 0.02% bromophenol blue
(w/v)

IEF

TBE (1×)

89 mM Tris-HCl, 89 mM boric acid, 2 mM EDTA pH 8.0

DNA
Visualization

TBS (1×)

50 mM Tris-HCl pH 7.6, 150 mM NaCl

Protein
Visualization

TBST (1×)

10 mM Tris-HCl pH 8, 150 mM NaCl, 0.1% Tween-20

Protein
Visualization

Towbin Semi-dry
Transfer Buﬀer

191 mM glycine, 50 mM Tris

Protein
Visualization

Tris-Glycine
Running Buﬀer (1×)

192 mM glycine, 25 mM Tris, 0.1% (w/v) SDS, pH 8.3–8.6

Protein
Visualization
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Appendix F: Supporting information for the LFIA Test Kit relative validation study (raw data)
Inclusivity study

#

1

2

3

4

5

6

7

8

9

10

Culture
Collection
PHAC

PHAC

PHAC

PHAC

PHAC

PHAC

PHAC

PHAC

PHAC

PHAC

Reference

EC20060233

EC20040339

EC20011244

EC20011236

EC20011231

EC20010294

EC20001018

EC20000673

EC20000671

EC19990951

Strain

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Serotype

O157:H7

O157:H7

O157:H7

O157:H7

O157:H7

O157:H7

O157:H7

O157:H7

O157:H7

O157:H7

Source/ Origin

Bovine, ground

Bovine, meat

Bovine, ground

Bovine, ground

Bovine, ground

Bovine, ground

Bovine, ground

Bovine, meat

Bovine, ground

Bovine, salami

Decision
Point ™ Test
Kit
A

B

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

-

+

+

-

+

-

+

-

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

-

+
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#

11

12

13

14

15

16

17

18

19

20

21

Culture
Collection
PHAC

PHAC

PHAC

PHAC

PHAC

PHAC

PHAC

PHAC

PHAC

PHAC

PHAC

Reference

EC19970515

EC19970462

EC19970419

EC19970409

EC19950095

EC20130376

EC20130395

EC20132075

EC20130390

EC20130378

EC19961016

Strain

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Serotype

O157:H7

O157:H7

O157:H7

O157:H7

O157:NM

O157:H7

O157:NM

O157:H7

O157:NM

O157:H7

O157:H7

Source/ Origin

Bovine, meat

Bovine, meat

Bovine, meat

Bovine, meat

Bovine, meat

Bovine, feces

Bovine, feces

Bovine, feces

Bovine, feces

Bovine, feces

Human, clinical

Decision
Point ™ Test
Kit
A

B

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+
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#

22

23

24

25

26

27

28

29

30

31

32

Culture
Collection
PHAC

PHAC

PHAC

PHAC

PHAC

PHAC

PHAC

PHAC

PHAC

PHAC

PHAC

Reference

EC19961090

EC19961025

EC19961027

EC20020335

EC19930553

EC19930038

EC19920333

EC19960266

EC19960274

EC20050147

EC20060754

Strain

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Serotype

O157:H7

O157:H7

O157:H7

O157:H7

O157:H7

O157:H7

O157:H7

O157:H7

O157:H7

O157:H12

O157:H29

Source/ Origin

Human, clinical

Human, clinical

Human, clinical

Human, clinical

Human, clinical

Human, clinical

Human, clinical

Human, clinical

Human, clinical

Bovine, feces

Bovine, feces

Decision
Point ™ Test
Kit
A

B

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

-

+

-

+

-

+

+

+

+

+

+

+
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#

33

34

35

36

37

38

39

40

41

42

43

Culture
Collection
PHAC

PHAC

CRIFS

CRIFS

CRIFS

CRIFS

CRIFS

CRIFS

CRIFS

CRIFS

DSMZ

Reference

EC19970524

EC19970465-1

C480

EC20321

ATCC 43888

ATCC 43894

ATCC 700927

EC960282

EC940076

EC930195;
32511

DSM 17076/
NCTC 12900

Strain

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Serotype

O157:H42

O157:H45

O157:H7

O157:H7

O157:H7

O157:H7

O157:H7

O157:H25

O157:H19

O157:NM

O157:H7

Source/ Origin

Bovine, meat

Bovine, meat

N/A

L.Goodridge

Human, feces

Human, feces

Derived from
ATCC43895

Bovine

Bovine

L.Goodridge

Human, clinical

Decision
Point ™ Test
Kit
A

B

-

+

-

+

-

+

+

-

+

-

+

-

+

+

+

+

-

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

-

+

-

+

-

-

+

-

+

-

+

+

+

-

+

+

+

+

+

+

+

+

+
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#

44

45

46

47

48

49

50

Culture
Collection
UofM

UofM

UofM

UofM

UofM

CRIFS

CRIFS

Reference

00-3581

02-0304

02-0627

02-0628

02-1840

380-94

9490

Strain

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Escherichia
coli

Serotype

O157:H7

O157:H7

O157:H7

O157:H7

O157:NM

O157:H7

O157:H7

Source/ Origin

Human, clinical

Human, clinical

Human, clinical

Human, clinical

Human, clinical

Bovine, salami

USDA

Decision
Point ™ Test
Kit
A

B

-

+

+

+

-

+

+

+

+

+

+

+

-

+

-

+

-

+

+

+

-

+

+

+

-

+

-

+

-

+

+

+

+

+

+

+

+

+

+

+

+
+
PHAC: Public Health Agency of Canada, Guelph; CRIFS: Canadian Research Institute for Food Safety,
Guelph; DSMZ: Leibniz Institute DSMZ- German Collection of Microorganisms and Cell Cultures; UofM:
University of Manitoba. N/A: not available.
Exclusivity study

#

Culture
Collection

Reference

Strain

1

PHAC

ATCC 7966

Aeromonas
hydrophila

2

UWO

ATCC 13883
UWO#479

Klebsiella
pneumoniae

3

PHAC

ATCC 6051

Serotype

Origin/
Source
From tin
of milk
with a
fishy
odor
NCTC
HJ Conn

DECISION
Point TM
Test Kit
A
B
-

-
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#

Culture
Collection

Reference

Strain

Serotype

Bacillus
subtilis
Citrobacter
braakii
(freundii)
Enterobacter
aerogenes

Origin/
Source

4

PHAC

ATCC 43162

Clinical
isolate,
California
N/A

5

PHAC

NO152388

6

PHAC

ATCC 13047

Enterobacter
cloacae

Spinal
fluid

7

PHAC

ATCC 49149

Enterococcus
faecalis

Clinical
isolate

8

PHAC

ATCC 25922

Escherichia
coli

O6

Human,
clinical

9

PHAC

ATCC 700926

Escherichia
coli

OR:H48:K-

10

PHAC

ATCC 12014

Escherichia
coli

O55:NM

Derived
from
parent
strain
W1485
CDC

11

PHAC

ATCC 43887

Escherichia
coli

O111:NM

Human,
feces

12

PHAC

EC20130476

Escherichia
coli

O25:NM

N/A

13

PHAC

EC20130473

Escherichia
coli

O78:H11

N/A

14

PHAC

EC20130469

Escherichia
coli

O28ac:NM

N/A

15

PHAC

EC20130467

Escherichia
coli

O3:H2

N/A

16

PHAC

EC20130466

Escherichia
coli

O44:H18

N/A

17

PHAC

EC20130463

Escherichia
coli

O21:H4

N/A

18

PHAC

EC20130462

Escherichia
coli

O75:H5

N/A

19

CRIFS

EC 920232

Escherichia
coli

O2:H5

Bovine

DECISION
Point TM
Test Kit
A
B
+
+
-

-
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#

Culture
Collection

Reference

Strain

Serotype

Origin/
Source

20

CRIFS

EC 930004

Escherichia
coli

O103:H2

N/A

21

CRIFS

EC 910040

Escherichia
coli

O145:NM

N/A

22

CRIFS

EC 910005

Escherichia
coli

O111:NM

N/A

23

CRIFS

EC 910060

Escherichia
coli

O121:H7

N/A

24

ATCC

ATCC43893, CDC
EDL 1284 [929-78]

Escherichia
coli

O124:NM

Human,
feces

25

ATCC

ATCC 43886, CDC
E2539-C1

Escherichia
coli

O25:K98:NM

Human,
feces

26

PHAC

ATCC 33650

Escherichia
hermanii

27

PHAC

MB1914

Hafnia alvei

Human,
female
toe
N/A

28

PHAC

ATCC 49347

Shigella
dysenteriae

Human,
feces

29

PHAC

ATCC 25929

Shigella
flexneri

Human,
feces

30

PHAC

ATCC 25931

Shigella sonnei

Human,
feces

31

PHAC

ATCC 23715

Yersinia
enterocolitica

Human,
blood

32

UWO

LT-2

N/A

33

CRIFS

C398

Salmonella
enterica ser.
Typhimurium
Salmonella
newport

34

CRIFS

C390

Salmonella
Heidenberg

N/A

35

CRIFS

C417

Salmonella
Enteritidis

N/A

36

CRIFS

C1116

Salmonella
javiana

N/A

37

ATCC

ATCC 19114

N/A

4a

DECISION
Point TM
Test Kit
A
B
+
+
+
-
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DECISION
Point TM
#
Reference
Strain
Serotype
Test Kit
A
B
Listeria
Animal,
monocytogenes
tissue
38 HC
HPB 5949
Listeria
1/2C
Food,
monocytogenes
ready-toeat
PHAC: Public Health Agency of Canada, Guelph; UWO: Western University, Department of Microbiology
and Immunology; CRIFS: Canadian Research Institute for Food Safety, Guelph; ATCC: American Type
Culture Collection; HC: Health Canada, Listeriosis Reference Service; N/A: not available.
Culture
Collection

Origin/
Source

Estimation of the (H) and (L) inoculum levels for each food item evaluated

Target
Level

Cell Titre
(CFU/ml)

10-fold
Serial
Dilution
Selected

Volume
Inoculated
(ml)1

CFU
Inoculated2

Estimated
Inoculation
Level
(CFU/25g)

Raw
ground beef

Low

1.26× 108

1.00× 10-7

4.0

50.4

1.26

Raw
ground beef

High

1.50× 108

1.00× 10-6

4.0

600

15

Raw
ground veal

Low

1.26× 108

1.00× 10-7

4.0

50.4

1.26

Raw
ground veal

High

1.50× 108

1.00× 10-6

4.0

600

15

Raw beef
trim

Low

1.26× 108

1.00× 10-7

4.0

50.4

1.26

Raw beef
trim

High

1.50× 108

1.00× 10-6

4.0

600

15

Carpaccio

Low

1.26× 108

1.00× 10-7

4.0

50.4

1.26

Carpaccio

High

1.50× 10

8

-6

4.0

600

15

Raw
sausage*

Low

9.6× 107

1.00× 10-7

4.0

38.4

0.96

Raw
sausage*

High

9.60× 107

1.00× 10-6

4.0

384

9.6

Raw burger
patty*

Low

9.6× 107

1.00× 10-7

4.0

38.4

0.96

Raw burger
patty*

High

9.60× 107

1.00× 10-6

4.0

384

9.6

Raw
meatballs*

Low

9.6× 107

1.00× 10-7

4.0

38.4

0.96

Raw
meatballs*

High

9.60× 107

1.00× 10-6

4.0

384

9.6

Food Item

1.00× 10
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Food Item
Raw
kebabs*

Target
Level

Cell Titre
(CFU/ml)

10-fold
Serial
Dilution
Selected

Volume
Inoculated
(ml)1

CFU
Inoculated2

Estimated
Inoculation
Level
(CFU/25g)

Low

9.6× 107

1.00× 10-7

4.0

38.4

0.96

Raw
High
9.60× 107
1.00× 10-6
4.0
384
9.6
kebabs*
1Volume from the selected dilution that was used to inoculate 1.0kg of each food item.
2Total number of CFU that were inoculated into 1.0kg of each food item.
*These food items were inoculated with strain 380-94, which was stressed as described in the Inoculum
Preparation Section.
AM results for the fresh meats (unprocessed) food type.
Sample Item

Inoculation Level

MPN/25g

AM ground beef H1

H

AM ground beef H2

Alternative Results
Presumptive

Conﬁrmation

Final*

25

POS

POS

TP

H

25

POS

POS

TP

AM ground beef H3

H

25

POS

POS

TP

AM ground beef H4

H

25

POS

POS

TP

AM ground beef H5

H

25

POS

POS

TP

AM ground veal H1

H

13.3

POS

POS

TP

AM ground veal H2

H

13.3

POS

POS

TP

AM ground veal H3

H

13.3

POS

POS

TP

AM ground veal H4

H

13.3

POS

POS

TP

AM ground veal H5

H

13.3

POS

POS

TP

AM beef trim H1

H

13.3

POS

POS

TP

AM beef trim H2

H

13.3

POS

POS

TP

AM beef trim H3

H

13.3

POS

POS

TP

AM beef trim H4

H

13.3

POS

POS

TP

AM beef trim H5

H

13.3

POS

POS

TP

AM carpaccio H1

H

8.25

POS

POS

TP

AM carpaccio H2

H

8.25

POS

POS

TP

AM carpaccio H3

H

8.25

POS

POS

TP

AM carpaccio H4

H

8.25

POS

POS

TP

AM carpaccio H5

H

8.25

POS

POS

TP

AM ground beef L1

L

1.2

NEG

NEG

TN

AM ground beef L2

L

1.2

NEG

NEG

TN

AM ground beef L3

L

1.2

POS

POS

TP

AM ground beef L4

L

1.2

NEG

NEG

TN
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Sample Item

Inoculation Level

MPN/25g

AM ground beef L5

L

AM ground veal L1

Alternative Results
Presumptive

Conﬁrmation

Final*

1.2

NEG

NEG

TN

L

0.5

POS

POS

TP

AM ground veal L2

L

0.5

PO

POS

TP

AM ground veal L3

L

0.5

NEG

NEG

TN

AM ground veal L4

L

0.5

NEG

NEG

TN

AM ground veal L5

L

0.5

NEG

NEG

TN

AM beef trim L1

L

1.3

POS

POS

TP

AM beef trim L2

L

1.3

NEG

NEG

TN

AM beef trim L3

L

1.3

NEG

NEG

TN

AM beef trim L4

L

1.3

NEG

NEG

TN

AM beef trim L5

L

1.3

POS

POS

TP

AM carpaccio L1

L

1.3

NEG

NEG

TN

AM carpaccio L2

L

1.3

POS

POS

TP

AM carpaccio L3

L

1.3

NEG

NEG

TN

AM carpaccio L4

L

1.3

NEG

NEG

TN

AM carpaccio L5

L

1.3

NEG

NEG

TN

AM ground beef U1

U

-

NEG

NEG

TN

AM ground beef U2

U

-

NEG

NEG

TN

AM ground veal U

U

-

NEG

NEG

TN

AM beef trim U

U

-

NEG

NEG

TN

AM carpaccio U
U
NEG
NEG
*Alternative Final Results are defined as True Positives (TP) or True Negatives (TN).

TN

AM results for the ready-to cook (processed) food type.
Sample Item

Inoculation Level

MPN/25g

Alternative Results
Presumptive

Conﬁrmation

Final*

AM raw sausage H1

H

13.3

POS

POS

TP

AM raw sausage H2

H

13.3

POS

POS

TP

AM raw sausage H3

H

13.3

POS

POS

TP

AM raw sausage H4

H

13.3

POS

POS

TP

AM raw sausage H5

H

13.3

POS

POS

TP

AM raw patty H1

H

13.3

POS

POS

TP

AM raw patty H2

H

13.3

POS

POS

TP

AM raw patty H3

H

13.3

POS

POS

TP

AM raw patty H4

H

13.3

POS

POS

TP
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Sample Item

Inoculation Level

MPN/25g

Alternative Results
Presumptive

Conﬁrmation

Final*

AM raw patty H5

H

13.3

POS

POS

TP

AM raw meatball H1

H

8.3

POS

POS

TP

AM raw meatball H2

H

8.3

POS

POS

TP

AM raw meatball H3

H

8.3

POS

POS

TP

AM raw meatball H4

H

8.3

POS

POS

TP

AM raw meatball H5

H

8.3

POS

POS

TP

AM raw kebab H1

H

25

POS

POS

TP

AM raw kebab H2

H

25

POS

POS

TP

AM raw kebab H3

H

25

POS

POS

TP

AM raw kebab H4

H

25

POS

POS

TP

AM raw kebab H5

H

25

POS

POS

TP

AM raw sausage L1

L

1.3

POS

POS

TP

AM raw sausage L2

L

1.3

NEG

NEG

TN

AM raw sausage L3

L

1.3

POS

POS

TP

AM raw sausage L4

L

1.3

NEG

NEG

TN

AM raw sausage L5

L

1.3

NEG

NEG

TN

AM raw patty L1

L

0.5

POS

POS

TP

AM raw patty L2

L

0.5

NEG

NEG

TN

AM raw patty L3

L

0.5

POS

POS

TP

AM raw patty L4

L

0.5

NEG

NEG

TN

AM raw patty L5

L

0.5

POS

POS

TP

AM raw meatball L1

L

1.3

POS

POS

TP

AM raw meatball L2

L

1.3

NEG

NEG

TN

AM raw meatball L3

L

1.3

NEG

NEG

TN

AM raw meatball L4

L

1.3

NEG

NEG

TN

AM raw meatball L5

L

1.3

NEG

NEG

TN

AM raw kebab L1

L

1.3

POS

POS

TP

AM raw kebab L2

L

1.3

NEG

NEG

TN

AM raw kebab L3

L

1.3

NEG

NEG

TN

AM raw kebab L4

L

1.3

NEG

NEG

TN

AM raw kebab L5

L

1.3

POS

POS

TP

AM raw sausage U1

U

-

NEG

NEG

TN

AM raw sausage U2

U

-

NEG

NEG

TN

AM raw patty U

U

-

NEG

NEG

TN
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Sample Item

Inoculation Level

AM raw meatball U

U

MPN/25g
-

Alternative Results
Presumptive

Conﬁrmation

Final*

NEG

NEG

TN

AM raw kebab U
U
NEG
NEG
*Alternative Final Results are defined as True Positives (TP) or True Negatives (TN).
RM results for the fresh meats (unprocessed) food type.
Sample Item

Inoculation Level

MPN/25g

MFHPB-10 Results

RM ground beef H1

H

25

POS

RM ground beef H2

H

25

POS

RM ground beef H3

H

25

POS

RM ground beef H4

H

25

POS

RM ground beef H5

H

25

POS

RM ground veal H1

H

13.3

POS

RM ground veal H2

H

13.3

POS

RM ground veal H3

H

13.3

POS

RM ground veal H4

H

13.3

POS

RM ground veal H5

H

13.3

POS

RM beef trim H1

H

13.3

POS

RM beef trim H2

H

13.3

POS

RM beef trim H3

H

13.3

POS

R beef trim H4

H

13.3

POS

RM beef trim H5

H

13.3

POS

RM carpaccio H1

H

8.25

POS

RM carpaccio H2

H

8.25

POS

RM carpaccio H3

H

8.25

POS

RM carpaccio H4

H

8.25

POS

RM carpaccio H5

H

8.25

POS

RM ground beef L1

L

1.2

NEG

RM ground beef L2

L

1.2

POS

RM ground beef L3

L

1.2

NEG

RM ground beef L4

L

1.2

POS

RM ground beef L5

L

1.2

NEG

RM ground veal L1

L

0.5

NEG

RM ground veal L2

L

0.5

POS

RM ground veal L3

L

0.5

NEG

RM ground veal L4

L

0.5

POS

TN
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Sample Item

Inoculation Level

MPN/25g

MFHPB-10 Results

RM ground veal L5

L

0.5

NEG

RM beef trim L1

L

1.3

POS

RM beef trim L2

L

1.3

NEG

RM beef trim L3

L

1.3

NEG

RM beef trim L4

L

1.3

NEG

RM beef trim L5

L

1.3

NEG

RM carpaccio L1

L

1.3

POS

RM carpaccio L2

L

1.3

POS

RM carpaccio L3

L

1.3

POS

RM carpaccio L4

L

1.3

NEG

RM carpaccio L5

L

1.3

NEG

RM ground beef U1

U

-

NEG

RM ground beef U2

U

-

NEG

RM ground veal U

U

-

NEG

RM beef trim U

U

-

NEG

RM carpaccio U

U

-

NEG

RM results for the ready-to-cook (processed) food type.
Sample Item

Inoculation Level

MPN/25g

MFHPB-10Results

RM raw sausage H1

H

13.3

POS

RM raw sausage H2

H

13.3

POS

RM raw sausage H3

H

13.3

POS

RM raw sausage H4

H

13.3

POS

RM raw sausage H5

H

13.3

POS

RM raw patty H1

H

13.3

POS

RM raw patty H2

H

13.3

POS

RM raw patty H3

H

13.3

POS

RM raw patty H4

H

13.3

POS

RM raw patty H5

H

13.3

POS

RM raw meatball H1

H

8.3

POS

RM raw meatball H2

H

8.3

POS

RM raw meatball H3

H

8.3

POS

RM raw meatball H4

H

8.3

POS

RM raw meatball H5

H

8.3

POS

RM raw kebab H1

H

25

POS

RM raw kebab H2

H

25

POS
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Sample Item

Inoculation Level

MPN/25g

MFHPB-10Results

RM raw kebab H3

H

25

POS

RM raw kebab H4

H

25

POS

RM raw kebab H5

H

25

POS

RM raw sausage L1

L

1.3

POS

RM raw sausage L2

L

1.3

NEG

RM raw sausage L3

L

1.3

POS

RM raw sausage L4

L

1.3

NEG

RM raw sausage L5

L

1.3

POS

RM raw patty L1

L

0.5

POS

RM raw patty L2

L

0.5

NEG

RM raw patty L3

L

0.5

NEG

RM raw patty L4

L

0.5

NEG

RM raw patty L5

L

0.5

POS

RM raw meatball L1

L

1.3

POS

RM raw meatball L2

L

1.3

NEG

RM raw meatball L3

L

1.3

NEG

RM raw meatball L4

L

1.3

NEG

RM raw meatball L5

L

1.3

NEG

RM raw kebab L1

L

1.3

POS

RM raw kebab L2

L

1.3

NEG

RM raw kebab L3

L

1.3

POS

RM raw kebab L4

L

1.3

NEG

RM raw kebab L5

L

1.3

POS

RM raw sausage U1

U

-

NEG

RM raw sausage U2

U

-

NEG

RM raw patty U

U

-

NEG

RM raw meatball U

U

-

NEG

RM raw kebab U

U

-

NEG
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